tigecycline profile

ID Source	ID
PubMed CID	54686904
CHEMBL ID	376140
CHEBI ID	149836
SCHEMBL ID	237962
SCHEMBL ID	105082
SCHEMBL ID	101795
MeSH ID	M0305009

Synonym
AC-1798
t1c ,
gar-936
9-t-butylglycylamido minocycline
(4s,4as,5ar,12as)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
(4s,12as)-4,7-bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide
tygacil(tm)
tigilcycline
tbg-mino
tygacil
gar936
220620-09-7
way-gar-936
gar 936
tigecycline ,
DB00560
(4s,4as,5ar,12as)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
tigecycline (jan/usp)
D01079
tygacil (tn)
tigecycline [usan]
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)-
121GE002
CHEMBL376140
CHEBI:149836 ,
(4s,4as,5ar,12as)-9-[(n-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
NCGC00183095-01
dtxsid2048581 ,
tox21_112910
dtxcid8028507
cas-220620-09-7
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)-
A815890
(4s,4as,5ar,12as)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1
tigecycline [usan:inn:ban]
hsdb 8172
unii-70je2n95kr
70je2n95kr ,
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((2-((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)-
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)-
haizheng li xing
gar-936,tigecycline
BCPP000045
tigecycline hydrate
S1403
AKOS015895663
FPZLLRFZJZRHSY-HJYUBDRYSA-N
SCHEMBL237962
tigecycline [ep monograph]
tigecycline [inn]
tigecycline [who-dd]
tigecycline [ema epar]
tigecycline [orange book]
(4s,4as,5ar,12as)-9-[2-(tert-butylamino)acetamido]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
tigecycline [vandf]
tigecycline [usp-rs]
tigecycline [mart.]
tigecycline [jan]
tigecycline [usp monograph]
tigecycline [mi]
HY-B0117
CS-1876
(4s,4as,5ar,12as)-9-[2-(tert-butylamino)acetamido]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
smr002530064
MLS006010079
SCHEMBL105082
SCHEMBL101795
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[2-[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)-
AM20090708
T3589
Q-101396
tigecycline, antibiotic for culture media use only
(4s,4as,5ar,12as)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
AB01566818_01
AKOS025401452
(4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
mfcd00935753
tigecycline 95%
(4s,4as,5ar,12as)-9-(2-t-butylaminoacetylamino)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydronaphthacene-2-carboxamide
HMS3714I13
SOVUOXKZCCAWOJ-HJYUBDRYSA-N
bdbm50247905
Q420595
(4s,4as,5ar,12as)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxa
9-tert-butylglycylamidominocycline
AS-30703
BCP01397
CCG-270150
gtpl10929
AKOS037643695
nsc794945
nsc-794945
EN300-19769236
(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-9-[[2-[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; tygacil; way-gar 936; glycylcycline;
9-t-butylglycylamido-minocycline

Excerpt	Reference	Relevance
" Nausea and vomiting were the most common adverse events."	( Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Ellis-Grosse, EJ; Green, SL; Klein, SR; Loh, E; Postier, RG, 2004)	0.32
" Adverse events were similar, with increased nausea and vomiting in the tigecycline group and increased rash and elevated hepatic aminotransferase levels in the vancomycin-aztreonam group."	( The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Babinchak, T; Dartois, N; Ellis-Grosse, EJ; Loh, E; Rose, G, 2005)	0.33
"719]) were the most frequently reported adverse events."	( The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Babinchak, T; Dartois, N; Ellis-Grosse, E; Loh, E; Rose, GM, 2005)	0.33
" Safety was assessed by physical examination, laboratory analyses, and adverse event reporting."	( Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Campos, ME; Curcio, D; Ellis-Grosse, E; Embil, JM; Loh, E; Penn, RL; Rose, G; Sacchidanand, S, 2005)	0.33
" Frequency of adverse events was similar between groups, although patients receiving tigecycline had higher incidence of nausea, vomiting, dyspepsia, and anorexia, while increased ALT/SGPT, pruritus, and rash occurred significantly more often in V + A-treated patients."	( Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Campos, ME; Curcio, D; Ellis-Grosse, E; Embil, JM; Loh, E; Penn, RL; Rose, G; Sacchidanand, S, 2005)	0.33
"435]) were the most frequently reported adverse events."	( A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. Babinchak, T; Campos, M; Ellis-Grosse, EJ; Loh, E; Oliva, ME; Pasternak, J; Rekha, A; Rose, GM; Yellin, A, 2005)	0.33
" Safety was assessed by physical examination, laboratory results, and adverse event reporting."	( Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Breedt, J; Dartois, N; Ellis-Grosse, EJ; Gardovskis, J; Gioud-Paquet, M; Loh, E; Maritz, FJ; Ross, DP; Teras, J; Vaasna, T, 2005)	0.33
" q12h) in adults is safe and generally well tolerated for up to 11."	( Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. Rello, J, 2005)	0.33
"Tigecycline is safe and effective in hospitalized patients with serious infection caused by MRSA."	( Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. Babinchak, T; Beuran, M; Bochan, M; Cooper, CA; Dartois, N; Dimov, R; Dukart, G; Ellis-Grosse, EJ; Fichev, G; Florescu, I; Gandjini, H; Razbadauskas, A, 2008)	0.35
" Most commonly reported treatment emergent adverse events for tigecycline and imipenem/cilastatin were nausea (14."	( The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. Babinchak, T; Castaing, N; Cooper, A; Dartois, N; De Vane, N; Fomin, P; Koalov, S; Tellado, J, 2008)	0.35
" Safety was assessed by physical examination, laboratory results and adverse event reporting."	( Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective. Cooper, A; Dartois, N; Dukart, G; Gardovskis, J; Jouve, S; Kupcs, U; Pupelis, G; Teras, J; Vaasna, T, 2008)	0.35
" Nausea, vomiting, and diarrhoea were the most frequently reported adverse events."	( Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. Calistru, PI; Castaing, N; Chernyak, V; Cooper, CA; Dartois, N; Gandjini, H; Milutinovic, S; Strausz, J; Tanaseanu, C; Zolubas, M, 2009)	0.35
"Tigecycline was generally safe and well tolerated in the treatment of secondary bacteremia associated with cSSSI, cIAI, and CAP; cure rates were similar to comparative standard therapies."	( Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Babinchak, T; Cooper, A; Dukart, G; Gardiner, D, 2010)	0.36
" The most common treatment-emergent adverse events in healthy volunteers were nausea (56."	( Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. Baird-Bellaire, SJ; Böhmer, GM; Buecheler, R; Gleiter, CH; Korth-Bradley, JM; Morgan, MY; Patat, AA; Troy, SM, 2011)	0.37
" The overall incidence of treatment-emergent adverse events was 80."	( Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. Bi, J; Chen, X; Chen, Z; Cooper, A; Leng, X; Li, R; Liu, D; Ma, X; Maroko, R; Quan, Z; Wei, J; Wu, J; Wu, Z; Yan, L; Yu, Y; Zhang, Y, 2010)	0.36
"Tigecycline monotherapy is a safe and effective therapy for cSSSIs in geographically distinct populations in Asia."	( Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. Aradhya, S; Chang, CM; Chuang, YC; Cooper, A; Dartois, N; Jouve, S; Nagari, B; Pai, V, 2011)	0.37
" The secondary outcome included clinical and microbiological failure, superinfections and adverse events (AEs)."	( Efficacy and safety of tigecycline: a systematic review and meta-analysis. Lador, A; Leibovici, L; Paul, M; Yahav, D, 2011)	0.37
" Adverse events were more frequent in the tigecycline group than in the control groups (1·45, 1·11-1·88), with significantly more vomiting and nausea."	( Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Arvanitidou, M; Haidich, AB; Kokkali, S; Tasina, E, 2011)	0.37
"Spontaneous reports in the United States Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) database generated between January 1997 and December 2010."	( Tigecycline-related pancreatitis: a review of spontaneous adverse event reports. Brown, J; Engell, C; Okon, E; van Manen, R, 2013)	0.39
" Disproportionality analysis uses an adverse event relative reporting ratio (RRR) to compare the occurrence of a specific adverse event with an index drug of interest to the occurrence of the same adverse event with similar agents or with all other FDA-approved prescription drugs."	( Tigecycline-related pancreatitis: a review of spontaneous adverse event reports. Brown, J; Engell, C; Okon, E; van Manen, R, 2013)	0.39
"Data on adverse events (AEs) were available for 198 cSSTI and 590 cIAI patients in three studies."	( Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. Bassetti, M; Bodmann, KF; Capparella, MR; Dupont, H; Eckmann, C; Guirao, X; Heizmann, WR; Montravers, P; Sánchez García, M; Simoneau, D, 2013)	0.39
" The most common adverse events were nausea and vomiting."	( Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. Gandhi, A; Korth-Bradley, J; Matschke, K; Yamashita, N, 2014)	0.4
" Main adverse effects were gastrointestinal."	( [Evaluation of the efficacy and safety of tigecycline for treatment of respiratory tract infections: systematic review of literature]. Márquez-Peláez, S; Molina Linde, JM; Motiva Sánchez, V; Moya Cordero, P; Ruiz-Aragón, J, 2013)	0.39
" This retrospective observation study evaluated two-colistin and tigecycline-antibiotics profiles like treatment success rate, negative conversion rate, the length of hospital stay, intensive care unit (ICU) stay and antibiotics use, mortality rate during hospital stay and adverse event rate, based on the medical record of XDR-AB positive patients who were treated at least 5 d with those intravenous antibiotics."	( Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii. Ahn, HL; Han, OY; Kwon, SH; La, HO, 2014)	0.4
" Adverse events and all-cause mortality were more common in the tigecycline group."	( Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Deng, Y; Fang, M; Han, Q; Shen, F; Xie, D; Zeng, H, 2015)	0.42
"Tigecycline is not as effective as other antibiotics with relatively more frequency of adverse events and higher mortality rate."	( Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Deng, Y; Fang, M; Han, Q; Shen, F; Xie, D; Zeng, H, 2015)	0.42
" The primary outcome was the rate of clinical cure, and the secondary outcomes were mortality and adverse events (AEs)."	( Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia. Chen, L; Du, S; Long, LH; Wang, YL; Wu, Y; Xu, L, 2016)	0.43
"Because patients with abdominal solid organ transplants (SOTs) are at increased risk of polymicrobial intraabdominal infections (IAIs) following transplantation, the objective of this study was to compare the effectiveness and adverse event profile of tigecycline with those of other broad-spectrum therapies for polymicrobial IAIs in this population."	( Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections. Bingen, E; Liebenstein, T; Musuuza, J; Rose, WE; Safdar, N; Schulz, LT; Viesselmann, C, 2017)	0.46
" Patients receiving tigecycline experienced a higher rate of adverse events than those receiving comparator antibiotics (29."	( Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections. Bingen, E; Liebenstein, T; Musuuza, J; Rose, WE; Safdar, N; Schulz, LT; Viesselmann, C, 2017)	0.46
"Patients receiving tigecycline were less likely to achieve optimal clinical outcomes and had more adverse events."	( Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections. Bingen, E; Liebenstein, T; Musuuza, J; Rose, WE; Safdar, N; Schulz, LT; Viesselmann, C, 2017)	0.46
" Secondary outcomes were all-cause mortality and nephrotoxic and non-nephrotoxic adverse events."	( Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. Apisarnthanarak, A; Chaiyakunapruk, N; Kengkla, K; Kongpakwattana, K; Saokaew, S, 2018)	0.48
" The primary outcome was treatment mortality rate, while the secondary outcomes were adverse events."	( Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies. Bai, XR; Jiang, DC; Liu, JM; Yan, SY, 2018)	0.48
"A total of 28 women were enrolled, and 25 patients completed the study protocol, because 3 patients reported adverse drug effects resulting in treatment interruption."	( Safety and efficacy of tigecycline in complicated and uncomplicated pelvic inflammatory disease. Baroni, C; Cecchi, E; Domenici, L; Garibaldi, S; Perutelli, A; Salerno, MG; Tascini, C, 2018)	0.48
"Despite the limited sample size, tigecycline seemed an effective and safe treatment for women with complicated/resistant PID."	( Safety and efficacy of tigecycline in complicated and uncomplicated pelvic inflammatory disease. Baroni, C; Cecchi, E; Domenici, L; Garibaldi, S; Perutelli, A; Salerno, MG; Tascini, C, 2018)	0.48
" However, the adverse events (AEs) remain controversial."	( Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Chen, Z; Shi, X, 2018)	0.48
" Studies were included if they compared tigecycline-based regimens with other antibiotic regimens for treating AB pulmonary infections and we pooled the clinical outcomes, microbiological response, adverse events or mortality."	( Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis. Cai, Y; Mei, H; Wang, J; Wang, R; Yang, T, 2019)	0.51
" The primary outcome was mortality, and the secondary outcomes were clinical response rate, microbiological eradiation rate and adverse events (AEs)."	( Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: A meta-analysis. Du, G; Gong, J; Lin, Y; Liu, G; Shang, J; Su, D; Sun, Z; Yu, H, 2019)	0.51
" The rate of dose reduction or discontinuation of tigecycline owing to adverse drug reactions was 57."	( Efficacy and safety of tigecycline for Mycobacterium abscessus disease. Daley, CL; Huitt, GA; Kasperbauer, SH; Kwon, YS; Levin, A, )	0.13
" However, considering the poor microbiological response and the common adverse effects, selection of patients for tigecycline treatment and monitoring for adverse drug reactions should be performed carefully."	( Efficacy and safety of tigecycline for Mycobacterium abscessus disease. Daley, CL; Huitt, GA; Kasperbauer, SH; Kwon, YS; Levin, A, )	0.13
" Rates for all-cause mortality, clinical cure, microbiological eradication and adverse events were analysed."	( Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis. French, N; Guo, J; Pan, L; Tefsen, B; Villanueva, EV; Zha, L, 2020)	0.56
"0003), and without increasing adverse events rates."	( Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis. French, N; Guo, J; Pan, L; Tefsen, B; Villanueva, EV; Zha, L, 2020)	0.56
"High dose tigecycline treatment is effective and safe for severe infections owing to its lower all-cause mortality, higher clinical cure, microbiological eradication and comparable adverse events."	( Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis. French, N; Guo, J; Pan, L; Tefsen, B; Villanueva, EV; Zha, L, 2020)	0.56
" In the ventilator-associated pneumonia (VAP) and bloodstream infection (BSI) subgroups, the sole independent predictor of clinical cure was the HD of TIG, and no significant adverse events were observed."	( Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: A retrospective analysis. Jiang, R; Xia, G, 2020)	0.56
" Method All DILI cases of tetracycline antibiotics as primary suspected drugs were extracted from the US Food and Drug Administration adverse event reporting system (FAERS)."	( A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data. Jiang, A; Liu, Y; Wei, C; Wu, B, 2022)	0.72
" Adverse drug reactions (ADRs) were observed in 41 patients (35."	( Drug use investigation on the safety and efficacy of tigecycline in Japan (all-case post-marketing surveillance). Ohashi, T; Sugiyama, N; Uryu, T; Watanabe, T; Yoshinaga, Y, 2022)	0.72
" Hepatotoxicity was classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (5."	( Risk Factors for Tigecycline-Associated Hepatotoxicity in Patients in the Intensive Care Units of 2 Tertiary Hospitals: A Retrospective Study. Chen, S; Feng, H; Huang, L; Huang, X; Huang, Y; Jiang, T; Lin, J; Liu, Q; Weng, C; Zhuang, Y, 2022)	0.72
" Statistically significant trends were observed favoring cefotaxime plus metronidazole, which exhibited fewer discontinuations because of adverse events (AEs) when compared with eravacycline, meropenem and ceftolozane/tazobactam plus metronidazole (OR = 0."	( Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis. Deng, T; Kong, W; Li, S; Shu, Y; Wu, Y, 2023)	0.91
" However, the plasma concentration of tigecycline is not correlated with clinical efficacy and adverse reactions."	( Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units. Bai, XR; Fan, L; Li, WC; Lou, R; Qu, X; Wang, YG; Wang, ZZ; Wu, YC; Yan, SY; Zhang, L; Zhang, W, 2023)	0.91

Excerpt	Reference	Relevance
"The in vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) were assessed in an experimental murine thigh infection model in neutropenic mice."	( In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Andes, D; Conklin, B; Craig, WA; Stamstad, TJ; van Ogtrop, ML; Vesga, O; Weiss, WJ, 2000)	0.31
" Full pharmacokinetic profiles of tigecycline were determined in two of these studies."	( Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Micalizzi, M; Muralidharan, G; Raible, D; Speth, J; Troy, S, 2005)	0.33
" The peak tigecycline concentration and half-life in serum were greater than those in blister fluid."	( Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Harper, D; Nicolau, DP; Nightingale, CH; Ong, CT; Sun, HK; Troy, S; Umer, A, 2005)	0.33
" Except for the volumes of distribution at steady state (approximately 350 liters in women versus 500 liters in men), there were no significant differences in tigecycline pharmacokinetic parameters."	( Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Fruncillo, RJ; Micalizzi, M; Muralidharan, G; Raible, DG; Troy, SM, 2005)	0.33
"The steady-state serum and intrapulmonary pharmacokinetic and pharmacodynamic parameters of tigecycline were determined after intravenous administration in 30 subjects."	( Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Conte, JE; Golden, JA; Kelly, MG; Zurlinden, E, 2005)	0.33
" Pharmacokinetic analysis of data from phase 1 trials of healthy subjects indicate that tigecycline has a large volume of distribution, signifying extensive tissue penetration, and a long terminal elimination half-life (approximately 40 h), easily allowing for twice-daily dose administration."	( Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Ambrose, PG; Ellis-Grosse, EJ; Grasela, TH; Meagher, AK, 2005)	0.33
"We inoculated an in vitro pharmacodynamic model simultaneously with clinical isolates of methicillin-resistant Staphylococcus aureus and an enterocin-producing enterococcus (vancomycin-resistant Enterococcus faecalis, ampicillin susceptible) at 7 log10 CFU/ml to examine enterocin effects and antimicrobial activity on staphylococci."	( Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Chin, JN; LaPlante, KL; Leuthner, KD; Rybak, MJ, 2006)	0.33
" A population pharmacokinetic (PK) model for tigecycline was developed for patients with cSSSI or cIAI enrolled in two phase 2 clinical trials, and the influence of selected demographic factors and clinical laboratory measures was investigated."	( Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Cirincione, BB; Korth-Bradley, JM; Ludwig, EA; Meagher, AK; Owen, JS; Van Wart, SA, 2006)	0.33
" A structural population pharmacokinetic model for tigecycline was developed based on data pooled from 5 phase I studies."	( Population pharmacokinetics of tigecycline in healthy volunteers. Cirincione, BB; Korth-Bradley, JM; Ludwig, EA; Meagher, AK; Owen, JS; Van Wart, SA, 2007)	0.34
" After the final dose, the pharmacokinetics of tigecycline in serum showed a long half-life (55."	( Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. DeMaio, W; Harper, D; Hoffmann, M; Jordan, RA; Scatina, J; Speth, J; Talaat, R, 2007)	0.34
"Tigecycline and ciprofloxacin were employed as the model compounds to study the effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA), which is used during plasma sample preparations, on the determination of pharmacokinetic parameters."	( Effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA) on the estimation of pharmacokinetic parameters: A case study with tigecycline and ciprofloxacin. Chen, Q; Ciccotto, SL; Ortiga, R; Ramsay, KA; Strauss, JR; Tang, W; Tung, EC, 2008)	0.35
"A pharmacodynamic model was used to generate supportive data comparing tigecycline with other broad-spectrum agents against pathogens implicated in hospital-acquired pneumonia (HAP)."	( A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. Dowzicky, M; Kuti, JL; Nicolau, DP, 2008)	0.35
" We predicted the pharmacodynamic cumulative fraction of response (CFR) of tigecycline against bacteria implicated in complicated skin and skin structure infections and compared it with the CFRs for piperacillin/tazobactam, ceftriaxone, levofloxacin, and imipenem/cilastatin."	( Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. Dowzicky, M; Kuti, JL; Nicolau, DP, 2008)	0.35
"Tigecycline monotherapy had a likelihood of achieving its requisite pharmacodynamic exposure similar to that of combinations of piperacillin/tazobactam or imipenem/cilastatin plus vancomycin for the empiric treatment of complicated skin and skin structure infections."	( Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. Dowzicky, M; Kuti, JL; Nicolau, DP, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"Free drug serum concentrations of minocycline associated with the doses given to humans (100 mg every 12 hours for 24 hours) were simulated in an in vitro hollow-fiber pharmacokinetic model."	( Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. Bowker, KE; Macgowan, AP; Noel, AR, 2008)	0.35
" Significant pharmacokinetic data are now available from the studies of infected patients, as is information on tissue distribution."	( Tigecycline pharmacokinetic/pharmacodynamic update. MacGowan, AP, 2008)	0.35
" The consideration of the pharmacokinetic and pharmacodynamic properties of tigecycline may aid in further understanding the therapeutic role of this agent."	( Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Dimopoulos, G; Falagas, ME; Karageorgopoulos, DE, 2009)	0.35
" A previously derived patient population pharmacokinetic model and Monte Carlo simulation (9999 patients) were used to create a likelihood distribution of tigecycline exposure, as measured by the area under the concentration-time curve at 24 h (AUC(24))."	( Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Ambrose, PG; Bhavnani, SM; Cirincione, BB; Ellis-Grosse, E; Meagher, AK; Passarell, JA; Van Wart, SA, 2009)	0.35
" Although this compound is under investigation for this indication, supportive pharmacodynamic data are not yet available at this infection site."	( Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. Kim, A; Koomanachai, P; Nicolau, DP, 2009)	0.35
"The pharmacokinetic profile of tigecycline was evaluated in infected neutropenic mice."	( Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. Kim, A; Koomanachai, P; Nicolau, DP, 2009)	0.35
"Tigecycline displayed linear pharmacokinetics with a mean half-life of 11."	( Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. Kim, A; Koomanachai, P; Nicolau, DP, 2009)	0.35
" TGC displayed linear PK and had a mean half-life of 10."	( Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Banevicius, MA; Crandon, JL; Koomanachai, P; Nicolau, DP; Peng, L, 2009)	0.35
" Pharmacokinetic data were derived using noncompartmental methods."	( Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. Baird-Bellaire, SJ; Böhmer, GM; Buecheler, R; Gleiter, CH; Korth-Bradley, JM; Morgan, MY; Patat, AA; Troy, SM, 2011)	0.37
"This study explored tigecycline exposure-bacterial responses in pharmacodynamic simulations (in vitro kinetic model) using different inocula."	( Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. Aguilar, L; Alou, L; Cafini, F; Garcia-Escribano, N; Garcia-Rey, C; Giménez, MJ; González, N; Prieto, J; Sevillano, D; Torrico, M, 2010)	0.36
" Lastly, we explain the combination of these three antibiotics administered to increase microbiologic and pharmacodynamic yield."	( A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects. Barrientos, A; Calvo, N; Candel, FJ; Culebras, E; Head, J; Matesanz, M; Picazo, J; Sánchez, A, 2010)	0.36
" Herein, tigecycline disposition in patients with community- or hospital-acquired pneumonia was described using a population pharmacokinetic model."	( Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. Ambrose, PG; Bhavnani, SM; Cooper, A; Dukart, G; Forrest, A; Korth-Bradley, J; Rubino, CM, 2010)	0.36
" The present article reviews the pharmacokinetic properties of vancomycin, linezolid, tigecycline and daptomycin."	( Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Derendorf, H; Estes, KS, 2010)	0.36
" An in vitro pharmacodynamic model was used to simulate adult steady-state epithelial lining fluid concentrations of tigecycline (50 mg every 12 h) given alone and in combination with either meropenem (2 g by 3-hour infusion every 8 h) or rifampin (600 mg every 12 h)."	( In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Koomanachai, P; Kuti, JL; Nicasio, AM; Nicolau, DP; Wiskirchen, DE, 2011)	0.37
"The pharmacokinetic parameters of tigecycline were assessed in subjects with severe renal impairment (creatinine clearance <30 mL/min, n = 6), subjects receiving hemodialysis (4 received tigecycline before and 4 received tigecycline after hemodialysis), and subjects with age-adjusted, normal renal function (n = 6) after administration of single 100-mg doses."	( Tigecycline pharmacokinetics in subjects with various degrees of renal function. Fruncillo, RJ; Korth-Bradley, JM; Matschke, K; Muralidharan, G; Raible, DG; Speth, JL; Troy, SM, 2012)	0.38
"The aim of this study was to assess the pharmacokinetic (PK) properties, safety profile, and descriptive efficacy of tigecycline."	( Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Balter, I; Cooper, CA; Dartois, N; Jouve, S; Korth-Bradley, J; Purdy, J; Yan, JL, 2012)	0.38
"The methodology included the following steps: acquisition of microbiological and pharmacokinetic data, Monte Carlo simulation, estimation of the probability of target attainment (PTA), and calculation of the cumulative fraction of response (CFR)."	( Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Betriu, C; Canut, A; Gascón, AR; Isla, A, 2012)	0.38
" baumannii using an in vitro pharmacodynamic model."	( In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. Hagihara, M; Housman, ST; Kuti, JL; Nicolau, DP, 2013)	0.39
" Serial blood samples and urine were collected, drug concentrations determined, and pharmacokinetic parameters calculated."	( Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. Gandhi, A; Korth-Bradley, J; Matschke, K; Yamashita, N, 2014)	0.4
" baumannii isolates were evaluated using an in vitro pharmacodynamic model."	( In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Hagihara, M; Housman, ST; Kuti, JL; Nicolau, DP, 2014)	0.4
" This validated method was successfully applied to a pharmacokinetic study in critically ill patients."	( Quantitative analysis and pharmacokinetics study of tigecycline in human serum using a validated sensitive liquid chromatography with tandem mass spectrometry method. Cheng, X; Dong, H; Dong, Y; Wang, T; Wang, X; Wang, Y; Xie, J; Xing, J; Zheng, X; Zhou, L, 2014)	0.4
" The goal of our research was to assess the clinical efficacy of tigecycline at different doses by using a pharmacokinetic/pharmacodynamic (PK/PD) model which can incorporate pharmacokinetic data of tigecycline from patients with pneumonia and MICs of MDR-Ab from a tertiary hospital."	( A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii. Bai, N; Cai, Y; Cui, JC; Liang, BB; Liu, YP; Ni, WT; Wang, R, 2014)	0.4
" Based on the MICs and the population pharmacokinetic parameters of the investigated antimicrobials, a Monte Carlo simulation was performed to simulate the pharmacokinetic/pharmacodynamic (PK/PD) indices of different regimens."	( A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia. Cai, X; Cui, J; Ni, W; Wei, C, 2015)	0.42
" Here, the pharmacodynamic activities of polymyxin B (PMB) (2-20 mg/L) and tigecycline (0."	( Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. Bulitta, JB; Diep, J; Forrest, A; Holden, PN; Li, J; Ly, NS; Nation, RL; Rao, GG; Tsuji, BT, 2016)	0.43
" Values of half-life in the elimination phase were 23."	( Pharmacokinetics of tigecycline in turkeys following different routes of administration. Jaroszewski, JJ; Jasiecka-Mikołajczyk, A; Ziółkowski, H, 2018)	0.48
" This validated method was successfully applied to a TIG pharmacokinetic study in turkey after intravenous and oral administration at a dose of 10 mg/kg at various time-points."	( Determination of tigecycline in turkey plasma by LC-MS/MS: validation and application in a pharmacokinetic study. Jaroszewski, JJ; Jasiecka-Mikołajczyk, A, 2017)	0.46
"In order to characterize the intracellular pharmacokinetic properties of tigecycline, we developed and fully validated a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for quantification of tigecycline in human lung epithelial (BEAS-2B) cells and polymorphonuclear neutrophils (PMNs)."	( Determination of tigecycline in human lung epithelial cells and polymorphonuclear neutrophils by liquid chromatography/tandem mass spectrometry and its application in a cellular pharmacokinetics study. Dong, Y; Li, S; Wang, H; Xie, J; Yang, Q; Zhang, K; Zhang, Y; Zhao, Y, 2021)	0.62

Excerpt	Reference	Relevance
"Microdilution chequerboard analysis of tigecycline in combination with amikacin, ampicillin/sulbactam, azithromycin, ciprofloxacin, colistin, imipenem, levofloxacin, piperacillin, piperacillin/tazobactam, polymyxin B, rifampicin, minocycline and vancomycin resulted in an interpretation of either no interaction or synergy."	( In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. Bradford, PA; Jones, CH; Labthavikul, P; Petersen, PJ, 2006)	0.33
"The activities of tigecycline alone and in combination with other antimicrobials are not well defined for carbapenem-intermediate or -resistant Acinetobacter baumannii (CIRA)."	( In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Noskin, GA; Obias, A; Postelnick, MJ; Qi, C; Scheetz, MH; Warren, JR; Zembower, T, 2007)	0.34
"To test the activity of tigecycline combined with 16 antimicrobials in vitro against 22 gram-positive and 55 gram-negative clinical isolates."	( In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens. Entenza, JM; Giddey, M; Moreillon, P; Vouillamoz, J, 2008)	0.35
"This study evaluated vancomycin susceptibility and activity alone and in combination with rifampicin and tigecycline against low-biofilm- and high-biofilm-producing methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates."	( Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. Poppens, PT; Rose, WE, 2009)	0.35
" Time-kill analysis was performed on six low- and six high-biofilm-producing isolates with 15 mg/L vancomycin alone and in combination with rifampicin or tigecycline at 4x MIC."	( Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. Poppens, PT; Rose, WE, 2009)	0.35
"Tigecycline has been investigated in combination with other antibacterials against a wide range of susceptible and multiresistant Gram-positive and Gram-negative bacteria."	( Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Entenza, JM; Moreillon, P, 2009)	0.35
" We investigated the effects of vancomycin (VAN), daptomycin (DAP), fosfomycin (FOS), tigecycline (TGC), and ceftriaxone (CRX), alone and in combination with azithromycin (AZI), on established biofilms of Staphylococcus epidermidis."	( Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. Graninger, W; Hajdu, S; Hirschl, AM; Holinka, J; Lassnigg, AM; Presterl, E, 2009)	0.35
"We investigated the activity of tigecycline in combination with gentamicin for the treatment of biofilm-forming methicillin-resistant and sensitive Staphylococcus aureus in an in vitro pharmacodynamic model."	( In vitro activity of tigecycline in combination with gentamicin against biofilm-forming Staphylococcus aureus. LaPlante, KL; McConeghy, KW, 2010)	0.36
"This study evaluated the activity of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli co-producing extended-spectrum β-lactamases and acquired AmpC β-lactamases."	( Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Hur, J; Kim, HS; Lee, KM; Park, MJ; Park, MS; Song, W; Woo, H; Yim, H, 2011)	0.37
" In conclusion, our results suggested a strong activity of tigecycline alone and in combination with other antimicrobial agents against multi-resistant Gram-positive organisms isolated from wound infections."	( In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection. Arzeni, D; Brescini, L; Cirioni, O; Ganzetti, G; Ghiselli, R; Giacometti, A; Guerrieri, M; Offidani, A; Orlando, F; Provinciali, M; Silvestri, C; Simonetti, O; Staffolani, S, 2012)	0.38
" The purpose of this study was to investigate the clinical outcomes of patients with healthcare-associated infections (HAIs) caused by MDRAB who were treated with imipenem/cilastatin and sulbactam, and TG alone or in combination with other antibiotics."	( Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Hsueh, PR; Lee, YT; Tsao, SM, 2013)	0.39
"The aim of this study was to evaluate the in vitro activity of doripenem (DOR) alone and in combination with a variety of commonly used anti-Acinetobacter chemotherapeutic agents against 22 primary multidrug-resistant (MDR) Acinetobacter baumannii isolates (including 17 isolates that were resistant to DOR) from Intensive Care Unit patients."	( In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Bordi, E; Capone, A; D'Arezzo, S; Di Caro, A; Mazzarelli, A; Petrosillo, N; Principe, L, 2013)	0.39
"5% of the strains for meropenem combination with tigecycline."	( Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Labrou, M; Manousaka, S; Michail, G; Pitiriga, V; Pournaras, S; Sakellaridis, N; Tsakris, A, 2013)	0.39
" Tigecycline in combination with rifampin demonstrated higher activity against bacteria embedded in biofilms than tigecycline alone."	( Antimicrobial activity of tigecycline alone or in combination with rifampin against Staphylococcus epidermidis in biofilm. Kaznowski, A; Szczuka, E, 2014)	0.4
" We compared the synergistic activity and post-antibiotic effect (PAE) of colistin in combination with other antimicrobials against colistin-susceptible and -resistant KPC-Kp bloodstream isolates."	( In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. Ambretti, S; Bonora, S; Gaibani, P; Landini, MP; Lewis, RE; Lombardo, D; Mercuri, M, 2014)	0.4
" In time-kill assays, COL combined with either RIF or TGC was superior to single agents, but only the COL/RIF regimen was reliably bactericidal."	( Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Betts, JW; Phee, LM; Wareham, DW; Woodford, N, 2014)	0.4
" Moreover, tigecycline in combination with cefoperazone-sulbactam appeared to be more effective than tigecycline in combination with sulbactam against XDRAB."	( In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. Bai, Y; Di, X; Liu, B; Liu, Y; Wang, J; Wang, R; Zhang, X, 2015)	0.42
"Several antibiotics have shown promising anti-malarial effects and have been useful for malarial chemotherapy, particularly in combination with standard anti-malarial drugs."	( In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine. Sahu, R; Tekwani, BL; Walker, LA, 2014)	0.4
"Tigecycline was tested in vitro against chloroquine (CQ)-sensitive (D6) and resistant strains (W2) of Plasmodium falciparum alone and in combination with CQ."	( In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine. Sahu, R; Tekwani, BL; Walker, LA, 2014)	0.4
"Results indicate prominent anti-malarial action of tigecycline in vitro and in vivo in combination with CQ and support further evaluation of tigecycline as a potential combination candidate for treatment of drug-resistant cases of malaria."	( In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine. Sahu, R; Tekwani, BL; Walker, LA, 2014)	0.4
"Colistin, tigecycline, levofloxacin, tobramycin, and rifampin alone and in combination with doripenem were investigated for their in vitro activities and postantibiotic effects (PAEs) on Klebsiella pneumoniae."	( Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit. Mataraci-Kara, E; Ozbek Celik, B; Yilmaz, M, 2014)	0.4
" haemolyticus strains isolated from bloodstream infections and assess in vitro the activity of rifampicin combined with daptomycin or tigecycline against bacteria growing in a biofilm."	( In Vitro Activity of Rifampicin Combined with Daptomycin or Tigecycline on Staphylococcus haemolyticus Biofilms. Grabska, K; Kaznowski, A; Szczuka, E, 2015)	0.42
" Synergy was observed when plazomicin was combined with meropenem, colistin or fosfomycin against both isolates, whilst the combination with tigecycline resulted in indifference."	( In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Culebras, E; Pena, I; Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I, 2015)	0.42
"This study investigated the minimum inhibitory concentration (MIC) values and in vitro activity of colistin in combination with tigecycline against carbapenem-resistant Acinetobacter baumannii strains isolated from patients with ventilator-associated pneumonia (VAP) using the E-test method."	( In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia. Aydin, M; Ceylan, MR; Cikman, A; Gulhan, B; Karagoz, A; Karakecili, F; Parlak, M, 2015)	0.42
" The in vitro activity of colistin in combination with tigecycline was evaluated using the fractional inhibitor concentration (FIC) index."	( In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia. Aydin, M; Ceylan, MR; Cikman, A; Gulhan, B; Karagoz, A; Karakecili, F; Parlak, M, 2015)	0.42
" The in vivo studies showed that azithromycin (20 mg/kg/day twice daily) alone or in combination with minocycline (10 mg/kg/day twice daily) significantly decreased the fungal burden."	( In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. Alves, SH; Azevedo, MI; Driemeier, D; Ferreiro, L; França, RT; Jesus, FP; Lopes, ST; Loreto, ÉS; Ludwig, A; Pilotto, MB; Ribeiro, TC; Santurio, JM; Souza, SO; Tondolo, JS, 2016)	0.43
" In this study, we aimed to evaluate the efficacy of LPC in combination with colistin, tigecycline, or imipenem in experimental murine models of peritoneal sepsis and pneumonia."	( Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models. Ayerbe Algaba, R; Díaz, C; Gutiérrez Valencia, A; Jiménez Mejías, ME; López Cortés, LF; Pachón Ibáñez, ME; Pachón, J; Parra Millán, R; Pérez Del Palacio, J; Sánchez Encinales, V; Smani, Y, 2016)	0.43
" Using a murine thigh-infection model, we examined the in vivo efficacy of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin, or sulbactam against 12 XDR-AB strains."	( Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model. Cong, Y; Fan, B; Guan, J; Wang, X, 2016)	0.43
" We investigated the activity of various antibiotics in combination with polymyxin B using time-kill studies (TKS)."	( In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B. Cai, Y; Chan, EC; Hong, Y; Hsu, LY; Koh, TH; Kwa, AL; Lee, W; Lim, TP; Sasikala, S; Tan, TT; Tan, TY; Teo, J, 2016)	0.43
" The SBPI analysis showed that CAZ-AVI in combination with imipenem achieved higher SBPI values than other CAZ-AVI-based combinations."	( In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Ambretti, S; Campoli, C; Gaibani, P; Giannella, M; Landini, MP; Lewis, RE; Re, MC; Viale, P; Volpe, SL, 2017)	0.46
" The lead candidate was then tested against a panel of clinical CREs, a bactericidal/static determination assay, a time-kill assay and a checkerboard assay to evaluate its suitability for use in combination with Tigecycline against CRE infections."	( Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections. Chia, CSB; Ching, HSV; Hill, J; Jureen, R; Ng, FM; Ng, SMS; Sioson, JSP; Teo, JWP; Yap, JM, 2018)	0.48
"To investigate the activity of 5 antibiotic monotherapies, including colistin (COL), meropenem (MEM), amikacin (AMK), levofloxacin (LEV), and tigecycline (TGC), when combined with 4 other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae (CRKP) in vitro."	( Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro. Fu, Y; Guo, Y; Li, C; Wang, Y; Yu, L; Zhang, J; Zhang, X; Zhao, J; Zhao, Y, 2019)	0.51
" Thus, we performed synergy testing of fosfomycin combined with tigecycline by E-test, which was easy to perform and to determine results, compared with microdilution checkerboard, which is considered to be the "gold standard", to evaluate the agreement between the two methods."	( Synergy Testing by E-Test and Microdilution Checkerboard for Fosfomycin Combined with Tigecycline against KPC-Producing Klebsiella pneumoniae. Huang, L; Sun, L; Wang, M, 2019)	0.51
" Synergy testing of fosfomycin combined with tigecycline was performed by E-test (E-test stripes were placed at 90° angle), with microdilution chequerboard performed in parallel."	( Synergy Testing by E-Test and Microdilution Checkerboard for Fosfomycin Combined with Tigecycline against KPC-Producing Klebsiella pneumoniae. Huang, L; Sun, L; Wang, M, 2019)	0.51
"The aim of this study was to compare the effectiveness of cefoperazone-sulbactam alone and combined with tigecycline in the treatment of multi-drug resistant acinetobacter baumannii pulmonary infection."	( Effectiveness of Cefoperazone-sulbactam alone and Combined with Tigecycline in the Treatment of Multi-drug Resistant Acinetobacter Baumannii Pulmonary Infection. Chen, L; Deng, Y; Lv, Q; Ruan, J; Zhu, X, 2020)	0.56
" The in-vitro bactericidal and synergistic activities of ceftazidime/avibactam alone or in combination with other antibiotics were determined by time-kill curve assays."	( Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. Istanbullu Tosun, A; Mataraci Kara, E; Özbek Çelik, B; Yilmaz, M, 2020)	0.56
" Chequerboard tests and time-kill assays were performed for 20 CR-KP isolates to evaluate in vitro synergistic effects of tigecycline combined with aminoglycosides."	( In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae. Cui, J; Gao, Z; Guan, J; Liu, Y; Ni, W; Xi, W; Xu, Y; Yang, D; Zhao, L; Zhou, D, 2021)	0.62
"Compared with single drugs, tigecycline combined with aminoglycosides could exert synergistic effects and reduce the emergence of tigecycline resistance."	( In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae. Cui, J; Gao, Z; Guan, J; Liu, Y; Ni, W; Xi, W; Xu, Y; Yang, D; Zhao, L; Zhou, D, 2021)	0.62
" However, the synergistic effects of tigecycline in combination with other antibiotics including colistin or amikacin remain unclear."	( In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii. Feng, H; He, L; Wu, H; Xu, P; Zhang, H, 2021)	0.62
"Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia."	( Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia. Chen, L; Deng, Y; Huang, X; Yang, Y; Yu, H; Yue, M, 2022)	0.72

Excerpt	Reference	Relevance
" Several analogs have also shown promising oral bioavailability in rats and cynomolgus monkey."	( Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs. Clark, RB; Hunt, DK; Lofland, D; O'Brien, WJ; Plamondon, L; Sun, C; Xiao, XY, 2011)	0.37
" Two compounds were identified that exhibit both oral bioavailability in rat and clinically relevant bacterial susceptibility profiles against major respiratory pathogens."	( Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. Achorn, C; Chen, CL; Clark, RB; Deng, Y; Fyfe, C; Grossman, TH; He, M; Hogan, PC; Hunt, DK; O'Brien, WJ; Plamondon, L; Rönn, M; Sutcliffe, JA; Xiao, XY; Zhu, Z, 2012)	0.38

Excerpt	Relevance	Reference
"5 CFU/g for four different dosing regimens."	( Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Edelstein, MA; Edelstein, PH; Weiss, WJ, 2003)	0.32
" Tigecycline is only available in an injectable formulation for clinical use unlike currently marketed tetracyclines that are available in oral dosage forms."	( The glycylcyclines: a comparative review with the tetracyclines. Embil, J; Gin, A; Hoban, DJ; Homenuik, K; Karlowsky, JA; Nichol, K; Noreddin, A; Vercaigne, L; Zhanel, GG, 2004)	0.32
" Unlike existing tetracyclines, tigecycline is only available as an intravenous preparation, is administered twice daily although its long half life and post-antibiotic effect may make once daily dosing possible, appears to have good tissue penetration (e."	( Tigecycline: clinical evidence and formulary positioning. Nathwani, D, 2005)	0.33
" Based on pharmacokinetics, no dosage adjustment is warranted based on age or sex."	( Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Fruncillo, RJ; Micalizzi, M; Muralidharan, G; Raible, DG; Troy, SM, 2005)	0.33
" Intravenously administered tigecycline (recommended dosage regimen 100 mg initially, followed by 50 mg every 12 hours for 5-14 days) has been approved by the US FDA for the treatment of cSSSIs and cIAIs."	( Tigecycline. Curran, MP; Frampton, JE, 2005)	0.33
"The pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy, adverse events, dosage and administration, drug interactions, and place in therapy of tigecycline are reviewed."	( Tigecycline: a new glycylcycline antimicrobial agent. Kasbekar, N, 2006)	0.33
" Hepatic dosage adjustment is necessary for severe disease; however, no dosage adjustments are necessary for patients with renal impairment."	( Tigecycline: a new glycylcycline antimicrobial agent. Kasbekar, N, 2006)	0.33
" The recommended dosage of tigecycline is 100 mg IV given as a loading dose, followed by 50 mg IV g12h for 5 to 14 days."	( Tigecycline: a glycylcycline antimicrobial agent. Doan, TL; Fung, HB; Mehta, D; Riska, PF, 2006)	0.33
" Tigecycline was aggressively administered at twice the recommended dosage for overt liver failure in light of the severity of this patient's condition."	( Peritoneal fluid penetration of tigecycline. Nicolau, DP; Noskin, GA; Postelnick, MJ; Reddy, P; Scheetz, MH; Stosor, V; Zembower, TR, 2006)	0.33
" Area under the concentration time curve to minimum inhibitory concentration (AUC/MIC) values for tigecycline ranged from 79 to 158 microg h/mL and tigecycline concentrations remained above the MIC (T>MIC) throughout the simulated dosing interval."	( In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Garrison, MW; Nuemiller, JJ, 2007)	0.34
" It has rapid bactericidal activity against growing and stationary-phase bacteria, once-daily dosing regimen, and has a low potential for the development of resistance."	( Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Ziglam, H, 2007)	0.34
" Therefore, a correct dosing regimen for the time-dependent molecules (i."	( [Pharmacological rationale for choice of antibiotics for intraabdominal infections]. Mazzei, T; Novelli, A, 2008)	0.35
" In contrast, fractionation of the dose at a free AUC associated with a static effect indicated that once daily dosing was superior."	( Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. Bowker, KE; Macgowan, AP; Noel, AR, 2008)	0.35
" This article reviews the clinical efficacy, side effect profile, dosing and administration schedule of tigecycline."	( Tigecycline: a new antibiotic. Hylands, J, 2008)	0.35
"These results suggest that a dosage adjustment of either drug is not necessary during coadministration of tigecycline and warfarin."	( Evaluation of a potential tigecycline-warfarin drug interaction. Harper, DM; Matschke, K; Raible, DG; Speth, JL; Zimmerman, JJ, 2008)	0.35
" As new pharmacokinetic data emerge, clarification of the pharmacokinetic/pharmacodynamic (PK/PD) profile of colistin as well as appropriate dosing seems urgent, while development of resistance must be carefully monitored."	( Multidrug-resistant Gram-negative infections: what are the treatment options? Giamarellou, H; Poulakou, G, 2009)	0.35
"56 log(10) cfu/mL at 12 h (time of one dosing interval), with a bacteriostatic profile when considering 24 h colony counts (similar counts at 0 and 24 h)."	( In vitro effect of physiological concentrations of human albumin on the antibacterial activity of tigecycline. Aguilar, L; Alou, L; Cafini, F; García-Escribano, N; García-Rey, C; Giménez, MJ; González, N; Prieto, J; Sevillano, D; Torrico, M, 2009)	0.35
" Reduced CSF concentrations urge caution in the treatment of cerebritis with standard dosing of tigecycline."	( Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Levasseur, K; Nicolau, DP; Ray, L; Scheetz, MH, 2010)	0.36
" No adjustment of tigecycline maintenance dosage is warranted in patients with compensated or moderately decompensated cirrhosis; doses should be reduced by 50%, to 25 mg, every 12 hours in patients with severely decompensated disease."	( Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. Baird-Bellaire, SJ; Böhmer, GM; Buecheler, R; Gleiter, CH; Korth-Bradley, JM; Morgan, MY; Patat, AA; Troy, SM, 2011)	0.37
" A computerised pharmacodynamic bicompartmental model simulated three tigecycline twice-daily dosing regimens over 48h: 50mg (100mg loading dose); 100mg; and 150 mg."	( Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. Aguilar, L; Alou, L; Cafini, F; Garcia-Escribano, N; Garcia-Rey, C; Giménez, MJ; González, N; Prieto, J; Sevillano, D; Torrico, M, 2010)	0.36
" Nearly 70% of the respondent hospitals reported having a vancomycinspecific dosing or monitoring guideline in place."	( Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus. Hennenfent, J; Lambert, BL; McBride, MV; Rodvold, KA; Schiff, G; Schumock, GT; Trese, AM; Tverdek, F; Yang, Y, 2010)	0.36
" the absence of a control group, their retrospective nature, variable dosing and duration of therapy, simultaneous administration of other antibiotics in >70% and a lack of resistance development monitoring."	( Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Giamarellou, H, 2010)	0.36
" For a successful therapy it is of vital importance that these compounds are used judiciously and dosed appropriately."	( Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Derendorf, H; Estes, KS, 2010)	0.36
" Based on these pharmacokinetic data, tigecycline requires no dosage adjustment in patients with renal impairment."	( Tigecycline pharmacokinetics in subjects with various degrees of renal function. Fruncillo, RJ; Korth-Bradley, JM; Matschke, K; Muralidharan, G; Raible, DG; Speth, JL; Troy, SM, 2012)	0.38
"Tigecycline, a broad-spectrum antibiotic used for treating serious bacterial infections in adults, may be suitable for pediatric use once an appropriate dosage is determined."	( Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Balter, I; Cooper, CA; Dartois, N; Jouve, S; Korth-Bradley, J; Purdy, J; Yan, JL, 2012)	0.38
"A tigecycline dosage of ∼1."	( Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Balter, I; Cooper, CA; Dartois, N; Jouve, S; Korth-Bradley, J; Purdy, J; Yan, JL, 2012)	0.38
" In this mouse model of surgical implant MSSA or MRSA infection, daptomycin and tigecycline prophylaxis were effective over a broader dosage range than vancomycin."	( Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice. Billi, F; Francis, KP; Miller, LS; Niska, JA; Pribaz, JR; Ramos, RI; Shahbazian, JH, 2012)	0.38
" Minimal organ toxicity and lack of dosage adjustment in most patients are important considerations for tigecycline use."	( Tigecycline: an update. Babinchak, T; Stein, GE, 2013)	0.39
"6% for all patients who received the standard dosage (183/230), 86."	( Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. Bassetti, M; Bodmann, KF; Capparella, MR; Dupont, H; Eckmann, C; García, MS; Guirao, X; Heizmann, WR; Montravers, P; Simoneau, D, 2013)	0.39
" A lower CFR is predicted against certain Gram-negative pathogens with the current standard tigecycline dosing regimen, irrespective of TBW."	( Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. Pai, MP, 2014)	0.4
" However, when the MPCs of dual-drug therapy were in conjunction with clinical pharmacokinetic profiles, combinations may not strictly curb the occurrence of resistance at current dosage regimen."	( In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii. Bai, N; Cai, X; Cai, Y; Cui, J; Liang, B; Ni, W; Wang, R, 2013)	0.39
" Adverse events were not correlated with dosing strategy."	( Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database. Christensen, DM; Griffin, AT; Harting, JA, 2013)	0.39
" Subjects in an ascending single-dose study (n = 40) received 25-150 mg intravenously, whereas subjects in two multiple-dose studies received every 12-hour (q12h) dosing with 25 mg (n = 10) or 25, 50, or 100 then 50 mg (n = 30)."	( Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. Gandhi, A; Korth-Bradley, J; Matschke, K; Yamashita, N, 2014)	0.4
" The aim of this study was to evaluate the current standard tigecycline dosage regimen from a pharmacokinetic/pharmacodynamic (PK/PD) perspective."	( Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Cai, J; Chen, S; Dong, H; Dong, Y; Hu, S; Sun, J; Wang, T; Wang, X; Xie, J; Zhang, D; Zhang, W, 2014)	0.4
"Tigecycline exhibits excellent in vitro antimicrobial activity, however the standard tigecycline dosing regimen fails to achieve the best outcome in vivo for the common drug-resistant strains, including Acinetobacter baumannii, Enterobacter spp, and Klebsiella pneumoniae."	( Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Cai, J; Chen, S; Dong, H; Dong, Y; Hu, S; Sun, J; Wang, T; Wang, X; Xie, J; Zhang, D; Zhang, W, 2014)	0.4
"In the absence of new drugs on the horizon, rather than using a single fixed dosing regimen, tigecycline dosing needs to be optimized in order to achieve the desired successful clinical response and to prevent an escalation in drug resistance."	( Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Cai, J; Chen, S; Dong, H; Dong, Y; Hu, S; Sun, J; Wang, T; Wang, X; Xie, J; Zhang, D; Zhang, W, 2014)	0.4
"62% was predicted for tigecycline at current dosage (50 mg q12h)."	( A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii. Bai, N; Cai, Y; Cui, JC; Liang, BB; Liu, YP; Ni, WT; Wang, R, 2014)	0.4
" Tigecycline is relatively unstable after reconstitution, and this instability may limit the use of the drug in ambulatory infusions for the treatment of infection and may prevent the development of optimal dosing schedules for the treatment of AML."	( A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. Goard, CA; Gronda, M; Hurren, R; Jhas, B; Jitkova, Y; Schimmer, AD; Wang, X, 2014)	0.4
" The safety profile and efficacy of high dosing regimen use were investigated."	( High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Antonelli, M; Bello, G; Bernini, V; De Pascale, G; Maviglia, R; Montini, L; Pennisi, M; Spanu, T; Tumbarello, M, 2014)	0.4
" The objective of this in vitro study has been to determine what dosage of TG causes changes in the morphology and number of osteoblasts."	( In vitro evaluation of a multifunctional nano drug delivery system based on tigecycline-loaded calcium-phosphate/ poly-DL-lactide-co-glycolide. Ignjatović, NL; Lyngstadaas, SP; Ninkov, P; Sabetrasekh, R; Uskoković, DP, 2014)	0.4
" Dosage regimen of tigecycline: loading dose 100 mg, 50 mg every 12 hours as maintenance therapy for 2-4 weeks."	( [Efficacy of tigecycline in treating severe infections of patients with hematological diseases]. Fu, R; Gao, S; Guan, J; Hu, Z; Li, L; Liu, H; Qu, W; Shao, Q; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wang, Y; Wu, Y; Xing, L; Yu, H, 2014)	0.4
" These studies show that aggressive polymyxin-based dosing in combination with clinically achievable tigecycline concentrations results in early synergistic activity that is not sustained beyond 8 h, whereas combinations with higher tigecycline concentrations result in sustained bactericidal activity against both isolates at both inocula."	( Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. Bulitta, JB; Diep, J; Forrest, A; Holden, PN; Li, J; Ly, NS; Nation, RL; Rao, GG; Tsuji, BT, 2016)	0.43
" Omadacycline offers once daily oral and IV dosing and a clinical tolerability and safety profile that compares favorably with contemporary antibiotics used across serious community-acquired infections where resistance has rendered many less effective."	( Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Steenbergen, J; Tanaka, SK; Villano, S, 2016)	0.43
"Tigecycline, one of the few therapeutic options against multidrug-resistant Acinetobacter baumannii, reaches subinhibitory serum concentrations only with cautious clinical dosing and pharmacokinetics."	( Biofilm Formation Restrained by Subinhibitory Concentrations of Tigecyclin in Acinetobacter baumannii Is Associated with Downregulation of Efflux Pumps. Cao, J; Chen, H; Liu, H; Zhang, X; Zhou, C; Zhou, T, 2017)	0.46
" Designing rational dosage regimens for patients to maximize the antimicrobial activity and minimize the emergence and prevalence of resistance is recommended."	( Systematic Review of Antimicrobial Resistance of Clinical Acinetobacter baumannii Isolates in Iran: An Update. Ardebili, A; Mardaneh, J; Razavi Nikoo, H, 2017)	0.46
"We present the case of a 72-year-old Greek woman with postoperative spondylodiscitis caused by a multidrug-resistant Acinetobacter baumannii strain that was successfully treated, after she declined surgical treatment, with prolonged and high dosage of tigecycline."	( Prolonged and high dosage of tigecycline - successful treatment of spondylodiscitis caused by multidrug-resistant Acinetobacter baumannii: a case report. Chrysanthidis, T; Georgiou, A; Loli, G; Metallidis, S; Morfesis, P; Nanoudis, S; Tsachouridou, O; Zebekakis, P, 2017)	0.46
"A 47-year-old male patient with severe acute cholangitis who developed sepsis was treated with a high dosage (100 mg twice daily) of tigecycline."	( A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Dong, L; Wu, X; Zhang, X; Zhao, P, 2017)	0.46
" The pharmacokinetics (PK) of tigecycline in intensive care unit (ICU) patients can be affected by severe pathophysiological changes so that standard dosing might not be adequate."	( Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock. Borsuk-De Moor, A; Borys, M; Czuczwar, M; Onichimowski, D; Piwowarczyk, P; Potręć, B; Raszewski, G; Rypulak, E; Sysiak, J; Wiczling, P, 2018)	0.48
" She was successfully treated with intravenous tigecycline for 2 weeks at a starting dosage of 100 mg daily."	( Severe Streptococcal Infection Following Cat Scratch. Minuti, A; Veraldi, S, 2018)	0.48
" • Six dosage models and different infection types were observed in our series, with different improvement and eradication rate, indicating that more data are required to identify a proper tigecycline dosage."	( Preliminary experience with tigecycline treatment for severe infection in children. Lin, S; Ye, S; Zhang, C, 2018)	0.48
" The risk of side effects was related to the TGC duration, although not increased as the dosage rose."	( Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Chen, Z; Shi, X, 2018)	0.48
" This effect was more pronounced if prolonged infusion of meropenem and high tigecycline dosing were used."	( Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates. Daikos, GRL; Georgiou, PC; Meletiadis, J; Mouton, JW; Pournaras, S; Tsala, M; Vourli, S, 2019)	0.51
" Once-a-week dosing had the same efficacy as daily therapy for the same cumulative dose; thus, tigecycline efficacy was linked to the AUC0-24/MIC ratio."	( Once-a-week tigecycline for the treatment of drug-resistant TB. Bendet, P; Cirrincione, KN; Deshpande, D; Dheda, K; Gumbo, T; Lee, PS; Magombedze, G; Martin, KR; Srivastava, S, 2019)	0.51
" By combining parallel experimental evolution with high-throughput dose-response measurements, we measure phenotypic profiles of collateral sensitivity and resistance for a total of 900 mutant-drug combinations."	( Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance. Maltas, J; Wood, KB, 2019)	0.51
" A lack of pediatric-specific comparative effectiveness data, uncertain pediatric dosing regimens for several agents, and a relative lack of new antibiotics with pediatric indications approved by the US Food and Drug Administration (FDA) collectively present unique challenges for children."	( Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children. Chiotos, K; Gerber, JS; Hayes, M; Tamma, PD, 2020)	0.56
"The objective of this study was to investigate the cumulative fraction of response (CFR) of various tigecycline dosing regimens in patients with hepatic or renal impairment."	( Optimization of tigecycline dosage regimen for different infections in the patients with hepatic or renal impairment. Li, MX; Li, N; Liu, W; Zhu, LQ, 2020)	0.56
"It is necessary to optimize tigecycline dosage regimens in patients with hepatic or renal impairment in order to maximise clinical response and minimise the probability of exposure-related toxicity."	( Optimization of tigecycline dosage regimen for different infections in the patients with hepatic or renal impairment. Li, MX; Li, N; Liu, W; Zhu, LQ, 2020)	0.56
"Tigecycline is one of few antibiotics active against multidrug-resistant bacteria; however, the assessment of dosing strategies to optimize its activity is needed."	( Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. Kispal, B; Walker, SAN, 2021)	0.62
"Publications that evaluated tigecycline dosing regimens and provided mean PK variables of interest (minimum 2 of: elimination rate constant or half-life and volume of distribution or clearance), with SDs, were included."	( Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. Kispal, B; Walker, SAN, 2021)	0.62
" For TGC, conventional dosing regimens failed to reach 90% PTA against a MIC of 2 mg/L."	( Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation. Cui, Y; Huang, C; Shi, Q; Wang, G; Xiao, Y; Yu, W, 2021)	0.62
" Generally, a higher dosage of tigecycline for the treatment of serious infections has been recommended in previous reports."	( Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline. Leng, B; Shen, C; Wang, C; Wang, W; Yan, G; Zhang, W, 2021)	0.62
"The use of standard tigecycline dosing is predicted to have a good clinical outcome for patients suffering from complicated skin and skin structure infection (cSSSI) with MICs ≤ 0."	( Analysis based on Monte Carlo simulation: How effective is tigecycline in routine antimicrobial therapy? Bai, H; Fan, G; Jiang, K; Jin, L; Liu, X; Liu, Y; Ren, F; Sun, N; Wu, S, 2021)	0.62
" aeruginosa isolates, the combined susceptibility rates (susceptible at standard dosing regimen plus susceptible at increased exposure) were highest to ceftazidime-avibactam, colistin and amikacin (≥82."	( In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard, D; Stone, GG, 2021)	0.62
" We aimed to describe tigecycline PK in patients with decompensated cirrhosis and severe bacterial infections, identify the sources of PK variability and assess the performance of different dosing regimens to optimize the PK/pharmacodynamic (PD) target."	( Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections. Aziz, F; Bastida, C; Brunet, M; Cariqueo, M; Fernández, J; Fortuna, V; Hernández-Tejero, M; Sanz, M; Soy, D, 2022)	0.72
" Dosing regimens are recommended to reach several PK/PD targets considering this clinical variable and any MIC within the susceptibility range."	( Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections. Aziz, F; Bastida, C; Brunet, M; Cariqueo, M; Fernández, J; Fortuna, V; Hernández-Tejero, M; Sanz, M; Soy, D, 2022)	0.72
" Therefore, conventional or standard dosing regimens do not achieve satisfactory anti-infective effects."	( A UPLC-MS/MS method for simultaneous determination of eight special-grade antimicrobials in human plasma and application in TDM. Liu, G; Qi, Y, 2022)	0.72
"Various analytical methods such as spectrometric, fluorimetric and chromatographic methods have been discussed for estimation of TIG from its bulk and different dosage form."	( A Review on Analytical Methods for Tigecycline Estimation From Its Bulk and Dosage Form. Patel, A; Patel, G; Patel, S; Patel, Y; Rakholiya, B; Shah, P, 2023)	0.91

Pathway	Proteins	Compounds
Tigecycline Action Pathway	1	4

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	26.6032	0.0015	30.6073	15,848.9004	AID1224841; AID1224842
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	16.9301	0.0002	29.3054	16,493.5996	AID743075
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	0.4731	0.0016	28.0151	77.1139	AID1259385
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	49.1940	0.0391	47.5451	146.8240	AID1224845
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	2.9847	0.0006	27.2152	1,122.0200	AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1801)

Assay ID	Title	Year	Journal	Article
AID544793	Antibacterial activity against Klebsiella pneumoniae assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID283396	Antimicrobial activity against Nocardia veterana after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID583235	Antibacterial activity against Enterobacter spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID258280	Antibacterial activity against Minocycline sensitive Escherichia coli 90-5	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID562250	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated form patient blood measured after 18 to 24 hrs on day 1 isolation by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.
AID1773506	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate M-13 assessed as inhibition of visible growth incubated for 16 to 18 hrs by CLSI method
AID531521	Antibacterial activity against Bacteroides stercoris isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID544817	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID561854	Antibacterial activity against extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 255 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID542859	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543775	Antibacterial activity against Klebsiella pneumoniae assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID559795	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 4 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID532675	Antimicrobial activity against ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID576578	Cmax in plasma of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID544544	Antibacterial activity against pandrug-resistant Acinetobacter baumannii clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID498821	Antimicrobial activity against Klebsiella pneumoniae WH76T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID543094	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by via	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID546344	fT>MIC in methicillin-sensitive Staphylococcus aureus ATCC 25923-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID529827	Antimicrobial activity against Acinetobacter baumannii by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID325401	Antibacterial activity against Streptococcus anginosus	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID373467	Penetration ratio, ratio of AUC (0 to 24 hrs) for human colon wall tissue to AUC (0 to 24 hrs) for human serum at 5th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID562071	Ratio of fAUC to MIC in carbapenemase producing Klebsiella pneumoniae isolate 321-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID422659	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 29 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID373455	Volume of distribution in human colon wall tissue	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID571698	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 6 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID577255	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB125 with PFGE subgroup A1 containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID577251	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB099 with PFGE subgroup H containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID533142	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 ST 376 expressing beta-lactamase SHV-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID510502	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate C1AC9-24 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID428292	Antimicrobial activity against Acinetobacter baumannii BM4579 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID544779	Antibacterial activity against vancomycin-resistant Enterococcus faecalis assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID425978	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID542839	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count me	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID544787	Antibacterial activity against Acinetobacter baumannii assessed as post antibiotic effect at 6 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID521825	Antimicrobial activity against beta-lactam resistant Streptococcus pneumoniae clinical isolate by broth dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
AID428256	Antimicrobial activity against KPC2/3 carbapenemase producing Enterobacter cloacae by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID544783	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID584555	Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID556392	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in MIG level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID588129	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 7 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID542872	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID373466	AUC (0 to 24 hrs) in human colon wall tissue at 95th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID528979	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID571894	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 11 expressing ompA, adeB, adeM, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID601194	Apparent volume of distribution in Sprague-Dawley rat at 1 mg/kg, iv administered as single dose measured after 24 to 48 hrs	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID560058	Antimicrobial activity against ESBL-producing Klebsiella pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID422687	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID543790	Drug level in patient serum at 100 mg, iv followed by 50 mg every 12 hrs after 60 mins post dose	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID559361	Antimicrobial activity against compound-resistant Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID533148	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 ST 327 expressing beta-lactamase TEM-1 and CTX-M-2 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID258273	Antibacterial activity against Staphylococcus aureus Smith	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID528825	Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID206302	In vitro antibacterial activity against Staphylococcus aureus UBMS 88-7 Tet K	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID534361	Antibacterial activity against Acinetobacter baumannii GIL1 isolate harboring intrinsic blaOXA-51/69-like gene by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Carbapenem-resistant Acinetobacter baumannii isolates expressing the blaOXA-23 gene associated with ISAba4 in Belgium.
AID544786	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as post antibiotic effect at 2 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID285167	Antimicrobial activity against catheter-associated biofilm of methicillin-sensitive Staphylococcus aureus assessed as reduction of CFU	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters.
AID495512	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4666 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID544790	Antibacterial activity against Enterobacter cloacae assessed as post antibiotic effect at 2 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID1698684	Antibacterial activity against Escherichia coli ATCC 25922 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID531526	Antibacterial activity against Bacteroides distasonis isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID546354	fCmax/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 144-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID559782	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 0.25 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID546392	Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected in immunocompetent ICR mouse assessed as reduction in bacterial load at 1.56 ug/ml after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID508010	Decrease in sasF gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID511383	Antibacterial activity against vancomycin resistant Enterococcus faecalis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID556179	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL1-beta level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID511393	Antibacterial activity against Levofloxacin resistant Streptococcus pneumoniae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID546340	fAUC in serum of methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse at 1.56 to 400 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID546384	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 156-infected neutropenic ICR mouse at stasis dose	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID556180	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL1-beta level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 6 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID564690	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID577249	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB166 with PFGE subgroup A3 containing carbapenemase OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID521962	Antibacterial activity against Enterobacteriaceae isolate obtained from intra-abdominal infection patient	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.
AID559358	Antimicrobial activity against compound-resistant Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID428269	Antimicrobial activity against Klebsiella sp. by CLSI broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID396032	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID565333	Antibacterial activity against Enterobacter cloacae UCN63 by broth microdilution method after 3 weeks of treatment	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.
AID546371	fAUC/MIC in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse at 50% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID428257	Antimicrobial activity against KPC2 carbapenemase producing Enterobacter cloacae by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID518822	Antibacterial activity against Enterobacteriaceae assessed as resistant breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID559551	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID508352	Increase in ssaA expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID508353	Decrease in tst expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID533139	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 transformant by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID507998	Increase in rplD gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID565085	Cmax in BALB/c mouse infected with Staphylococcus aureus at 50 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID520957	Antimicrobial activity against Corynebacterium jeikeium isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID70922	In vitro antibacterial activity against Escherichia coli J3272 Tet D	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID322778	Antimicrobial activity against Bacteroides vulgatus isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID559801	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 2 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID556399	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL-10 level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID574670	Antimicrobial activity against Escherichia coli isolate 157T expressing beta-lactamase KPC2 and PFGE cluster 3 isolated from urine of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID511391	Antibacterial activity against Citrobacter freundii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID546362	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 147-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID559797	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 0.125 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID498844	Antimicrobial activity against Klebsiella pneumoniae XJ81T expressing TEM-1, SHV-12, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID528837	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID283395	Antimicrobial activity against Nocardia nova after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID560088	Bactericidal activity against Pseudomonas aeruginosa isolate 1037 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID542837	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID508264	Increase in dnaG gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID546359	fAUC/MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 56-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID528983	Antimicrobial activity against Haemophilus influenzae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID373458	AUC (0 to 24 hrs) in human serum at 25th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID544806	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID576593	AUC (0 to 24 hrs) in thigh interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID543121	Antimicrobial activity against Aeromonas caviae assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID581667	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level after 24 hrs in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID521841	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID531529	Antibacterial activity against Bacteroides uniformis isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID553694	Bactericidal activity against Staphylococcus aureus assessed as log reduction in bacterial count	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID322791	Antimicrobial activity against Bacteroides merdae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID546385	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 infected in neutropenic ICR mouse assessed as change in bacterial load after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID511389	Antibacterial activity against Enterobacter cloacae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID428294	Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID510505	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-4 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID533137	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 transformant by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID559563	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID544959	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID498824	Antimicrobial activity against Citrobacter freundii SZ62 expressing IMP-4, TEM-1, CMY-2, qnrS1, aac(6')-Ib-cr by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID425985	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 20 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID524827	Antibacterial activity against erythromycin susceptible Campylobacter sp. assessed as resistance breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID1528455	Antibacterial activity against Haemophilus influenzae assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID562810	Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID508005	Decrease in capG gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID587845	Volume of distribution in Sprague-Dawley rat at 1 mg/kg, iv and 10 mg/kg, po	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID498819	Antimicrobial activity against Klebsiella pneumoniae GZ64T expressing IMP-4 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID396503	Antibacterial activity against tetracycline-susceptible Escherichia coli clinical isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID572142	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 38 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID509841	Antibacterial activity against Salmonella enterica serovar Hadar VA5649 expressing ACYC177 plasmid by both microdilution assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID556406	AUC (0 to 24 hrs) in human serum at 100 mg/kg, iv followed by regimen of 50 mg/kg for every 12 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID565096	Half life in BALB/c mouse infected with Staphylococcus aureus at 25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID543116	Antimicrobial activity against Aeromonas hydrophila assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID577227	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB018 with PFGE subgroup G containing carbapenemase OXA-58 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID507995	Increase in rplK gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID531519	Antibacterial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID508020	Increase in clfB expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID70929	In vitro antibacterial activity against Escherichia coli UBMS 90-4 Tet M	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID519482	Antibacterial activity against Staphylococcus aureus T2019 with G2576T mutation in 23S rRNA genes by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.
AID544534	Antibacterial activity against colistin-susceptible Acinetobacter baumannii clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID373459	AUC (0 to 24 hrs) in human serum at 50th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID561851	Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 322 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID575282	Antimicrobial activity against multiple dug-resistant Acinetobacter baumannii by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID531525	Antibacterial activity against Bacteroides ovatus isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID322785	Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID511305	Antibacterial activity against methicillin resistant coagulase negative Staphylococcus by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID528978	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID511304	Antibacterial activity against ciprofloxacin and methicillin resistant Staphylococcus aureus by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID425987	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 33 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID518817	Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID499065	Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes WH85 deficient in TEM-1, CTX-M-3, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID322779	Antimicrobial activity against Bacteroides caccae isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID322780	Antimicrobial activity against Bacteroides eggerthii isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID511397	Antibacterial activity against Acinetobacter baumannii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID543144	Antimicrobial activity against Salmonella serogroup O7 assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID324879	Inhibition of AdeABC efflux pump protein in Acinetobacter baumannii A24D assessed as ethidium bromide accumulation at 100 uM	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID559561	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID560085	Bactericidal activity against Pseudomonas aeruginosa isolate 796 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID571912	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 20 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID576600	Plasma protein binding diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses measured after 6 hr by ultrafiltration	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID206303	In vitro antibacterial activity against Staphylococcus aureus UBMS 90-1 Tet M	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID508354	Decrease in capC expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID558043	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S6 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID544546	Antibacterial activity against extensively drug-resistant Acinetobacter baumannii clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID511399	Antibacterial activity against Haemophilus influenzae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID428250	Antimicrobial activity against KPC2/3 carbapenemase producing Klebsiella oxytoca by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID528848	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID325409	Antibacterial activity against Acinetobacter haemolyticus	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID1698704	Antibacterial activity against Vancomycin-resistant Enterococcus by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID556398	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL-6 level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID508257	Decrease in dinR gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543114	Antimicrobial activity against Aeromonas hydrophila assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID576988	Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 25 mg/litre at ambient temperature of 35 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID544807	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID558413	Drug level in body fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus MRG3 at 7 mg/kg, sc BID measured on day 7 postdose	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.
AID324873	Antimicrobial activity against Acinetobacter baumannii C75 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID646219	Antibacterial activity against tetracycline-resistant Klebsiella pneumoniae 153	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID524828	Antibacterial activity against erythromycin resistant Campylobacter sp. after 48 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID546118	AUC (0 to 24 hrs) in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 50 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID559565	Bactericidal activity against compound-resistant Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells assessed as decrease in bacterial titer at 4 ug/ml after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID601177	Antimicrobial activity against methicillin-, tetracycline-resistant Staphylococcus aureus isolate 161 harboring tetM gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID496413	Reduction in ospA gene expression in heart base tissue of SCID mouse transplanted with tibiotarsal and heart base tissue from Borrelia burgdorferi infected 50 mg/kg treated mouse	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID581665	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID520963	Antimicrobial activity against Arcanobacterium haemolyticum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID1698693	Antibacterial activity against Haemophilus influenzae ATCC 43095 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID258275	Antibacterial activity against Escherichia coli UBMS 88-1 carrying tetB-resistant determinant	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID543149	Antimicrobial activity against Salmonella serogroup O8 assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID601268	Antimicrobial activity against tetracycline-susceptible Staphylococcus aureus Smith isolate 100 infected in po dosed mouse systemic infection model assessed as survival of mouse administered 60 mins post infection measured after 48 hrs	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID576579	Tmax in plasma of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID587842	Antibacterial activity against Escherichia coli by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1592959	Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 2697/14 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID1698677	Antibacterial activity against Methicillin-resistant Staphylococcus aureus by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID528850	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1528445	Antibacterial activity against Enterobacter aerogenes assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID543146	Antimicrobial activity against Salmonella serogroup O7 assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID576594	Terminal half life in thigh interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID322790	Antimicrobial activity against Bacteroides eggerthii assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID560070	Antimicrobial activity against Klebsiella pneumoniae isolate 5436 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID495514	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4668 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1442633	Antibacterial activity against gram-negative Pseudomonas aeruginosa PA555 by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID509840	Antibacterial activity against Salmonella enterica serovar Hadar VA5649 harboring ramR-5649 mutant gene by both microdilution assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID584565	Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID544814	Antibacterial activity against beta-lactamase deficient and ampicillin-resistant Haemophilus influenzae by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID324851	Antimicrobial activity against Acinetobacter baumannii D54 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID556183	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL-12 level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 6 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID508343	Decrease in capG expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID562057	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 255-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID544795	Antibacterial activity against Escherichia coli assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID562070	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 320-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID1442636	Antibacterial activity against gram-positive Staphylococcus aureus SA161 harboring tet(M) by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID543083	Antibacterial activity against beta-lactamase deficient and ampicillin-resistant Haemophilus influenzae assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID396273	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID559557	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID528842	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID498837	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU8 deficient in SHV-11, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID322792	Antimicrobial activity against Bacteroides stercoris assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID508003	Increase in cspB gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543155	Antimicrobial activity against Salmonella serogroup O9 assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID571904	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 16 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID507990	Increase in tsf gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID544956	Antimicrobial activity against Proteus mirabilis extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID70931	In vitro antibacterial activity against Escherichia coli UBMS 90-5 sensitive	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID322777	Antimicrobial activity against Bacteroides uniformis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID528827	Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID533853	Antibacterial activity against nonpigmented rapidly growing Mycobacterium chelonae after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID576986	Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 1 mg/litre at ambient temperature of 35 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID508348	Increase in icaC expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID577231	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB127 with PFGE subgroup I containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID373460	AUC (0 to 24 hrs) in human serum at 75th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID396504	Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID576970	Antimicrobial activity against Staphylococcus epidermidis isolate OR1 treated in solution at 45 degC after 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID671555	Antibacterial activity against Klebsiella pneumoniae ATCC 13883	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID556403	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in KC level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID559776	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as resistant isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID425964	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 48 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID543169	Antimicrobial activity against Vibrio parahaemolyticus assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID510514	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID584576	Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID520961	Antimicrobial activity against Corynebacterium urealyticum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID583885	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 56 (494) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID544778	Antibacterial activity against beta-lactamase deficient and ampicillin-resistant Haemophilus influenzae assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID520964	Antimicrobial activity against Rhodococcus equi isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID583240	Antibacterial activity against Staphylococcus spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID562062	Ratio of fAUC to MIC in Escherichia coli isolate 120-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID528828	Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1442612	Antibacterial activity against Pseudomonas aeruginosa PA1145 in BALB/c mouse model of lung infection administered as iv bid for 2 to 12 hrs of post-infection measured after 24 hrs	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID428266	Antimicrobial activity against carbapenemase producing Enterobacteriaceae by CLSI broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID565111	Ratio of fAUC (0 to 8 hrs) in epithelial lining fluid to plasma of Staphylococcus aureus-infected BALB/c mouse at 50 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID587844	Clearance in Sprague-Dawley rat at 1 mg/kg, iv and 10 mg/kg, po	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID544785	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID508014	Decrease in clpC gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID572134	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 34 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID511302	Antibacterial activity against methicillin susceptible Staphylococcus aureus by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID529196	Antibacterial activity against ESBL-producing Escherichia coli isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID543129	Antimicrobial activity against Salmonella serotype Choleraesuis assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID546363	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 156-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID1228680	Antibacterial activity against Staphylococcus aureus 101 ATCC 29213 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID559554	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID425968	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 14 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID560092	Bactericidal activity against Klebsiella pneumoniae isolate 5436 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID601191	Cmax in Sprague-Dawley rat at 1 mg/kg, iv administered as single dose measured after 24 to 48 hrs	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID1442615	Antibacterial activity against Pseudomonas aeruginosa PA1145 in BALB/c mouse model of lung infection assessed as reduction in log10CFU per gram of lung at 40 mg/kg, iv bid administered 2 to 12 hrs of post-infection measured after 24 hrs relative to untrea	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID572124	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 29 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID511396	Antibacterial activity against Streptococcus viridans by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID285691	Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID531964	Antibacterial activity against Klebsiella pneumoniae urine isolate A28009 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID571910	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 19 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID575280	Antimicrobial activity against Proteus mirabilis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID544951	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID584800	Volume of distribution in central compartment in patient with community or hospital-acquired pneumonia at 100 mg/kg, iv loading dose followed by 50 mg/kg administered every 12 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
AID671554	Antibacterial activity against Escherichia coli isolate EC155 expressing tetA gene	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID562091	Antibacterial activity against extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 266 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID533151	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 transformant by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID543123	Antimicrobial activity against Aeromonas sobria assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID373453	Volume of distribution in human serum	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID544967	Antimicrobial activity against Proteus mirabilis expressing beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID533856	Antibacterial activity against nonpigmented rapidly growing Mycobacterium mucogenicum after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID322773	Antimicrobial activity against Bacteroides fragilis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID422681	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID511385	Antibacterial activity against vancomycin resistant Enterococcus faecium by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID544798	Antibacterial activity against beta-lactamase deficient and ampicillin-resistant Haemophilus influenzae assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID425977	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID562066	Ratio of fAUC to MIC in Klebsiella pneumoniae isolate 134-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID528834	Antimicrobial activity against CTX-M ESBL producing Escherichia coli assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID581659	Fraction unbound in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID544962	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV and CTX by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID558047	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S10 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID495511	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4665 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID323255	Antimicrobial activity against carbapenem-intermediate or resistant Acinetobacter baumannii isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
AID428268	Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as resistant isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID562063	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Escherichia coli isolate 315-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID510509	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC4AC9-30 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID576584	fCmax in plasma of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID562271	Antimalarial activity against Plasmodium falciparum isolates assessed as parasite growth inhibition after 72 hrs by ELISA based histidine-rich protein 2 in vitro drug susceptibility assay	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID535724	Antibacterial activity against Escherichia coli DH10B by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID543776	Antibacterial activity against Klebsiella pneumoniae assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 2 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID531523	Antibacterial activity against Bacteroides eggerthii isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID520962	Antimicrobial activity against Corynebacterium xerosis isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID1890025	Invivo antibacterial activity against multidrug resistant Acinetobacter baumannii NCTC 13420 infected in mouse thigh infection model assessed as log change in bacterial burden at 20 mg/kg, iv administered at 1 hr post infection and measured after 8 hrs re	2022	Bioorganic & medicinal chemistry letters, 06-01, Volume: 65	Discovery and structure-activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors.
AID565126	Ratio of fAUC to MIC in community-acquired methicillin-resistant Staphylococcus aureus 156-infected BALB/c mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID529832	Bactericidal activity against Acinetobacter baumannii isolate 1826 at 8 ug/ml after 4 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID556181	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL-12 level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 1 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID509833	Antibacterial activity against Salmonella enterica serovar Hadar VA5649 by both microdilution assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID528977	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID325394	AUC at 24 hrs steady state in patient with complicated skin and skin structure infection at 100 mg loading dose followed by 50 mg every 12 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID396265	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID577253	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB113 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID529831	Bactericidal activity against Acinetobacter baumannii isolate 1826 at 8 ug/ml up to 4 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID565119	Ratio of fAUC to MIC in community-acquired methicillin-resistant Staphylococcus aureus 144-infected BALB/c mouse at 505 maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID560504	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate bd4768 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID508279	Decrease in sasF gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543067	Antibacterial activity against Escherichia coli assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID576588	Tmax in wound interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID511386	Antibacterial activity against ciprofloxacin resistant Escherichia coli by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID543157	Antimicrobial activity against Salmonella serogroup O9 assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID543135	Antimicrobial activity against Salmonella serotype Typhimurium assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID577235	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB106 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID646206	Antibacterial activity against Staphylococcus aureus ATCC 101 29213	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID521960	Serum clearance in intra-abdominal infection patient at 100 mg followed by 50 mg every 12 hrs for 5 to 14 days	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.
AID533149	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 transformant by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID560520	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate sh07043 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID396499	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID562095	AUC in ICR mouse at 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID511395	Antibacterial activity against Streptococcus agalactiae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID1329014	Antibacterial activity against Staphylococcus aureus USA400	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID556396	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL-4 level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID565099	Volume of distribution in BALB/c mouse infected with Staphylococcus aureus at 12.5 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID499072	Antimicrobial activity against Citrobacter freundii RJ78 expressing CMY-2, qnrA1, aac(6')-Ib-cr, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID546356	fCmax/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 156-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID575283	Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID576582	Clearance at steady state in plasma of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID325410	Antibacterial activity against Citrobacter koseri	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID511388	Antibacterial activity against Klebsiella pneumoniae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID507980	Decrease in capC gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID546112	Cmax in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 12.5 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID324865	Antimicrobial activity against Acinetobacter baumannii A24D after 4 days in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID576595	Drug penetration in wound interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID544955	Antimicrobial activity against Klebsiella pneumoniae extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1539484	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa ATCC 1744 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID529198	Antibacterial activity against AmpC-producing Escherichia coli assessed as sensitive isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID574682	Antimicrobial activity against Escherichia coli isolate 544 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from abscess of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID559570	Bactericidal activity against compound-resistant Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells assessed as decrease in bacterial titer at 4 ug/ml after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID508342	Decrease in capC expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID575276	Antimicrobial activity against Escherichia coli by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID1698679	Antibacterial activity against community-acquired Methicillin -resistant Staphylococcus aureus ATCC BAA-1556 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID562812	Antimicrobial activity against Escherichia coli DH5[alpha]	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID1395482	Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Klebsiella pneumoniae ATCC BAA-2146 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID508355	Decrease in capG expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID565098	Volume of distribution in BALB/c mouse infected with Staphylococcus aureus at 6.25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID508004	Decrease in tst gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543075	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 2 times MIC concentration for 1 hr followed by	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID559774	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID558048	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S11 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID1329017	Antibacterial activity against Staphylococcus aureus USA400 in mouse thigh wound infection model assessed as reduction in bacterial load administered intravenously as single dose after 2 hrs of infection measured after 24 hrs post treatment	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID584568	Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID562083	Antibacterial activity against Escherichia coli isolate 54 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID546116	Tmax in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 12.5 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID285169	Antimicrobial activity against catheter-associated biofilm of Klebsiella pneumoniae assessed as reduction of CFU	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters.
AID396279	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(D), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID278065	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from deployed military patient	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.
AID576989	Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 1 mg/litre at ambient temperature of 40 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID564685	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID496403	Antimicrobial activity against Borrelia burgdorferi N40	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID565102	Protein binding in Staphylococcus aureus-infected BALB/c mouse serum at 6.25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID546396	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected-immunocompetent ICR mouse at 1.56 ug/ml, sc QD	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID322789	Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID576968	Antimicrobial activity against Staphylococcus aureus isolated from human prosthetic joint infection site by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID283393	Antimicrobial activity against Nocardia abscessus after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID428255	Antimicrobial activity against KPC3 carbapenemase producing Citrobacter freundii by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID577244	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB018 with PFGE subgroup G containing carbapenemase OXA-58 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID428258	Antimicrobial activity against NMC-A carbapenemase producing Enterobacter cloacae by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID576962	Antimicrobial activity against Staphylococcus epidermidis DSM3269 by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID519481	Antibacterial activity against Staphylococcus aureus T991 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.
AID544960	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID507988	Increase in infA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID542876	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by vi	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID562760	Antimicrobial activity against Klebsiella pneumoniae PFGE clone C expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID1698689	Antibacterial activity against Enterococcus faecalis ATCC 29212 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID422673	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 18 passages with levofloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID533858	Antibacterial activity against nonpigmented rapidly growing Mycobacterium alvei after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID543164	Antimicrobial activity against Vibrio vulnificus assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID543163	Antimicrobial activity against Vibrio vulnificus assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID587840	Antibacterial activity against Streptococcus pneumoniae by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID543126	Antimicrobial activity against Aeromonas sobria assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID576967	Antimicrobial activity against Staphylococcus aureus isolated from human preoperative skin by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID529839	Bactericidal activity against Acinetobacter baumannii isolate 1198 at 2 ug/ml after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID543089	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID560501	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gz06040 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID498834	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU3 deficient in DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID422649	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID565118	Ratio of fAUC to MIC in methicillin-susceptible Staphylococcus aureus ATCC 29213-infected BALB/c mouse at 505 maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID528816	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID574678	Antimicrobial activity against Escherichia coli isolate 386T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from wound of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID559784	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID1395498	Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Enterobacter cloacae 13-1 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID508265	Increase in recU gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID544952	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX and SHV by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID562251	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated form patient blood measured after 18 to 24 hrs on day 1 post isolation by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.
AID1442629	Antibacterial activity against gram-positive Enterococcus faecalis EFs327 harboring tet(M) by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID574684	Antimicrobial activity against Escherichia coli isolate 547T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from blood of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID499052	Antimicrobial activity against Escherichia coli PU60T expressing CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID576589	AUC (0 to 24 hrs) in wound interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID425983	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1442639	Antibacterial activity against gram-positive Streptococcus pneumoniae SP160 harboring tet(M) by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID498827	Antimicrobial activity against Citrobacter freundii SZ63T expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID396501	Antibacterial activity against tetracycline-resistant Escherichia coli with single drug resistance determinant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID546374	fAUC/MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 152-infected neutropenic ICR mouse at 50% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID542866	Antibacterial activity against beta-lactamase deficient and ampicillin-resistant Haemophilus influenzae assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID521839	Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID206304	In vitro antibacterial activity against Staphylococcus aureus UBMS 90-3 sensitive	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID258270	Antibacterial activity against Staphylococcus aureus UBMS 90-2 carrying tetM-resistant determinant	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID507993	Increase in rpmI gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID565090	AUC (0 to 24 hrs) in BALB/c mouse infected with Staphylococcus aureus at 6.25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID562081	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 320-infected ICR mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID587841	Antibacterial activity against Haemophilus influenzae by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID533144	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 ST 376 expressing beta-lactamase SHV-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID577261	Antibacterial activity against Multidrug-resistant Acinetobacter baumannii by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID562048	Antibacterial activity against carbapenemase producing Klebsiella pneumoniae isolate 321 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID542874	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID561853	Antibacterial activity against Klebsiella pneumoniae isolate 135 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID507982	Decrease in capG gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID584575	Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID574680	Antimicrobial activity against Escherichia coli isolate 543 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 4 isolated from synovial fluid of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID543781	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed b	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID524829	Antibacterial activity against erythromycin susceptible Campylobacter sp. after 48 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID577254	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB118 with PFGE subgroup B2 containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID425986	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 41 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID577237	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB118 with PFGE subgroup B2 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID562073	Ratio of fAUC to MIC in Escherichia coli isolate 120-infected ICR mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID587839	Antibacterial activity against Staphylococcus aureus by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID581663	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID373609	Penetration ratio, ratio of AUC (0 to 24 hrs) for human colon wall tissue to AUC (0 to 24 hrs) for human serum at 25th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID646233	Apparent volume of distribution in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS-MS analysis	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID544776	Antibacterial activity against Enterobacter cloacae assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID508017	Decrease in TSST1 production in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at after 24 hrs by antibody agglutination assay relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID511398	Antibacterial activity against Pseudomonas aeruginosa by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID565087	Tmax in BALB/c mouse infected with Staphylococcus aureus at 12.5 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID543148	Antimicrobial activity against Salmonella serogroup O8 assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID560059	Antimicrobial activity against AmpC-depressed Enterobacter cloacae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID546404	Plasma protein binding in mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID560502	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gz06051 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID341089	Antimicrobial activity against Clostridium difficile clinical isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
AID571914	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 21 expressing ampC, ompA, adeB, adeM, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID511392	Antibacterial activity against Levofloxacin susceptible Streptococcus pneumoniae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID499058	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX24 deficient in TEM-1, DHA-1, aac(6')-Ib, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID498811	Antimicrobial activity against Escherichia coli ZJ86T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID560508	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b3k5923 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID574672	Antimicrobial activity against Escherichia coli isolate 329T expressing beta-lactamase KPC2 and PFGE cluster 2 isolated from blood of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID322775	Antimicrobial activity against Bacteroides ovatus isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID584572	Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID565335	Antibacterial activity against Enterobacter cloacae UCN62 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.
AID322774	Antimicrobial activity against Bacteroides distasonis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID559800	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID322783	Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID546383	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 147-infected neutropenic ICR mouse at stasis dose	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID577262	Antibacterial activity against Multidrug-resistant Acinetobacter baumannii clinical isolate by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID428274	Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as resistant isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID583241	Antibacterial activity against Acinetobacter spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID560505	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate b2k4781 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID559366	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID283392	Antimicrobial activity against Nocardia otitidiscaviarum after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID546375	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 144-infected neutropenic ICR mouse at 50% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID530814	Antibacterial activity against Klebsiella pneumoniae 11978 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID1698688	Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 51559 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID583234	Antibacterial activity against Escherichia coli by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID543127	Antimicrobial activity against Aeromonas sobria assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID543832	Antibacterial activity against Escherichia coli assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543101	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID532935	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID325402	Antibacterial activity against Streptococcus constellatus	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID543115	Antimicrobial activity against Aeromonas hydrophila assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID1773509	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate M-16 assessed as inhibition of visible growth incubated for 16 to 18 hrs by CLSI method
AID396496	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(B), tet(D) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID601190	Antimicrobial activity against tetracycline-susceptible Staphylococcus aureus Smith isolate 100 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID544957	Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID508351	Decrease in sasF expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543154	Antimicrobial activity against Salmonella serogroup O9 assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID546397	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected-immunocompetent ICR mouse at 3.13 ug/ml, sc QD	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID560074	Antimicrobial activity against Enterobacter cloacae isolate 5420 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID546395	Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected in immunocompetent ICR mouse assessed as reduction in bacterial load at 12.5 ug/ml after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID396028	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID425988	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 29 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID601193	Clearance in Sprague-Dawley rat at 1 mg/kg, iv administered as single dose measured after 24 to 48 hrs	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID583893	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 435 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID583239	Antibacterial activity against Serratia spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID521966	Antibacterial activity against Campylobacter jejuni assessed as resistant isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID588127	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 5 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID508271	Increase in dltB gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID646354	AUClast in Sprague-Dawley rat at 10 mg/kg, po by LC/MS-MS analysis	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID583887	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus isolate 145 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID564686	Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID583886	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus isolate 156 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID509839	Antibacterial activity against Salmonella enterica serovar Hadar VA5649 harboring wild type ramR-2313 gene by both microdilution assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID576598	Drug recovery in thigh interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID1539481	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae ATCC BAA-1705 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID574685	Antimicrobial activity against Escherichia coli isolate 1679 expressing beta-lactamase KPC2, SHV-12, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID559772	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID572146	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii unique clonal group isolate 40 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID546336	Protein binding in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse serum at 0.75 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID499062	Antimicrobial activity against carbapenem-resistant Escherichia coli HX74 deficient in TEM-1, CTX-M-14, CTX-M-3, aac(6')-Ibcr, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID283397	Antimicrobial activity against Nocardia transvalensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID576966	Antimicrobial activity against coagulase-negative Staphylococcus isolated from human preoperative skin by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID1698686	Antibacterial activity against Staphylococcus aureus ATCC 29213 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID560060	Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID646355	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg by LC/MS-MS analysis	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID543137	Antimicrobial activity against Salmonella serotype Typhimurium assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID508253	Increase in mnhE gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID556186	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in INF-gamma level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 6 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID558409	Antibacterial activity against methicillin-resistant Staphylococcus aureus MRG3 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.
AID587834	Antibacterial activity against tetracycline-resistant Streptococcus pneumoniae isolate 160 harboring tet(M) gene by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID542860	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID576608	Ratio of AUC (0 to 24 hrs) in thigh interstitial fluid of diabetic patient with chronic wound infection to MIC for methicillin-resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID428290	Antimicrobial activity against Acinetobacter baumannii BM4454 isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID1698691	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID495518	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4676 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID528975	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID577230	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB110 with PFGE subgroup C containing carbapenemase OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID322776	Antimicrobial activity against Bacteroides thetaiotaomicron isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID533152	Antimicrobial activity against Escherichia coli Genehogs by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID601267	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg administered as single dose	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID560069	Antimicrobial activity against Klebsiella pneumoniae isolate 5427 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID576607	Ratio of AUC (0 to 24 hrs) in wound interstitial fluid of diabetic patient with chronic wound infection to MIC for methicillin-resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID544777	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID66587	In vitro antibacterial activity against Enterococcus ATCC 29212	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID396271	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(B) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID543088	Antibacterial activity against Acinetobacter baumannii assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID546355	fCmax/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 147-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID543152	Antimicrobial activity against Salmonella serogroup O8 assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID542869	Antibacterial activity against Klebsiella pneumoniae assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID508016	Decrease in tst gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543174	Antimicrobial activity against Vibrio cholerae non-O1 assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID562472	Antimicrobial activity against Klebsiella pneumoniae isolate 2641/08 obtained from urine of patient with ischemic cardiomyopathy and several comorbidities by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID542879	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID544949	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC and extended-spectrum beta-lactamase by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID559569	Bactericidal activity against compound-resistant Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells assessed as decrease in bacterial titer at 4 ug/ml after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID531528	Antibacterial activity against Bacteroides caccae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID283399	Antimicrobial activity against Nocardia brasiliensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID576596	Drug penetration in thigh interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID559566	Bactericidal activity against compound-resistant Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells assessed as decrease in bacterial titer at 4 ug/ml after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID428247	Antimicrobial activity against KPC2/3 carbapenemase producing Klebsiella pneumoniae by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID531973	Antibacterial activity against Escherichia coli DH10B expressing KPC-2 CTX-M-2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID508358	Increase in cna expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID528984	Antimicrobial activity against Haemophilus influenzae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID543162	Antimicrobial activity against Vibrio vulnificus assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID577240	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB168 with PFGE subgroup A1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID528849	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID543106	Antibacterial activity against beta-lactamase deficient ampicillin-resistant Haemophilus influenzae assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution b	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID575279	Antimicrobial activity against Serratia marcescens by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID562052	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Escherichia coli isolate 315-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID584567	Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID285689	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID1539480	Antibacterial activity against carbapenem-resistant Escherichia coli BAA-2469 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID543128	Antimicrobial activity against Aeromonas sobria assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID565078	Antibacterial activity against community-acquired methicillin-resistant Staphylococcus aureus 156 by microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID560078	Antimicrobial activity against Pseudomonas aeruginosa isolate 956 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID496412	Reduction in dbpA gene expression in heart base tissue Borrelia burgdorferi infected mouse at 50 mg/kg	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID531719	Antibacterial activity against Bacteroides fragilis isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1528456	Antibacterial activity against Moraxella catarrhalis assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID543131	Antimicrobial activity against Salmonella serotype Choleraesuis assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID556397	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL-5 level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID562054	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Escherichia coli isolate 322-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID283400	Antimicrobial activity against Nocardia sp. after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID1698678	Antibacterial activity against hospital-acquired Methicillin -resistant Staphylococcus aureus ATCC BAA-811 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID544958	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID565088	Tmax in BALB/c mouse infected with Staphylococcus aureus at 25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID601192	AUC (0 to infinity) in Sprague-Dawley rat at 1 mg/kg, iv administered as single dose measured after 24 to 48 hrs	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID1395489	Antibacterial activity against extended-spectrum beta-lactamase harboring Escherichia coli 13-1 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID576605	Ratio of AUC (0 to 24 hrs) in plasma diabetic patient with chronic wound infection to MIC for methicillin-resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID544812	Antibacterial activity against Klebsiella pneumoniae by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID1442632	Antibacterial activity against gram-negative Proteus mirabilis PM385 by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID508000	Increase in rplN gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543080	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543111	Antimicrobial activity against Aeromonas hydrophila assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID498831	Antimicrobial activity against Escherichia coli C600 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID531527	Antibacterial activity against Bacteroides vulgatus isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID572144	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 39 expressing ampC, ompA, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID565106	AUC (0 to 8 hrs) in Staphylococcus aureus-infected BALB/c mouse epithelial lining fluid at 12.5 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID508258	Increase in gapR gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID646232	Clearance in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS-MS analysis	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID560065	Antimicrobial activity against Escherichia coli isolate 5401 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID577234	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB099 with PFGE subgroup H containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID562813	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID498817	Antimicrobial activity against Klebsiella pneumoniae FZ49T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1329036	Cmax in human at 50 mg, iv q12h	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID499064	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX56 deficient in ompC and expressing low levels of ompF DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID428253	Antimicrobial activity against KPC2/3 carbapenemase producing Citrobacter freundii by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID584556	Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID558046	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S9 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID584563	Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID565116	Ratio of fAUC to MIC in hospital-acquired methicillin-resistant Staphylococcus aureus 56-infected BALB/c mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID325395	AUC (24 hrs)/MIC in patient with baseline skin pathogens at 50 mg loading dose followed by 25 mg every 12 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID499057	Antimicrobial activity against Escherichia coli PU102T expressing TEM-1, CTX-M-14, CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID511381	Antibacterial activity against methicillin resistant coagulase negative Staphylococcus epidermidis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID571916	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 22 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID285690	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID422674	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 21 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID584579	Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID577259	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB097 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID396026	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID396268	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(D) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID425966	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID543081	Antibacterial activity against vancomycin-sensitive Enterococcus faecalis assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID531511	Antibacterial activity against Bacteroides merdae assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID543158	Antimicrobial activity against Salmonella serogroup O9 assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID560521	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate xa07029 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID581653	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU after 5 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID258271	Antibacterial activity against Staphylococcus aureus UBMS 90-3	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID646229	Antibacterial activity against tetracycline-resistant Staphylococcus aureus 191 infected in iv dosed CD-1 mouse assessed as dose required for 1 log bacterial burden reduction administered 1.5 hr post infection measured after 24 hrs	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID533861	Antibacterial activity against nonpigmented rapidly growing Mycobacterium septicum after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID531524	Antibacterial activity against Bacteroides spp. isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID498832	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY1 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID544808	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID1442637	Antibacterial activity against gram-positive Staphylococcus aureus SA158 harboring tet(K) by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID70928	In vitro antibacterial activity against Escherichia coli UBMS 88-1 Tet B	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID533852	Antibacterial activity against nonpigmented rapidly growing Mycobacterium abscessus after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID428251	Antimicrobial activity against KPC2 carbapenemase producing Klebsiella oxytoca by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID1329016	Antibacterial activity against Staphylococcus aureus USA300 in mouse thigh wound infection model assessed as reduction in bacterial load administered intravenously as single dose after 2 hrs of infection measured after 24 hrs post treatment	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID562074	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Escherichia coli isolate 315-infected ICR mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID373617	AUC (0 to 24 hrs) in human epithelial lining fluid at 95th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID520956	Antimicrobial activity against Corynebacterium amycolatum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID571896	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 12 expressing ompA, adeB, adeM, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID576597	Drug recovery in wound interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID428295	Antimicrobial activity against Acinetobacter baumannii BM4579 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID543117	Antimicrobial activity against Aeromonas caviae assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID498830	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae WH103 deficient in IMP-4, TEM-1, CTX-M-3, qnrS1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID546345	fT>MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 56-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID508334	Increase in cna expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID671552	Antibacterial activity against tetracycline-resistant Streptococcus pneumoniae isolate 160 expressing tetM gene	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID584573	Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID576590	Terminal half life in wound interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID511382	Antibacterial activity against Enterococcus faecalis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID1228687	Antibacterial activity against tet(A) tetracycline-resistant Escherichia coli 155 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID572138	Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 36 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID396270	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(M) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID422656	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID544953	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID543159	Antimicrobial activity against Vibrio vulnificus assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID507985	Decrease in capB gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID553698	Antibacterial activity against Staphylococcus aureus in murine thigh infection model	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID562051	Ratio of fAUC to MIC in Escherichia coli isolate 120-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID577258	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB173 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID646209	Antibacterial activity against Enterococcus faecalis ATCC 103 29212	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID531967	Antibacterial activity against Klebsiella pneumoniae blood isolate A28008 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID422665	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID508019	Decrease in capG expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID544789	Antibacterial activity against Acinetobacter baumannii assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID422671	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID565101	Volume of distribution in BALB/c mouse infected with Staphylococcus aureus at 50 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID562055	Ratio of fAUC to MIC in Klebsiella pneumoniae isolate 134-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID544773	Antibacterial activity against Acinetobacter baumannii assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID546125	Elimination half life in neutropenic ICR mouse infected with methicillin-sensitive Staphylococcus aureus ATCC 29213 at 6.25 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID1228686	Antibacterial activity against Escherichia coli 107 ATCC 25922 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID428260	Antimicrobial activity against VIM1 carbapenemase producing Enterobacter cloacae by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID543789	Antibacterial activity against Escherichia coli infected in neutropenic mouse thighs assessed as post antibiotic effect	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID583891	Antibacterial activity against vancomycin-heteroresistant Staphylococcus aureus isolate 38 (Mu3) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID583890	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 412 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID496408	Reduction in flaB gene expression in heart base tissue Borrelia burgdorferi infected mouse at 12.5 mg/kg	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID546399	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected-immunocompetent ICR mouse at 12.5 ug/ml, sc QD	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID528831	Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID556175	Antimicrobial activity against Mycoplasma pneumoniae ATCC 29342 infected in BALB/c mouse assessed as decrease in bacterial count in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 6 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID543153	Antimicrobial activity against Salmonella serogroup O9 assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID498812	Antimicrobial activity against Escherichia coli ZJ87 expressing KPC-2, TEM-1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID429077	Antibacterial activity against Escherichia coli J53 by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID511303	Antibacterial activity against ciprofloxacin susceptible and methicillin resistant Staphylococcus aureus by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID528970	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID511390	Antibacterial activity against Proteus mirabilis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID583237	Antibacterial activity against Proteus mirabilis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID546387	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 56 infected in neutropenic ICR mouse assessed as change in bacterial load after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID499049	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU104 deficient in TEM-1, SHV-11, CTX-M-15, qnrS1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID322782	Antimicrobial activity against Bacteroides merdae isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID562252	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated form patient blood measured after 18 to 24 hrs on day 1 isolation stratified with vancomycin MIC < 1.5 mh/L by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.
AID560500	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate sh06024 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID324863	Antimicrobial activity against Acinetobacter baumannii A24D after 4 days by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID508015	Increase in mnhG gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID507978	Increase in fnbA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID562949	Antimicrobial activity against Klebsiella pneumoniae PFGE clone F expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID546391	Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected in neutropenic ICR mouse assessed as change in bacterial load after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID373614	AUC (0 to 24 hrs) in human epithelial lining fluid at 25th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID373613	AUC (0 to 24 hrs) in human epithelial lining fluid at 5th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID528973	Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID583888	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 336 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID542840	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by vi	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID508363	Decrease in sasF expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543084	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID508001	Increase in rpsH gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543093	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by vi	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID1442630	Antibacterial activity against gram-positive Enterococcus faecium EFm404 harboring tet(M) by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID544961	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID544774	Antibacterial activity against Klebsiella pneumoniae assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID558040	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S3 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID1329013	Antibacterial activity against Staphylococcus aureus USA300	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1228689	Antibacterial activity against Proteus mirabilis 385 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID428249	Antimicrobial activity against VIM1 carbapenemase producing Klebsiella pneumoniae by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID341593	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 469 isolate producing KPC2, OXA4 and CTX-M-10 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID581670	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth at pH 5.5 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID565103	Protein binding in Staphylococcus aureus-infected BALB/c mouse serum at 12.5 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID559567	Bactericidal activity against compound-resistant Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells assessed as decrease in bacterial titer at 4 ug/ml after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID510511	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-19 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID546377	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 156-infected neutropenic ICR mouse at 50% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID528822	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID542865	Antibacterial activity against vancomycin-resistant Enterococcus faecalis assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID533855	Antibacterial activity against nonpigmented rapidly growing Mycobacterium fortuitum after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID70927	In vitro antibacterial activity against Escherichia coli PRP1 Tet A	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID576599	Plasma protein binding diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses measured after 1 hr by ultrafiltration	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID528829	Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID326278	Antibacterial activity against methicillin-resistant Staphylococcus aureus at 4 hrs daily exposure for 3 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.
AID498826	Antimicrobial activity against Citrobacter freundii SZ63 expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID520960	Antimicrobial activity against Corynebacterium striatum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID498802	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ18 deficient in KPC-2, SHV-28, DHA-1, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID511394	Antibacterial activity against Streptococcus pyogenes by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID529838	Bactericidal activity against Acinetobacter baumannii isolate 1198 at 1 ug/ml after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID422650	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 38 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID576606	Ratio of fAUC (0 to 24 hrs) in plasma of diabetic patient with chronic wound infection to MIC for methicillin-resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID285156	Antimicrobial activity against Streptococcus pneumoniae ATCC 49619	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.
AID396276	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(B), tet(D) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID546367	fAUC/MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 152-infected neutropenic ICR mouse at 80% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID574679	Antimicrobial activity against Escherichia coli isolate 540 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from synovial fluid of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID544794	Antibacterial activity against Escherichia coli assessed as post antibiotic effect at 6 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543785	Antibacterial activity against Escherichia coli assessed as post antibiotic effect	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID542847	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543100	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID520959	Antimicrobial activity against Corynebacterium pseudodiphtheriticum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID544775	Antibacterial activity against Escherichia coli assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID581666	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID508270	Increase in dltC gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID520965	Antimicrobial activity against Listeria monocytogenes isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID565114	Ratio of fAUC to MIC in community-acquired methicillin-resistant Staphylococcus aureus 156-infected BALB/c mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID563601	Antimicrobial activity against Escherichia coli isolate CKP048 transconjugant harboring beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID498804	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ70 deficient in KPC-2, SHV-11, CTX-M-14, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID575284	Antimicrobial activity against Burkholderia cepacia by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID518816	Antibacterial activity against Acinetobacter genomosp. 3 isolates by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID544954	Antimicrobial activity against Escherichia coli extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID511384	Antibacterial activity against Enterococcus faecium by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID559555	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID562077	Ratio of fAUC to MIC in Klebsiella pneumoniae isolate 134-infected ICR mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID544815	Antibacterial activity against vancomycin-resistant Enterococcus faecalis by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID531970	Antibacterial activity against Klebsiella pneumoniae blood isolate A28006 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID562056	Ratio of fAUC to MIC in Klebsiella pneumoniae isolate 135-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID584570	Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID558418	Antibacterial activity against methicillin-resistant Staphylococcus aureus MRG3 infected in Wistar rat assessed as bacterial load in body fluid at 7 mg/kg, sc BID after 1 day	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.
AID1329019	Antibacterial activity against Haemophilus influenzae PBS981	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID577252	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB106 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID531530	Antibacterial activity against Bacteroides thetaiotaomicron isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID533141	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 transformant by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID325407	Antibacterial activity against Acinetobacter calcoaceticus	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID565276	Ratio of fAUC to MIC in community-acquired methicillin-resistant Staphylococcus aureus 147-infected BALB/c mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID562947	Antimicrobial activity against Klebsiella pneumoniae PFGE clone D expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID496406	Reduction in ospA gene expression assessed as gene copies in per mg of SCID mouse ventricular/quadriceps tissue receiving Borrelia burgdorferi infected nymphal ticks from 50 mg/kg treated mouse	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID556400	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in granulocyte-macrophage colony stimulating factor level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/k	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID508269	Increase in pbp2 gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID1329015	Antibacterial activity against Streptococcus pneumoniae PBS1399	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID577241	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB173 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID565097	Half life in BALB/c mouse infected with Staphylococcus aureus at 50 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID1528447	Antibacterial activity against Escherichia coli assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID584562	Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID562069	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 266-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID556401	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in MIP-1alpha level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID560077	Antimicrobial activity against Pseudomonas aeruginosa isolate 796 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID546372	fAUC/MIC in methicillin-sensitive Staphylococcus aureus ATCC 25923-infected neutropenic ICR mouse at 50% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID577229	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB095 with PFGE subgroup E containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID560515	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 13b16 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID508267	Increase in rpoC gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543118	Antimicrobial activity against Aeromonas caviae assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID574675	Antimicrobial activity against Escherichia coli isolate 360 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from urine of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID565123	Ratio of fAUC to MIC in hospital-acquired methicillin-resistant Staphylococcus aureus 152-infected BALB/c mouse at 505 maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID560091	Bactericidal activity against Klebsiella pneumoniae isolate 5427 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID562050	Half life in ICR mouse at 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID576992	Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 1 mg/litre at ambient temperature of 45 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID543774	Antibacterial activity against Escherichia coli assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID428265	Antimicrobial activity against KPC2/3 carbapenemase producing Escherichia coli by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID583894	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 440 (A6298) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID1528458	Antibacterial activity against Stenotrophomonas maltophilia assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID498807	Antimicrobial activity against Klebsiella pneumoniae ZJ71T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID565104	Protein binding in Staphylococcus aureus-infected BALB/c mouse serum at 25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID520958	Antimicrobial activity against Corynebacterium minutissimum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID498805	Antimicrobial activity against Klebsiella pneumoniae ZJ70T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID559777	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as intermediate isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID530817	Antibacterial activity against Escherichia coli J53 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID588125	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 3 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID543778	Antibacterial activity against Enterobacter cloacae assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 2 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID428254	Antimicrobial activity against KPC2 carbapenemase producing Citrobacter freundii by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID508359	Increase in fnbB expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID542878	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID558051	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S14 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID542851	Antibacterial activity against Klebsiella pneumoniae assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID508361	Increase in isaA expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID560079	Antimicrobial activity against Pseudomonas aeruginosa isolate 1019 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID1395493	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 12-12 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID508277	Decrease in sdrD gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID1329039	Terminal half life in human at 50 mg, iv q12h	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID283391	Antimicrobial activity against Nocardia farcinica after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID577256	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB134 with PFGE subgroup A2 containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID542863	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID533857	Antibacterial activity against nonpigmented rapidly growing Mycobacterium mageritense after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID498815	Antimicrobial activity against Klebsiella pneumoniae FZ47T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID396266	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(B) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID422675	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 25 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID546400	Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected in neutropenic ICR mouse assessed as change in bacterial load at 1.56 ug/ml after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID373465	AUC (0 to 24 hrs) in human colon wall tissue at 75th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID1395494	Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Acinetobacter calcoaceticus 13-1 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID1528452	Antibacterial activity against Serratia marcescens assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID543130	Antimicrobial activity against Salmonella serotype Choleraesuis assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID1773513	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate M-20 assessed as inhibition of visible growth incubated for 16 to 18 hrs by CLSI method
AID510507	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-7 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID560089	Bactericidal activity against Enterobacter cloacae isolate 4073 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID646212	Antibacterial activity against tetracycline-resistant Streptococcus pneumoniae 160	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID422645	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID544810	Antibacterial activity against Enterobacter cloacae by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID561856	Antibacterial activity against extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 320 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID571694	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 3 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1509457	Antivirulence activity in Acinetobacter baumannii 4106 infected Galleria mellonella larvae model assessed as survival rate at 100 mg/kg measured at 24 hrs interval over 4 days	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Second-Generation Tryptamine Derivatives Potently Sensitize Colistin Resistant Bacteria to Colistin.
AID562053	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Escherichia coli isolate 321-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID562064	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Escherichia coli isolate 321-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID528969	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID528981	Antimicrobial activity against Haemophilus influenzae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID562087	Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 322 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID577243	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB096 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID508362	Decrease in mnhG expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID498839	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ66 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID325398	Antibacterial activity against Enterococcus faecium	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID324857	Antimicrobial activity against Acinetobacter baumannii A24A after 4 days by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID546386	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in neutropenic ICR mouse assessed as change in bacterial load after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID562085	Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 315 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID562068	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 255-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID422664	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1773504	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate M-11 assessed as inhibition of visible growth incubated for 16 to 18 hrs by CLSI method
AID1228691	Antibacterial activity against tet(A) tetracycline-resistant Enterobacter cloacae 603 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID1442635	Antibacterial activity against gram-positive Staphylococcus aureus SA101 by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID601184	Antimicrobial activity against tetracycline-resistant Escherichia coli isolate 155 harboring tetA gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID559370	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID543082	Antibacterial activity against vancomycin-resistant Enterococcus faecalis assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID560080	Antimicrobial activity against Pseudomonas aeruginosa isolate 1037 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID576586	fAUC (0 to 24 hrs) in plasma of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID543172	Antimicrobial activity against Vibrio cholerae non-O1 assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID322781	Antimicrobial activity against Bacteroides stercoris isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID559574	Bactericidal activity against compound-resistant Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells assessed as decrease in bacterial titer at 4 ug/ml after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID559550	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1698690	Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 51575 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID575278	Antimicrobial activity against ESBL-production Klebsiella pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID556178	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL1-beta level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 1 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID544784	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID542862	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID559575	Cytotoxicity against african green monkey Vero cells at 4 ug/ml	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID531522	Antibacterial activity against Bacteroides merdae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID543175	Antimicrobial activity against Vibrio cholerae non-O1 assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID1442626	Antibacterial activity against gram-negative Acinetobacter baumannii AB250 by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID278066	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from nondeployed military patient	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.
AID562060	Ratio of fAUC to MIC in carbapenemase producing Klebsiella pneumoniae isolate 321-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID546343	fT>MIC in methicillin-sensitive methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID575281	Antimicrobial activity against Acinetobacter baumannii by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID510506	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-6 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID543068	Antibacterial activity against Klebsiella pneumoniae assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID560086	Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560057	Antimicrobial activity against ESBL-producing Escherichia coli by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID543072	Antibacterial activity against Acinetobacter baumannii assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID396278	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(C), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID577257	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB168 with PFGE subgroup A1 containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID507984	Decrease in cap8H gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543103	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID1528450	Antibacterial activity against Morganella morganii assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID543150	Antimicrobial activity against Salmonella serogroup O8 assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID556393	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in MIG level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 6 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID577228	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB039 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID530815	Antibacterial activity against human urinary Klebsiella pneumoniae UCL-1 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID565105	Protein binding in Staphylococcus aureus-infected BALB/c mouse serum at 50 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID546119	AUC (0 to 24 hrs) in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 25 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID498809	Antimicrobial activity against Klebsiella pneumoniae ZJ99T expressing KPC-2, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID422652	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID556394	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in TNFalpha level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID509834	Antibacterial activity against Escherichia coli DH10B by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID601179	Antimicrobial activity against tetracycline-susceptible Enterococcus faecalis isolate 103 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID422658	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 49 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID559571	Bactericidal activity against compound-resistant Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells assessed as decrease in bacterial titer at 4 ug/ml after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID528823	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID565277	Ratio of fAUC to MIC in hospital-acquired methicillin-resistant Staphylococcus aureus 56-infected BALB/c mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID422661	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 15 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID560503	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 6zjsau7 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID518820	Antibacterial activity against Enterobacteriaceae assessed as susceptibility breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID508338	Increase in mnhG expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID422682	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID499050	Antimicrobial activity against Klebsiella pneumoniae PU104T expressing TEM-1, CTX-M-15 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID543086	Antibacterial activity against Klebsiella pneumoniae assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID571898	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 13 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID521967	Antibacterial activity against Campylobacter coli assessed as resistant isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID533136	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 ST 340 expressing beta-lactamase TEM-1, SHV-11 and OXA-2 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID577248	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB127 with PFGE subgroup I containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID542864	Antibacterial activity against vancomycin-sensitive Enterococcus faecalis assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID532938	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 transformant by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID373619	Penetration ratio, ratio of AUC (0 to 24 hrs) for human epithelial lining fluid to AUC (0 to 24 hrs) for human serum at 25th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID562059	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 320-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID341594	Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 469 transformants producing KPC2, OXA4 and CTX-M-10 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID544548	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID565110	Ratio of fAUC (0 to 8 hrs) in epithelial lining fluid to plasma of Staphylococcus aureus-infected BALB/c mouse at 25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID562951	Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID325403	Antibacterial activity against Streptococcus dysgalactiae	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID324869	Antimicrobial activity against Acinetobacter baumannii B46 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID556411	Ratio of Cmax in human lung to Cmax in human serum at 100 mg/kg, iv followed by 50 mg/kg regimen for every 12 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID542845	Antibacterial activity against vancomycin-resistant Enterococcus faecalis assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count metho	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID575277	Antimicrobial activity against Klebsiella pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID646218	Antibacterial activity against Klebsiella pneumoniae ATCC 109 13883	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID544813	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID499059	Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes PU41 deficient in CTX-M-14, DHA-1, qnrS1, ompC DEc, ompF by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID322786	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID528835	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID508259	Increase in saeR gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID560514	Antimicrobial activity against SCCmec type IV vancomycin-intermediate Staphylococcus aureus isolate 06b41 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID576994	Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 25 mg/litre at ambient temperature of 45 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID521837	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID543143	Antimicrobial activity against Salmonella serogroup O7 assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID508013	Increase in isaA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID542861	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543788	Antibacterial activity against Streptococcus pneumoniae infected in neutropenic mouse thighs assessed as post antibiotic effect	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID529194	Antibacterial activity against AmpC-producing Escherichia coli isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID325416	Antibacterial activity against Proteus mirabilis	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID373623	Protein binding in human serum	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID498814	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ47 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID396277	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(B), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID283398	Antimicrobial activity against Nocardia carnea after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID508254	Increase in mnhF gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID531513	Antibacterial activity against Bacteroides spp. assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID559793	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID325417	Antibacterial activity against Pseudomonas aeruginosa	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID542870	Antibacterial activity against Enterobacter cloacae assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID533150	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 ST 327 expressing beta-lactamase TEM-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID542850	Antibacterial activity against Escherichia coli assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID373621	Penetration ratio, ratio of AUC (0 to 24 hrs) for human epithelial lining fluid to AUC (0 to 24 hrs) for human serum at 75th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID1592958	Antibacterial activity against multi-drug resistant Escherichia coli NMI 3898/15 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID546389	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus isolate 144 infected in neutropenic ICR mouse assessed as change in bacterial load after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID511387	Antibacterial activity against ciprofloxacin susceptible Escherichia coli by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID373454	Clearance in human serum	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID562090	Antibacterial activity against extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 255 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID508007	Decrease in icaC gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID646215	Antibacterial activity against Acinetobacter baumannii ATCC 19606 110	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID574677	Antimicrobial activity against Escherichia coli isolate 386 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from wound of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID543073	Antibacterial activity against Acinetobacter baumannii assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID498841	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SX67 deficient in SHV-2, CTX-M-14, DHA-1, qnrB6/S1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID396033	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID529825	Antimicrobial activity against Acinetobacter baumannii isolate 1198 by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID508008	Increase in fnbB gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID1528448	Antibacterial activity against Klebsiella oxytoca assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID422666	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 35 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID546126	Protein binding in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse serum at 50 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID543077	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID556402	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IP-10 level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID565337	Antibacterial activity against Enterobacter hormaechei isolate UCN63 after 3 weeks of treatment	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.
AID601182	Antimicrobial activity against tetracycline-resistant Streptococcus pneumoniae isolate 160 harboring tetM gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID576604	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by CLSI method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID646207	Antibacterial activity against tetracycline- and methicillin-resistant Staphylococcus aureus 161	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID562061	Ratio of fAUC to MIC in Escherichia coli isolate 54-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID546353	fCmax/MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 152-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID588126	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 4 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID543176	Antimicrobial activity against Vibrio cholerae non-O1 assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID587843	AUC in Sprague-Dawley rat at 1 mg/kg, iv and 10 mg/kg, po	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID558412	Drug level in body fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus MRG3 at 7 mg/kg, sc BID measured on day 4 postdose	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.
AID325411	Antibacterial activity against Citrobacter freundii	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID325399	Antibacterial activity against Staphylococcus aureus	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID396027	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID544803	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as post antibiotic effect at 6 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID587832	Antibacterial activity against tetracycline-resistant Staphylococcus aureus isolate 158 harboring tet(K) gene by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID565112	Ratio of fAUC to MIC in methicillin-susceptible Staphylococcus aureus ATCC 29213-infected BALB/c mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID583242	Antibacterial activity against Pseudomonas aeruginosa by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID528980	Antimicrobial activity against Haemophilus influenzae assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID428291	Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeABC adeIJK double mutant isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID561847	Antibacterial activity against Escherichia coli isolate 54 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID507997	Increase in rplJ gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID562076	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Escherichia coli isolate 322-infected ICR mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID396275	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(B), tet(C) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID528833	Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID546381	fAUC/MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 152-infected neutropenic ICR mouse at stasis dose	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID1442642	Antibacterial activity against gram-negative Escherichia coli EC155 harboring tet(A) by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID530813	Antibacterial activity against Escherichia coli J53 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID546110	Cmax in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 50 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID559568	Bactericidal activity against compound-resistant Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells assessed as decrease in bacterial titer at 4 ug/ml after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID528836	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID543104	Antibacterial activity against vancomycin-sensitive Enterococcus faecalis assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count metho	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID528844	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID543780	Antibacterial activity against Acinetobacter baumannii assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID373620	Penetration ratio, ratio of AUC (0 to 24 hrs) for human epithelial lining fluid to AUC (0 to 24 hrs) for human serum at 50th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID373618	Penetration ratio, ratio of AUC (0 to 24 hrs) for human epithelial lining fluid to AUC (0 to 24 hrs) for human serum at 5th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID546337	Protein binding in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse serum at 1.5 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID422684	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID601189	Antimicrobial activity against tetracycline-resistant Klebsiella pneumoniae isolate 153 harboring tetA gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID543108	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID428271	Antimicrobial activity against Klebsiella sp. assessed as resistant isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID533147	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 transformant by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID422657	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID562049	Ratio of fAUC to MIC in Escherichia coli isolate 54-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID542848	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID542877	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by via	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543125	Antimicrobial activity against Aeromonas sobria assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID559771	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 4sy39 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID507989	Increase in infC gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543161	Antimicrobial activity against Vibrio vulnificus assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID521961	AUC in intra-abdominal infection patient at 100 mg followed by 50 mg every 12 hrs for 5 to 14 days	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.
AID546617	AUC in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID587833	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID584561	Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1329038	Systemic clearance in human at 50 mg, iv q12h	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID558420	Antibacterial activity against methicillin-resistant Staphylococcus aureus MRG3 infected in Wistar rat assessed as decrease in bacterial load in body fluid at 7 mg/kg, sc BID after 8 days	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.
AID584578	Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID528832	Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID542868	Antibacterial activity against Escherichia coli assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID574683	Antimicrobial activity against Escherichia coli isolate 547 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from blood of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID396497	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(B), tet(D), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID565083	Cmax in BALB/c mouse infected with Staphylococcus aureus at 12.5 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID508263	Decrease in polA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID544801	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as post antibiotic effect at 6 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID422644	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 44 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID258269	Antibacterial activity against Staphylococcus aureus UBMS 90-1 carrying tetM-resistant determinant	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID565093	AUC (0 to 24 hrs) in BALB/c mouse infected with Staphylococcus aureus at 50 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID533146	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 ST 376 expressing beta-lactamase SHV-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID559564	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID560522	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gz07030 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID508336	Decrease in icaC expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID544950	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID560509	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b4k6307 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID524826	Antibacterial activity against erythromycin resistant Campylobacter sp. assessed as resistance breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID543784	Antibacterial activity against Enterococcus faecalis assessed as post antibiotic effect	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID671559	Oral bioavailability in CD1 mouse at 30 mg/kg	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID574687	Antimicrobial activity against Escherichia coli DH10B by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID543151	Antimicrobial activity against Salmonella serogroup O8 assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID546349	fT>MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 156-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID560094	Bactericidal activity against Escherichia coli isolate 5411 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID1228683	Antibacterial activity against tet(M) tetracycline-resistant Enterococcus faecalis 327 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID508266	Increase in topA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID396269	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID543165	Antimicrobial activity against Vibrio parahaemolyticus assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID498842	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY75 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID584564	Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID529824	Antimicrobial activity against Acinetobacter baumannii isolate 853 by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID507987	Increase in infB gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID560517	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 07b63 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID341596	Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID558417	Antibacterial activity against methicillin-resistant Staphylococcus aureus MRG3 assessed as log decrease in bacterial count at 1 to 4 ug/ml by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.
AID560499	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 5zjsau3 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID544791	Antibacterial activity against Enterobacter cloacae assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID373456	Volume of distribution in human lung	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID556408	Cmax in neutropenic ICR/Swiss mouse infected with Streptococcus pneumoniae at 3 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID498838	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SZ61 deficient in TEM-1, SHV-1a, CMY-2, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID572122	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 28 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID542849	Antibacterial activity against Escherichia coli assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID565334	Antibacterial activity against Enterobacter cloacae UCN63 by Etest after 3 weeks of treatment	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.
AID508345	Decrease in clpC expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID558414	Drug level in plasma of Wistar rat infected with methicillin-resistant Staphylococcus aureus MRG3 at 7 mg/kg, sc BID measured on day 4 postdose	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.
AID1528454	Antibacterial activity against Burkholderia cepacia assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID373615	AUC (0 to 24 hrs) in human epithelial lining fluid at 50th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID546357	fAUC/MIC in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID601188	Antimicrobial activity against tetracycline-susceptible Klebsiella pneumoniae isolate 109 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID499071	Antimicrobial activity against Klebsiella pneumoniae WH97 expressing SHV-33, aac(6')-Ib, ompK35 DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID572140	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 37 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID560510	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b5k3529 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID544963	Antimicrobial activity against Klebsiella pneumoniae expressing extended-spectrum beta-lactamase and beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID508340	Increase in ssaA expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID646234	Elimination half life in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS-MS analysis	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID542842	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID324876	Inhibition of AdeABC efflux pump protein in Acinetobacter baumannii D54 assessed as ethidium bromide accumulation at 100 uM	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID323257	Bactericidal activity against carbapenem-resistant Acinetobacter baumannii AA557 by time kill curve analysis	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
AID543132	Antimicrobial activity against Salmonella serotype Choleraesuis assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID576602	fAUC (0 to 24 hrs) to MIC for Staphylococcus aureus infected in thigh of ICR mouse	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID1228690	Antibacterial activity against Pseudomonas aeruginosa 555 BAA-47 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID584797	Clearance in patient with community or hospital-acquired pneumonia at 100 mg/kg, iv loading dose followed by 50 mg/kg administered every 12 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
AID546614	Antimicrobial activity against carbapenem-intermediate,-resistant Acinetobacter baumannii assessed as decrease in bacterial count at 0.6 times of MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID571890	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 9 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID508357	Decrease in clpC expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID559572	Bactericidal activity against compound-resistant Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells assessed as decrease in bacterial titer at 4 ug/ml after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID396029	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID508356	Decrease in clfB expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID429078	Antibacterial activity against Escherichia coli J53 expressing Klebsiella pneumoniae Greece blaKPC-2 gene by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID544796	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as post antibiotic effect at 6 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count meth	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543078	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID528824	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID562072	Ratio of fAUC to MIC in Escherichia coli isolate 54-infected ICR mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID428293	Antimicrobial activity against Acinetobacter baumannii BM4651 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID571920	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 24 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID546369	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 147-infected neutropenic ICR mouse at 80% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID1395491	Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Klebsiella pneumoniae 13-1 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID562950	Antimicrobial activity against Klebsiella oxytoca expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID588123	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 1 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID565124	Ratio of fAUC to MIC in methicillin-susceptible Staphylococcus aureus ATCC 29213-infected BALB/c mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID576587	Cmax in wound interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID325393	AUC at 24 hrs steady state in patient with complicated skin and skin structure infection at 50 mg loading dose followed by 25 mg every 12 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID528821	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID531515	Antibacterial activity against Bacteroides distasonis assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID528830	Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID528838	Antimicrobial activity against vancomycin-resistant Enterococcus sp. assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID546405	Plasma protein binding in human	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID498840	Antimicrobial activity against Klebsiella pneumoniae GZ66T expressing SHV-11, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID587846	Half life in Sprague-Dawley rat at 1 mg/kg, iv and 10 mg/kg, po	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID556176	Antimicrobial activity against Mycoplasma pneumoniae ATCC 29342 infected in BALB/c mouse assessed as decrease in bacterial infection-induced lung histopathology at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID422672	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 19 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID425969	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 20 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID577233	Antibacterial activity against intI1-negative tigecycline-intermediate Acinetobacter baumannii AB098 with PFGE subgroup F containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID508250	Decrease in sodA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID495509	Antibacterial activity against Acinetobacter baumannii BM4587 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID496407	Reduction in flaB gene expression in heart base tissue Borrelia burgdorferi infected mouse at 50 mg/kg	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID495515	Antibacterial activity against Acinetobacter baumannii CIP70-10 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID510510	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-18 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID543113	Antimicrobial activity against Aeromonas hydrophila assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID576987	Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 5 mg/litre at ambient temperature of 35 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID529833	Bactericidal activity against Acinetobacter baumannii isolate 1826 at 2 ug/ml up to 4 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID428267	Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as susceptible isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID560498	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 16 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID509837	Antibacterial activity against Escherichia coli DH10B expressing Tn1721-tet(A) carrying plasmid SK2 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID574681	Antimicrobial activity against Escherichia coli isolate 543T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from synovial fluid of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID558042	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S5 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID546401	Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected in neutropenic ICR mouse assessed as change in bacterial load at 3.13 ug/ml after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID543156	Antimicrobial activity against Salmonella serogroup O9 assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID498808	Antimicrobial activity against Klebsiella pneumoniae ZJ99 expressing KPC-2, CTX-M-3, qnrS1, ompK35 DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID499048	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ83 deficient in SHV-11, CTX-M-14, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID543092	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count me	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID533138	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 ST 340 expressing beta-lactamase TEM-1 and SHV-11 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID671553	Antibacterial activity against Escherichia coli ATCC 25922 isolate 107	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID556391	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in MIG level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 1 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID1228694	Antibacterial activity against Burkholderia cenocepacia 240 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID571888	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 8 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID396500	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates without tet(B) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID561931	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate VA-566/00 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID508268	Increase in nusG gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID496409	Reduction in arp gene expression in heart base tissue Borrelia burgdorferi infected mouse at 50 mg/kg	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID508344	Decrease in clfB expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID531514	Antibacterial activity against Bacteroides ovatus assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID499069	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ91 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID495516	Antibacterial activity against multidrug-resistant Acinetobacter baumannii AYE by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID422651	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 26 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1395495	Antibacterial activity against carbapenem-resistant Acinetobacter calcoaceticus 12-6 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID324855	Antimicrobial activity against Acinetobacter baumannii A24 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID560073	Antimicrobial activity against Enterobacter cloacae isolate 4073 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID543091	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID571902	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 15 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID671550	Antibacterial activity against tetracycline-resistant Staphylococcus aureus isolate SA158 expressing TetK gene	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID528968	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID601178	Antimicrobial activity against tetracycline-resistant Staphylococcus aureus isolate 158 harboring tetK gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID543171	Antimicrobial activity against Vibrio cholerae non-O1 assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID325415	Antibacterial activity against Klebsiella pneumoniae	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID373463	AUC (0 to 24 hrs) in human colon wall tissue at 25th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID508262	Decrease in mecI gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID544966	Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID565080	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 56 by microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID544804	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID577238	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB125 with PFGE subgroup A1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID510512	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate W2AC8-S10 expressing OXA-51	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID560523	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gs07022 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID574671	Antimicrobial activity against Escherichia coli isolate 329 expressing beta-lactamase KPC2, CTX-M-2, TEM and PFGE cluster 2 isolated from blood of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID543096	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID559792	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 0.5 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID542856	Antibacterial activity against Acinetobacter baumannii assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID508012	Increase in ssaA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID498823	Antimicrobial activity against Klebsiella pneumoniae WH77T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID581656	Antibacterial activity against revertant Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1528444	Antibacterial activity against Citrobacter freundii assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID601269	Antimicrobial activity against tetracycline-susceptible Staphylococcus aureus Smith isolate 100 infected in iv dosed mouse systemic infection model assessed as survival of mouse administered 60 mins post infection measured up to 48 hrs	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID546398	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected-immunocompetent ICR mouse at 6.25 ug/ml, sc QD	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID577239	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB134 with PFGE subgroup A2 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID561849	Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 315 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID558050	Antimicrobial activity against blaKPC-positive Klebsiella oxytoca S13 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID576964	Antimicrobial activity against Staphylococcus aureus ATCC 29213 by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID581655	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID587837	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID559369	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID542858	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 2 times MIC concentration for 1 hr followed by	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID531520	Antibacterial activity against Bacteroides fragilis assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID285166	Antimicrobial activity against catheter-associated biofilm of methicillin-resistant Staphylococcus aureus assessed as reduction of CFU	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters.
AID425973	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID396272	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(D) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID565091	AUC (0 to 24 hrs) in BALB/c mouse infected with Staphylococcus aureus at 12.5 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID326276	Antibacterial activity against methicillin-resistant Staphylococcus aureus after 24 hrs by silicone disk biofilm colonization method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.
AID428272	Antimicrobial activity against carbapenemase producing Enterobacter sp. by CLSI broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID499060	Antimicrobial activity against Enterobacter aerogenes PU41T expressing CTX-M-14, DHA-1, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID323256	Antimicrobial activity against carbapenem-intermediate or resistant Acinetobacter baumannii assessed as percent susceptible isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
AID507979	Decrease in icaC gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID565113	Ratio of fAUC to MIC in community-acquired methicillin-resistant Staphylococcus aureus 144-infected BALB/c mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID1528453	Antibacterial activity against Acinetobacter baumannii assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID422882	Antimicrobial activity against Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID546117	Tmax in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 6.25 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID324877	Inhibition of AdeABC efflux pump protein in Acinetobacter baumannii B46 assessed as ethidium bromide accumulation at 100 uM	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID556404	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in MCP-1 level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID646230	Antibacterial activity against tetracycline-resistant Staphylococcus aureus 191 infected in iv dosed CD-1 mouse assessed as dose required for 3 log bacterial burden reduction administered 1.5 hr post infection measured after 24 hrs	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID530816	Antibacterial activity against Escherichia coli J53 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID562948	Antimicrobial activity against Klebsiella pneumoniae PFGE clone E expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID498820	Antimicrobial activity against Klebsiella pneumoniae WH76 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID587838	Inhibition of protein synthesis in Escherichia coli S30 extract by coupled transcription/translation assay	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID546127	Protein binding in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse serum at 25 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID587847	Oral bioavailability in Sprague-Dawley rat at 1 mg/kg, iv and 10 mg/kg, po	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1539482	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae ATCC BAA-2146 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID546388	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 152 infected in neutropenic ICR mouse assessed as change in bacterial load after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID546351	fCmax/MIC in methicillin-sensitive Staphylococcus aureus ATCC 25923-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID583236	Antibacterial activity against Klebsiella spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID498818	Antimicrobial activity against Klebsiella pneumoniae GZ64 expressing IMP-4, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID508341	Decrease in tst expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID373622	Penetration ratio, ratio of AUC (0 to 24 hrs) for human epithelial lining fluid to AUC (0 to 24 hrs) for human serum at 95th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID428264	Antimicrobial activity against SME1 carbapenemase producing Serratia marcescens by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID543079	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID428263	Antimicrobial activity against KPC2/3 carbapenemase producing Serratia marcescens by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID543119	Antimicrobial activity against Aeromonas caviae assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID562089	Antibacterial activity against Klebsiella pneumoniae isolate 135 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID560066	Antimicrobial activity against Escherichia coli isolate 5411 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID559553	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID428248	Antimicrobial activity against KPC2 carbapenemase producing Klebsiella pneumoniae by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID1442641	Antibacterial activity against gram-negative Escherichia coli EC107 by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID508261	Decrease in clpC gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID1228684	Antibacterial activity against tet(M) tetracycline-resistant Enterococcus faecium 404 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID559371	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID544536	Antibacterial activity against colistin-resistant Acinetobacter baumannii clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID587848	Antibacterial activity against Staphylococcus aureus ATCC 13709 infected in iv dosed mouse septicemia model assessed as mouse protection after 48 hrs	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID565115	Ratio of fAUC to MIC in community-acquired methicillin-resistant Staphylococcus aureus 147-infected BALB/c mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID601185	Antimicrobial activity against tetracycline-susceptible Acinetobacter baumannii isolate 110 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID507977	Increase in fnbB gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID531516	Antibacterial activity against Bacteroides caccae assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID559798	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 0.25 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID542838	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID528818	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID587831	Antibacterial activity against tetracycline-resistant Staphylococcus aureus isolate 161 harboring tet(M) gene by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID543791	Half life in patient serum at 100 mg, iv followed by 50 mg every 12 hrs after 60 mins post dose	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID425993	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID546616	Antimicrobial activity against carbapenem-intermediate,-resistant Acinetobacter baumannii assessed as decrease in bacterial count at 0.8 times of MIC after 48 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID543140	Antimicrobial activity against Salmonella serotype Typhimurium assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID646214	Antibacterial activity against tetracycline-resistant Escherichia coli 155	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID498845	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU105 deficient TEM-1, SHV-12, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID425994	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID562093	Antibacterial activity against carbapenemase producing Klebsiella pneumoniae isolate 321 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID584574	Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID544772	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID559559	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID561850	Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 321 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID324853	Antimicrobial activity against Acinetobacter baumannii A24 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID532936	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 transformant by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID571886	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 7 expressing ampC, ompA, adeB, adeM, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID498836	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU5 deficient in SHV-12, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID543782	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 2 times MIC concentration for 1 hr followed by	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID546358	fAUC/MIC in methicillin-sensitive Staphylococcus aureus ATCC 25923-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID543777	Antibacterial activity against Enterobacter cloacae assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID544782	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID576580	AUC (0 to 24 hrs) in plasma of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID571906	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 17 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID584566	Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID543085	Antibacterial activity against Escherichia coli assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID565108	AUC (0 to 8 hrs) in Staphylococcus aureus-infected BALB/c mouse epithelial lining fluid at 50 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID508002	Decrease in asp23 gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID544792	Antibacterial activity against Klebsiella pneumoniae assessed as post antibiotic effect at 2 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID508255	Decrease in icaR gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID533140	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 ST 376 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID559573	Bactericidal activity against compound-resistant Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells assessed as decrease in bacterial titer at 4 ug/ml after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID544809	Antibacterial activity against Acinetobacter baumannii by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543133	Antimicrobial activity against Salmonella serotype Choleraesuis assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID373611	Penetration ratio, ratio of AUC (0 to 24 hrs) for human colon wall tissue to AUC (0 to 24 hrs) for human serum at 75th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID646227	Antibacterial activity against tetracycline-resistant Escherichia coli 133 infected in iv dosed CD-1 mouse assessed as protection from infection administered 1 hr post infection measured after 24 hrs	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID562082	Ratio of fAUC to MIC in carbapenemase producing Klebsiella pneumoniae isolate 321-infected ICR mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID671560	Oral bioavailability in rat	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID429079	Antibacterial activity against Klebsiella pneumoniae Greece producing KPC-2 beta-lactamase by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID428261	Antimicrobial activity against KPC3 carbapenemase producing Enterobacter gergoviae by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID498822	Antimicrobial activity against Klebsiella pneumoniae WH77 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID373610	Penetration ratio, ratio of AUC (0 to 24 hrs) for human colon wall tissue to AUC (0 to 24 hrs) for human serum at 50th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID565089	Tmax in BALB/c mouse infected with Staphylococcus aureus at 50 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID584559	Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID546402	Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected in neutropenic ICR mouse assessed as change in bacterial load at 6.25 ug/ml after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID559802	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 4 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID428252	Antimicrobial activity against KPC3 carbapenemase producing Klebsiella oxytoca by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID1228688	Antibacterial activity against Klebsiella pneumoniae 457 harboring CTX-M-15 gene assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID646235	Elimination half life in Sprague-Dawley rat at 10 mg/kg, po by LC/MS-MS analysis	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID556405	Cmax in human serum at 100 mg/kg, iv followed by regimen of 50 mg/kg for every 12 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID572128	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 31 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID543107	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID498843	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae XJ81 deficient in TEM-1, SHV-12, DHA-1, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID556410	Antimicrobial activity against Mycoplasma pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID543105	Antibacterial activity against vancomycin-resistant Enterococcus faecalis assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count metho	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID646213	Antibacterial activity against Escherichia coli ATCC 107 25922	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID373616	AUC (0 to 24 hrs) in human epithelial lining fluid at 75th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID422688	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID546347	fT>MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 144-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID560519	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate zj07028 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID576601	Plasma protein binding diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses measured after 12 hr by ultrafiltration	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID498816	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ49 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1773512	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate M-19 assessed as inhibition of visible growth incubated for 16 to 18 hrs by CLSI method
AID524593	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
AID556177	Antimicrobial activity against Mycoplasma pneumoniae ATCC 29342 infected in BALB/c mouse assessed as decrease in bacterial infection-induced parenchymal cell histopathology at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured af	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID572132	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 33 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1395497	Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Enterobacter cloacae CDC1000654 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID508273	Increase in isaA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID601186	Antimicrobial activity against tetracycline-susceptible Pseudomonas aeruginosa isolate 111 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID562088	Antibacterial activity against Klebsiella pneumoniae isolate 134 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID574669	Antimicrobial activity against Escherichia coli isolate 157 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 3 isolated from urine of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID584571	Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID543087	Antibacterial activity against Enterobacter cloacae assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543112	Antimicrobial activity against Aeromonas hydrophila assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID531512	Antibacterial activity against Bacteroides eggerthii assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1442627	Antibacterial activity against gram-negative Stenotrophomonas maltophilia SM256 by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID563602	Antimicrobial activity against lacZ-negative, Nalidixic acid-, rifampicin-resistant Escherichia coli EC600 by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID496405	Antimicrobial activity against Borrelia burgdorferi B31	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID543098	Antibacterial activity against vancomycin-resistant Enterococcus faecalis assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count metho	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID576583	Volume of distribution at steady state in plasma of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID571696	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 5 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID507992	Increase in fus gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID528819	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID542846	Antibacterial activity against beta-lactamase deficient ampicillin-resistant Haemophilus influenzae assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution b	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID428259	Antimicrobial activity against IMP1 carbapenemase producing Enterobacter cloacae by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID533859	Antibacterial activity against nonpigmented rapidly growing Mycobacterium smegmatis after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID559562	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID507983	Decrease in capD gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID646217	Antibacterial activity against Enterobacter cloacae ATCC 108 13047	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID671548	Antibacterial activity against tetracycline-susceptible Staphylococcus aureus ATCC 13709 Smith isolate SA100	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID285688	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID583896	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 454 (NRS404) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID584577	Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID508275	Increase in sbi gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID559360	Antimicrobial activity against compound-susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID508260	Increase in sarA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID325406	Antibacterial activity against Streptococcus pyogenes	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID646236	AUClast in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS-MS analysis	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID559372	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID543141	Antimicrobial activity against Salmonella serogroup O7 assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID546370	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 156-infected neutropenic ICR mouse at 80% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID562474	Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase SHV-12 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID576993	Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 5 mg/litre at ambient temperature of 45 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID544780	Antibacterial activity against vancomycin-sensitive Enterococcus faecalis assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID498806	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ71 deficient in KPC-2, TEM-1, SHV-11, CTX-M-14, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID560511	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b5k3578 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID601112	Antimicrobial activity against tetracycline-susceptible Staphylococcus aureus isolate 101 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID499053	Antimicrobial activity against carbapenem-resistant Escherichia coli PU96 deficient in TEM-1, CTX-M-14, CMY-2, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID561934	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate RUH134 harboring plasmid ABVA01 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID577242	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB097 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID562086	Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 321 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID528845	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID496415	Reduction in beta-Actin gene expression in heart base tissue Borrelia burgdorferi infected mouse at 12.5 mg/kg	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID499066	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ88 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID533854	Antibacterial activity against nonpigmented rapidly growing Mycobacterium peregrinum after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID546113	Cmax in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 6.25 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID528976	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID542854	Antibacterial activity against Enterobacter cloacae assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 2 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID601180	Antimicrobial activity against tetracycline-resistant Enterococcus faecalis isolate 159 harboring teM gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID396502	Antibacterial activity against tetracycline-resistant Escherichia coli with multiple drug resistance determinant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID499061	Antimicrobial activity against carbapenem-resistant Escherichia coli PU43 deficient in TEM-1, CTX-M-14, aac(6')-Ib, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID546341	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 56 infected in neutropenic ICR mouse assessed as decrease in bacterial density at 1.56 to 400 mg/kg, sc after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID546361	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 144-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID1528449	Antibacterial activity against Klebsiella pneumoniae assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID528974	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID546394	Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected in immunocompetent ICR mouse assessed as reduction in bacterial load at 6.25 ug/ml after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID499063	Antimicrobial activity against Escherichia coli HX74T expressing CTX-M-3 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID325396	AUC (24 hrs)/MIC in patient with baseline skin pathogens at 100 mg loading dose followed by 50 mg every 12 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID324875	Inhibition of AdeABC efflux pump protein in Acinetobacter baumannii A24 assessed as ethidium bromide accumulation at 100 uM	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1442628	Antibacterial activity against gram-negative Burkholderia cenocepacia BC240 by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID529826	Antimicrobial activity against Acinetobacter baumannii isolate 1826 by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID544781	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as sub-MIC effect at 0.2 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID522125	Antibacterial activity against Campylobacter sp. assessed as resistance breakpoint by EUCAST method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID571688	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 1 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID498810	Antimicrobial activity against carbapenem-resistant Escherichia coli ZJ86 deficient in KPC-2, TEM-1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID325412	Antibacterial activity against Enterobacter cloacae	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID532937	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID558045	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S8 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID498829	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae RJ94 deficient in IMP-4, TEM-1, CTX-M-3, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID544965	Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID572120	Antimicrobial activity against Acinetobacter baumannii lambda clonal group isolate 27 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID577245	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB039 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID576603	Ratio of AUC (0 to 24 hrs) in patient with complicated skin and skin structure infections to MIC for Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID543074	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed b	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID542871	Antibacterial activity against Acinetobacter baumannii assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID559363	Antimicrobial activity against compound-susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID587835	Antibacterial activity against Escherichia coli ATCC 25922 by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID508021	Decrease in clpC expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID671551	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolate 106	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID499056	Antimicrobial activity against carbapenem-resistant Escherichia coli PU102 deficient in TEM-1, CTX-M-14, CMY-2, aac(6')-Ib, ompC DEc, ompF by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID562084	Antibacterial activity against Escherichia coli isolate 120 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID581654	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in absence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID583892	Antibacterial activity against vancomycin-heteroresistant Staphylococcus aureus isolate 443 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID565077	Antibacterial activity against community-acquired methicillin-resistant Staphylococcus aureus 144 by microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID581657	Antibacterial activity against normal phenotype Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID577246	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB095 with PFGE subgroup E containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID1228681	Antibacterial activity against methicillin-resistant, tet(M) tetracycline-resistant Staphylococcus aureus 161 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID559786	Antimicrobial activity against heterogeneous vancomycin-susceptible Staphylococcus aureus assessed as resistant isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID543173	Antimicrobial activity against Vibrio cholerae non-O1 assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID546115	Tmax in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 25 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID576990	Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 5 mg/litre at ambient temperature of 40 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID546122	Elimination half life in neutropenic ICR mouse infected with methicillin-sensitive Staphylococcus aureus ATCC 29213 at 50 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID396498	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(B), tet(D), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID543160	Antimicrobial activity against Vibrio vulnificus assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID508339	Decrease in sasF expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID425980	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID542873	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID565086	Tmax in BALB/c mouse infected with Staphylococcus aureus at 6.25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID543122	Antimicrobial activity against Aeromonas caviae assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID576591	Cmax in thigh interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID646228	Antibacterial activity against tetracycline-resistant Escherichia coli 133 infected in iv dosed CD-1 mouse assessed as reduction in bacterial burden administered 1 hr post infection measured after 24 hrs	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID546365	fAUC/MIC in methicillin-sensitive Staphylococcus aureus ATCC 25923-infected neutropenic ICR mouse at 80% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID581658	Cmax in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1228685	Antibacterial activity against tet(M) tetracycline-resistant Streptococcus pneumoniae 160 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID324859	Antimicrobial activity against Acinetobacter baumannii A24B after 4 days by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID529195	Antibacterial activity against ESBL-producing Escherichia coli assessed as sensitive isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID562759	Antimicrobial activity against Klebsiella pneumoniae PFGE clone B expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID499047	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ69 deficient in SHV-28, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID543124	Antimicrobial activity against Aeromonas sobria assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID544542	Cmax in human serum at 100 mg/kg, iv bolus dose followed by dose regimen of 50 mg/kg every 12 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID508364	Increase in ssaA expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID646211	Antibacterial activity against Streptococcus pneumoniae ATCC 106 49619	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID562065	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Escherichia coli isolate 322-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID528817	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID560513	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b6k7974 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID425975	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID587830	Antibacterial activity against wild type Staphylococcus aureus Smith ATCC 13709 by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1592960	Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 3081/09 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID1228682	Antibacterial activity against tet(K) tetracycline-resistant Staphylococcus aureus 158 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID601183	Antimicrobial activity against tetracycline-susceptible Escherichia coli isolate 107 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID508360	Decrease in icaC expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 15 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID325418	Antibacterial activity against Serratia marcescens	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID544964	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase DHA by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID528839	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID565081	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus 152 by microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID373457	AUC (0 to 24 hrs) in human serum at 5th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID508346	Increase in cna expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID529835	Bactericidal activity against Acinetobacter baumannii isolate 853 at 0.06 ug/ml at 6 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID521843	Antibacterial activity against Escherichia coli J53 by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID559799	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 0.5 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID560516	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 11b091 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID544799	Antibacterial activity against vancomycin-resistant Enterococcus faecalis assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID576585	fTmax in plasma of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID646208	Antibacterial activity against tetracycline-resistant Staphylococcus aureus 158	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID528971	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID425972	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID546348	fT>MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 147-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID496410	Reduction in arp gene expression in heart base tissue Borrelia burgdorferi infected mouse at 12.5 mg/kg	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID533862	Antibacterial activity against nonpigmented rapidly growing Mycobacterium wolinskyi after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID325397	Antibacterial activity against Enterococcus faecalis	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID544797	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count met	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID560507	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b2k3421 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID560087	Bactericidal activity against Pseudomonas aeruginosa isolate 1019 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID531517	Antibacterial activity against Bacteroides vulgatus assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID543071	Antibacterial activity against Enterobacter cloacae assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 2 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID565076	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID498803	Antimicrobial activity against Klebsiella pneumoniae ZJ18T expressing KPC-2, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID588128	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 6 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID1329018	Antibacterial activity against Streptococcus pneumoniae PBS1399 infected in mouse assessed as protection against bacterial infection by measuring mouse survival administered intravenously as single dose after 2 hrs of infection measured on day 7	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID546393	Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected in immunocompetent ICR mouse assessed as reduction in bacterial load at 3.13 ug/ml after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID1329020	Antibacterial activity against Haemophilus influenzae PBS981 infected in CD-1 mouse assessed as reduction in bacterial load in lungs administered intravenously as single dose after 2 hrs of infection measured after 24 hrs post treatment	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID584554	Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID531510	Antibacterial activity against Bacteroides stercoris assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID671556	Antibacterial activity against Staphylococcus aureus ATCC 13709 infected in CD-1 mouse assessed as increase in survival at 3 mg/kg, iv administered as single dose 1 hr post infection measured after 48 hrs post infection	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID543070	Antibacterial activity against Enterobacter cloacae assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID542867	Antibacterial activity against amoxicillin, clavulanate-resistant Haemophilus influenzae expressing beta-lactamase assessed as sub-MIC effect at 0.3 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID543787	Antibacterial activity against Enterobacter cloacae assessed as post antibiotic effect	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID565094	Half life in BALB/c mouse infected with Staphylococcus aureus at 6.25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID546129	Protein binding in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse serum at 6.25 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID562094	Cmax in ICR mouse at 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID1773505	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate M-12 assessed as inhibition of visible growth incubated for 16 to 18 hrs by CLSI method
AID1528451	Antibacterial activity against Proteus mirabilis assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID546376	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 147-infected neutropenic ICR mouse at 50% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID558052	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S15 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID496414	Reduction in oppA-2 gene expression in heart base tissue Borrelia burgdorferi infected mouse at 50 mg/kg	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID559556	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID558041	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S4 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID559796	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 16 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID571924	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 26 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID373461	AUC (0 to 24 hrs) in human serum at 95th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID587849	Antibacterial activity against Escherichia coli ATCC 25922 infected in iv dosed mouse septicemia model assessed as mouse protection after 48 hrs	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID509835	Antibacterial activity against Escherichia coli DH10B harboring Tn1721-tet(A) carrying plasmid by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID562058	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 266-infected ICR mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID508276	Increase in sstD gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID533145	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 transformant by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID546342	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus isolate 156 infected in neutropenic ICR mouse assessed as decrease in bacterial density at 1.56 to 400 mg/kg, sc after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID562078	Ratio of fAUC to MIC in Klebsiella pneumoniae isolate 135 at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID543090	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID562075	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Escherichia coli isolate 321-infected ICR mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID508335	Increase in fnbB expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID546366	fAUC/MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 56-infected neutropenic ICR mouse at 80% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID544788	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID507994	Increase in rpsE gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID558039	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S2 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID576609	Drug penetration in blister fluid of healthy human at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID529830	Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolates by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID285157	Antimicrobial susceptibility of tetracycline-resistant Streptococcus pneumoniae from respiratory tract disease patient assessed as percent susceptible isolates	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.
AID498825	Antimicrobial activity against Citrobacter freundii SZ62T expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID373612	Penetration ratio, ratio of AUC (0 to 24 hrs) for human colon wall tissue to AUC (0 to 24 hrs) for human serum at 95th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID576965	Antimicrobial activity against Staphylococcus epidermidis isolate KO8 isolated from healthy human skin by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID341595	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID546108	Antimicrobial activity against Hospital-acquired methicillin-resistant Staphylococcus aureus isolate 56 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID543138	Antimicrobial activity against Salmonella serotype Typhimurium assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID542855	Antibacterial activity against Acinetobacter baumannii assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID1442634	Antibacterial activity against gram-negative Enterobacter cloacae EC1603 harboring tet(A) by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID422667	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID544819	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID325413	Antibacterial activity against Escherichia coli	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID574673	Antimicrobial activity against Escherichia coli isolate 339 expressing beta-lactamase KPC2, TEM and PFGE cluster 5 isolated from peritoneal fluid of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID646231	Antibacterial activity against tetracycline-resistant Staphylococcus aureus 191 infected in iv dosed CD-1 mouse assessed as reduction in bacterial burden administered 1.5 hr post infection measured after 24 hrs	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID1395492	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 12-11 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID1228692	Antibacterial activity against tet(B) tetracycline-resistant Acinetobacter baumannii 250 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID546346	fT>MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 152-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID561932	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate N50 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID560093	Bactericidal activity against Escherichia coli isolate 5401 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID562475	Antimicrobial activity against rifampicin-resistant Escherichia coli A15 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID558044	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S7 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID543145	Antimicrobial activity against Salmonella serogroup O7 assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID546124	Elimination half life in neutropenic ICR mouse infected with methicillin-sensitive Staphylococcus aureus ATCC 29213 at 12.5 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID425979	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 49 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID584558	Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID499068	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ90 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1773507	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate M-14 assessed as inhibition of visible growth incubated for 16 to 18 hrs by CLSI method
AID496411	Reduction in ospA gene expression in heart base tissue Borrelia burgdorferi infected mouse at 50 mg/kg	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID572130	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 32 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID495517	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4675 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID601195	Elimination half life in Sprague-Dawley rat at 1 mg/kg, iv administered as single dose	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID533143	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 transformant by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID543166	Antimicrobial activity against Vibrio parahaemolyticus assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID565120	Ratio of fAUC to MIC in community-acquired methicillin-resistant Staphylococcus aureus 156-infected BALB/c mouse at 505 maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID528826	Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID546390	Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus isolate 147 infected in neutropenic ICR mouse assessed as change in bacterial load after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID556184	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in INF-gamma level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 1 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID577232	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB166 with PFGE subgroup A3 containing carbapenemase OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID543783	Antibacterial activity against Enterococcus faecium assessed as post antibiotic effect	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID499045	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ68T deficient in CTX-M-15, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID559778	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID542853	Antibacterial activity against Enterobacter cloacae assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID560518	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 15b52 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID422648	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID324871	Antimicrobial activity against Acinetobacter baumannii C75 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID565092	AUC (0 to 24 hrs) in BALB/c mouse infected with Staphylococcus aureus at 25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID587836	Antibacterial activity against tetracycline-resistant Escherichia coli isolate 155 harboring tet(A) gene by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID396274	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(M) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID546111	Cmax in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 25 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID544805	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID546364	fAUC/MIC in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse at 80% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID528847	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID556395	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL-2 level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID583889	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 360 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID559364	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID258279	Antibacterial activity against Escherichia coli UBMS 90-4 carrying tetM-resistant determinant	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID543136	Antimicrobial activity against Salmonella serotype Typhimurium assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID508349	Increase in isaA expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID561855	Antibacterial activity against extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 266 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID543139	Antimicrobial activity against Salmonella serotype Typhimurium assessed as resistant isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID646210	Antibacterial activity against tetracycline-resistant Enterococcus faecalis 159	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID584569	Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID565095	Half life in BALB/c mouse infected with Staphylococcus aureus at 12.5 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID325404	Antibacterial activity against Streptococcus equisimilis	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID565332	Antibacterial activity against Enterobacter hormaechei isolate UCN62	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.
AID543167	Antimicrobial activity against Vibrio parahaemolyticus assessed as intermediate isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID562080	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 266 at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID1773511	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate M-18 assessed as inhibition of visible growth incubated for 16 to 18 hrs by CLSI method
AID422683	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID543120	Antimicrobial activity against Aeromonas caviae assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID543147	Antimicrobial activity against Salmonella serogroup O8 assessed as susceptible isolate by FDA method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID546352	fCmax/MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 56-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID499051	Antimicrobial activity against carbapenem-resistant Escherichia coli PU60 deficient in TEM-1, CMY-2, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID584799	Volume of distribution at steady state in patient with community or hospital-acquired pneumonia at 100 mg/kg, iv loading dose followed by 50 mg/kg administered every 12 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
AID546350	fCmax/MIC in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID283394	Antimicrobial activity against Nocardia beijingensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID528841	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID543779	Antibacterial activity against Acinetobacter baumannii assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID558038	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S1 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID495510	Antibacterial activity against Acinetobacter baumannii BM4454 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID562473	Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase KPC-2/TEM-1 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID583238	Antibacterial activity against indole positive Proteae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID528846	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1329041	Protein binding in human plasma	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID283390	Antimicrobial activity against Nocardia cyriacigeorgica after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID559552	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1395496	Antibacterial activity against carbapenem-resistant Enterobacter aerogenes 11-4 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID543168	Antimicrobial activity against Vibrio parahaemolyticus assessed as intermediate isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID285170	Antimicrobial activity against catheter-associated biofilm of Acinetobacter baumannii assessed as reduction of CFU	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters.
AID571900	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 14 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1395490	Antibacterial activity against extended-spectrum beta-lactamase harboring Escherichia coli CDC1001728 after 18 hrs by CLSI broth microdilution method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID646216	Antibacterial activity against Pseudomonas aeruginosa ATCC 111 27853	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
AID558049	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S12 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID1539483	Antibacterial activity against carbapenem-resistant Acinetobacter baumannii ATCC BAA 1605 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID508278	Increase in cna gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID576969	Antimicrobial activity against coagulase-negative Staphylococcus isolated from human prosthetic joint infection site by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID565336	Antibacterial activity against Enterobacter cloacae UCN62 by Etest	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.
AID499054	Antimicrobial activity against carbapenem-resistant Escherichia coli PU101 deficient in TEM-1, CTX-M-14, CMY-2, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID544816	Antibacterial activity against vancomycin-sensitive Enterococcus faecalis by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID533860	Antibacterial activity against nonpigmented rapidly growing Mycobacterium porcinum after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID325408	Antibacterial activity against Acinetobacter baumannii	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID584557	Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID507999	Increase in rplB gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID508006	Decrease in capC gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID510503	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M2AC9-31 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID422686	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID546121	AUC (0 to 24 hrs) in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 6.25 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID553699	T>MIC in Staphylococcus aureus infected neutropenic mouse thigh infection model	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID546339	Protein binding in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse serum at 12 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID509836	Antibacterial activity against Escherichia coli DH10B expressing SK2 plasmid by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID425974	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID507981	Decrease in capF gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID556407	Ratio of AUC in human alveolar cells to AUC in human serum at 100 mg/kg, iv followed by 50 mg/kg regimen for every 12 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID542841	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by via	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID325400	Antibacterial activity against Streptococcus agalactiae	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID544802	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID1773508	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate M-15 assessed as inhibition of visible growth incubated for 16 to 18 hrs by CLSI method
AID576995	Antimicrobial activity against Staphylococcus isolates biofilms assessed as decrease in bacterial load at 100 mg/litre at ambient temperature of 35 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID396030	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID546380	fAUC/MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 56-infected neutropenic ICR mouse at stasis dose	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID428262	Antimicrobial activity against KPC2 carbapenemase producing Enterobacter hormaechei by disk approximation technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID571693	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 2 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID542843	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 6 times MIC concentration for 1 hr followed by 1:1000 dilution by	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID583884	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 152 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID562811	Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID559560	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID546360	fAUC/MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 152-infected neutropenic ICR mouse	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID509838	Antibacterial activity against wild type Salmonella enterica TY2313 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID546379	fAUC/MIC in methicillin-sensitive Staphylococcus aureus ATCC 25923-infected neutropenic ICR mouse at stasis dose	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID559365	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID584560	Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID543786	Antibacterial activity against Klebsiella pneumoniae assessed as post antibiotic effect	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID559794	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 2 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID542844	Antibacterial activity against vancomycin-sensitive Enterococcus faecalis assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count metho	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID546382	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 144-infected neutropenic ICR mouse at stasis dose	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID559783	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 0.125 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID546128	Protein binding in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse serum at 12.5 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID1442631	Antibacterial activity against gram-negative Klebsiella pneumoniae KP457 harboring blacTX-M-15 extended spectrum beta-lactamase gene by CLSI method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID1698692	Antibacterial activity against Streptococcus anginosus ATCC 33397 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID556182	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in IL-12 level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID556409	AUC in mouse pneumoniae model at 5 mg/kg	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID546120	AUC (0 to 24 hrs) in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 12.5 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID577250	Antibacterial activity against intI1-negative tigecycline-intermediate Acinetobacter baumannii AB098 with PFGE subgroup F containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID565084	Cmax in BALB/c mouse infected with Staphylococcus aureus at 25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID206301	In vitro antibacterial activity against Staphylococcus aureus Smith sensitive	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID544811	Antibacterial activity against Escherichia coli by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID508011	Increase in cna gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543097	Antibacterial activity against vancomycin-sensitive Enterococcus faecalis assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count metho	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID565117	Ratio of fAUC to MIC in hospital-acquired methicillin-resistant Staphylococcus aureus 152-infected BALB/c mouse at 80% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID543099	Antibacterial activity against beta-lactamase deficient ampicillin-resistant Haemophilus influenzae assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution b	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID373462	AUC (0 to 24 hrs) in human colon wall tissue at 5th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID507986	Increase in rho gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID544800	Antibacterial activity against vancomycin-sensitive Enterococcus faecalis assessed as post antibiotic effect at 10 times MIC concentration incubated for 1 hr measured after 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID499046	Antimicrobial activity against Klebsiella pneumoniae ZJ68T expressing CTX-M-15 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID565121	Ratio of fAUC to MIC in community-acquired methicillin-resistant Staphylococcus aureus 147-infected BALB/c mouse at 505 maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID285168	Antimicrobial activity against catheter-associated biofilm of methicillin-resistant Staphylococcus epidermidis assessed as reduction of CFU	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters.
AID543142	Antimicrobial activity against Salmonella serogroup O7 assessed as susceptible isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID1566490	Inhibition of Dicer mediated biotinylated pre-miRNA-21 (unknown origin) maturation at 1 mM measured after 15 mins by cat-ELCCA relative to control	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID528840	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID499067	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ89 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID422883	Antimicrobial activity against 8 ug/ml colistin-subcultured Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis and bacteremia by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID559368	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID561933	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate RUH134 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID324867	Antimicrobial activity against Acinetobacter baumannii B46 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID498813	Antimicrobial activity against Escherichia coli ZJ87T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID546338	Protein binding in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse serum at 6 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID574686	Antimicrobial activity against Escherichia coli isolate 1679T expressing beta-lactamase KPC2, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID508272	Increase in dltA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID571918	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 23 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, aphA6 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID559367	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1528446	Antibacterial activity against Enterobacter cloacae assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID510513	Antibacterial activity against Escherichia coli ATCC 25922 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID498835	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU4 deficient in SHV-1, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID571892	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 10 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID559787	Antimicrobial activity against heterogeneous vancomycin-susceptible Staphylococcus aureus assessed as intermediate isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID576963	Antimicrobial activity against Staphylococcus aureus ATCC 29213 administered as powder at 45 degC after 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID542875	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count me	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID565278	Ratio of fAUC to MIC in hospital-acquired methicillin-resistant Staphylococcus aureus 152-infected BALB/c mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID544818	Antibacterial activity against vancomycin-sensitive methicillin-resistant Staphylococcus aureus by macrodilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID565079	Antibacterial activity against community-acquired methicillin-resistant Staphylococcus aureus 147 by microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID1539479	Antibacterial activity against carbapenem-resistant Escherichia coli BAA-2452 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID322787	Antimicrobial activity against Bacteroides uniformis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID324878	Inhibition of AdeABC multidrug efflux pump in Acinetobacter baumannii C75 assessed as ethidium bromide accumulation at 100 uM	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID422670	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID576991	Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 25 mg/litre at ambient temperature of 40 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID1592957	Antibacterial activity against multi-drug resistant Escherichia coli NMI 3548/14 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID425967	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID588124	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 2 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID528966	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID562758	Antimicrobial activity against Klebsiella pneumoniae PFGE clone A expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID560090	Bactericidal activity against Enterobacter cloacae isolate 5420 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID508251	Increase in mnhD gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID671549	Antibacterial activity against tetracycline-resistant Staphylococcus aureus isolate SA161 expressing TetM gene	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID565125	Ratio of fAUC to MIC in community-acquired methicillin-resistant Staphylococcus aureus 144-infected BALB/c mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID428273	Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as susceptible isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID1890020	Invivo antibacterial activity against multidrug resistant Acinetobacter baumannii NCTC 13420 infected in mouse thigh infection model assessed in reduction in bacterial burden at 20 mg/kg, iv administered at 1 hr post infection and measured after 8 hrs (Rv	2022	Bioorganic & medicinal chemistry letters, 06-01, Volume: 65	Discovery and structure-activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors.
AID559770	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 4sy32 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID508350	Decrease in mnhG expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID572126	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 30 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID583895	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 453 (NRS23) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID508252	Increase in mnhG gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID499070	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ84 deficient in SHV-11, aac(6')-Ib-cr, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID601181	Antimicrobial activity against tetracycline-susceptible Streptococcus pneumoniae isolate 106 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID508256	Increase in tcaR gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID546123	Elimination half life in neutropenic ICR mouse infected with methicillin-sensitive Staphylococcus aureus ATCC 29213 at 25 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID581671	Antibacterial activity against normal phenotype Staphylococcus aureus in cation-adjusted MH 2 broth at pH 5.5 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID546378	fAUC/MIC in methicillin-sensitive Staphylococcus aureus ATCC 29213-infected neutropenic ICR mouse at stasis dose	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID507991	Increase in tuf gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID560512	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b6k1642 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID507996	Increase in rplC gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID325405	Antibacterial activity against Streptococcus intermedius	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID563600	Antimicrobial activity against Klebsiella pneumoniae isolate 048 expressing beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID562079	Ratio of fAUC to MIC in extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 255-infected ICR mouse at bacteriostatic concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID542852	Antibacterial activity against Klebsiella pneumoniae assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 2 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID562809	Antimicrobial activity against Escherichia coli J53	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID576592	Tmax in thigh interstitial fluid of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID556185	Immunological activity in BALB/c mouse infected with Mycoplasma pneumoniae ATCC 29342 assessed as decrease in INF-gamma level in bronchoalveolar lavage fluid at 10 mg/kg, sc on first day followed by regimen of 5 mg/kg for 5 days measured after 3 days	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.
AID521968	Antibacterial activity against Campylobacter sp. assessed as resistance breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID559558	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID508337	Increase in isaA expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID1329037	AUC(0 to 24 hrs) in human at 50 mg, iv q12h	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID572136	Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 35 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID496404	Reduction in beta-actin gene expression in heart base tissue Borrelia burgdorferi infected mouse at 50 mg/kg	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID322788	Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID581664	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID565109	Ratio of fAUC (0 to 8 hrs) in epithelial lining fluid to plasma of Staphylococcus aureus-infected BALB/c mouse at 12.5 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID546114	Tmax in neutropenic ICR mouse infected with Staphylococcus aureus ATCC 29213 at 50 mg/kg, sc by HPLC	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID559359	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID565100	Volume of distribution in BALB/c mouse infected with Staphylococcus aureus at 25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID518821	Antibacterial activity against Enterobacteriaceae assessed as intermediate breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID584798	Distributional clearance in patient with community or hospital-acquired pneumonia at 100 mg/kg, iv loading dose followed by 50 mg/kg administered every 12 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
AID577236	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB113 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID508249	Decrease in clpB gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543134	Antimicrobial activity against Salmonella serotype Choleraesuis assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID341597	Antibacterial activity against sEscherichia coli GeneHogs harboring blaKPC-encoding plasmids	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID510504	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-2 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID498828	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ92 deficient in IMP-4, TEM-1, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID546615	Antimicrobial activity against carbapenem-intermediate,-resistant Acinetobacter baumannii assessed as decrease in bacterial count at 0.7 times of MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID571695	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 4 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID508274	Increase in ssaA gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID543066	Antibacterial activity against Escherichia coli assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID1773510	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate M-17 assessed as inhibition of visible growth incubated for 16 to 18 hrs by CLSI method
AID559362	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID561852	Antibacterial activity against Klebsiella pneumoniae isolate 134 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID577003	Antimicrobial activity against Staphylococcus isolates biofilms assessed as decrease in bacterial load at 1 to 25 mg/litre at ambient temperature of 30 to 45 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID70921	In vitro antibacterial activity against Escherichia coli J3272 Tet C	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID529834	Bactericidal activity against Acinetobacter baumannii isolate 1826 at 2 ug/ml after 4 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID428270	Antimicrobial activity against Klebsiella sp. assessed as susceptible isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID544771	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID498833	Antimicrobial activity against Klebsiella pneumoniae CY1T expressing SHV-11, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID543069	Antibacterial activity against Klebsiella pneumoniae assessed as post-antibiotic sub-MIC effect at 0.3 times MIC concentration pretreated with 2 times MIC concentration for 1 hr followed by 1:1000 dilution by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID373464	AUC (0 to 24 hrs) in human colon wall tissue at 50th AUC percentile curve	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
AID583233	Antibacterial activity against Citrobacter spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID601187	Antimicrobial activity against tetracycline-susceptible Enterobacter cloacae isolate 108 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID325414	Antibacterial activity against Klebsiella oxytoca	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
AID543076	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as sub-MIC effect at 0.4 times MIC concentration incubated for 1 hr by viable plate count method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID574676	Antimicrobial activity against Escherichia coli isolate 360T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from urine of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID495513	Antibacterial activity against Acinetobacter baumannii BM4467 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID576581	Terminal half life in plasma of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
AID508018	Decrease in capC expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-1 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID521963	Ratio of AUC in intra-abdominal infection patient at 100 mg followed by 50 mg every 12 hrs for 5 to 14 days to MIC for Enterobacteriaceae isolate	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.
AID542857	Antibacterial activity against multidrug-resistant Acinetobacter baumannii producing OXA-24 and OXA-51 beta-lactamases assessed as post-antibiotic sub-MIC effect at 0.2 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed b	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID546368	fAUC/MIC in community acquired methicillin-resistant Staphylococcus aureus isolate 144-infected neutropenic ICR mouse at 80% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID499073	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ93 deficient in ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID560506	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b3k2345 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID528967	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID396031	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID565082	Cmax in BALB/c mouse infected with Staphylococcus aureus at 6.25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID574674	Antimicrobial activity against Escherichia coli isolate 339T expressing beta-lactamase KPC2 and PFGE cluster 5 isolated from peritoneal fluid of patient by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID422690	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 30 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID565122	Ratio of fAUC to MIC in hospital-acquired methicillin-resistant Staphylococcus aureus 56-infected BALB/c mouse at 505 maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID562272	Ratio of IC50 for Plasmodium falciparum isolates after 72 hrs to IC50 for Plasmodium falciparum isolates after 24 hrs by ELISA based histidine-rich protein 2 in vitro drug susceptibility assay	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.
AID577263	Steady state drug concentration in human serum	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID543170	Antimicrobial activity against Vibrio parahaemolyticus assessed as resistant isolate by EUCAST method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
AID528820	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID559788	Antimicrobial activity against heterogeneous vancomycin-susceptible Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID562067	Ratio of fAUC to MIC in Klebsiella pneumoniae isolate 135-infected ICR mouse at 50% maximal effective concentration	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID571908	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 18 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID499055	Antimicrobial activity against Escherichia coli PU101T expressing CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1698687	Antibacterial activity against Enterococcus faecium ATCC 35667 by CLSI method	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID535725	Antibacterial activity against Klebsiella pneumoniae urine isolate A28011 PFGE pattern A expressing KPC-2, CTX-M-2 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID508347	Decrease in fnbB expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16-2 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID258272	Antibacterial activity against Staphylococcus aureus UBMS 88-7 carrying the tetK-resistant determinant	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID565107	AUC (0 to 8 hrs) in Staphylococcus aureus-infected BALB/c mouse epithelial lining fluid at 25 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
AID571922	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 25 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID528972	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID577260	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB096 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID1528457	Antibacterial activity against Pseudomonas aeruginosa assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID324861	Antimicrobial activity against Acinetobacter baumannii A24C after 4 days by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID546373	fAUC/MIC in hospital-acquired methicillin-resistant Staphylococcus aureus isolate 56-infected neutropenic ICR mouse at 50% effective exposure index	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID546403	Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus isolate 156 infected in neutropenic ICR mouse assessed as change in bacterial load at 12.5 ug/ml after 24 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID671557	Antibacterial activity against Staphylococcus aureus ATCC 13709 infected in CD-1 mouse assessed as increase in survival at 30 mg/kg, po administered as single dose 1 hr post infection measured after 48 hrs post infection	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID258274	Antibacterial activity against Enterococcus faecalis ATCC 29212	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID425984	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID508009	Increase in clfB gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by RT-PCR relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID546109	Antimicrobial activity against Community-acquired methicillin-resistant Staphylococcus aureus isolate 156 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
AID577247	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB110 with PFGE subgroup C containing carbapenemase OXA-51 by Etest in presence of 64 mg/liter 1-(1-naphthylmethyl)-piperazine	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID543095	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus assessed as post-antibiotic sub-MIC effect at 0.4 times MIC concentration pretreated with 10 times MIC concentration for 1 hr followed by 1:1000 dilution by	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Postantibiotic effect of tigecycline against 14 gram-positive organisms.
AID322784	Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID531518	Antibacterial activity against Bacteroides uniformis assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID561848	Antibacterial activity against Escherichia coli isolate 120 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID396267	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(C) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID562092	Antibacterial activity against extended-spectrum beta-lactamase producing Klebsiella pneumoniae isolate 320 infected in ICR mouse assessed as change in bacterial load at 6.25 to 50 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
AID508280	Increase in clfB gene expression in biofilm-associated cells of epidemic methicillin-resistant Staphylococcus aureus isolate 16 at 4 times MIC incubated for 1 hr by whole genome microarray relative to untreated control	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.
AID510508	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC1AC9-26 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID1228693	Antibacterial activity against Stenotrophomonas maltophilia 256 assessed as bacterial growth inhibition by susceptibility testing assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID425995	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID564691	Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (0.15)	18.2507
2000's	503 (25.98)	29.6817
2010's	1042 (53.82)	24.3611
2020's	388 (20.04)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	68 (3.40%)	5.53%
Reviews	246 (12.31%)	6.00%
Case Studies	220 (11.01%)	4.05%
Observational	26 (1.30%)	0.25%
Other	1,439 (71.99%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multicenter, Randomized, Open-Label Comparison of the Safety And Efficacy of Tigecycline With That of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin And Skin Structure Infections [NCT00368537]	Phase 4	550 participants (Actual)	Interventional	2006-09-30	Completed
How to Optimize the Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae [NCT03950544]	Early Phase 1	80 participants (Anticipated)	Interventional	2019-01-01	Recruiting
The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial [NCT02800785]		1,552 participants (Actual)	Interventional	2016-05-31	Completed
Effectiveness and Safety of Tigecycline for Therapy of Infections Caused by Multi-Drug Resistant Acinetobacter Baumannii [NCT01342731]	Phase 4	30 participants (Anticipated)	Interventional	2011-07-31	Recruiting
A Randomized, Observer-blinded, Active-controlled, Phase Illb Study to Compare IV / Oral Delafloxacin Fixed-dose Monotherapy With Best Available Treatments in a Microbiologically Enriched Population With Surgical Site Infections [NCT04042077]	Phase 3	268 participants (Actual)	Interventional	2019-09-25	Terminated(stopped due to COVID-19 seriously affected the study execution as required by the protocol)
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) [NCT04310930]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2020-03-02	Recruiting
In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance [NCT01132417]		500 participants (Anticipated)	Observational	2009-09-30	Suspended(stopped due to researchers delay)
Randomized, 4-Way, Crossover Single Dose, Placebo And Active Controlled Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects [NCT01287793]	Phase 1	48 participants (Anticipated)	Interventional	2011-01-31	Completed
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML [NCT01332786]	Phase 1	27 participants (Actual)	Interventional	2011-03-31	Completed
Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock. [NCT04208763]		90 participants (Anticipated)	Interventional	2019-12-20	Recruiting
A Phase 2, Multicenter, Randomized, Double-Blind, Comparative Study Of The Safety And Efficacy of 2 Doses Of Tigecycline Versus Imipenem/Cilastatin For The Treatment Of Subjects With Hospital-Acquired Pneumonia [NCT00707239]	Phase 2	108 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to See termination reason in detailed description.)
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]	Phase 4	135 participants (Anticipated)	Interventional	2023-08-04	Enrolling by invitation
The Efficacy and Safety of Tigecycline for the Treatment of Infectious Diseases [NCT04937894]		300 participants (Anticipated)	Observational	2021-06-01	Recruiting
A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes [NCT00366249]	Phase 3	1,061 participants (Actual)	Interventional	2007-01-31	Completed
Dose Optimization by PK/PD of Antibiotics to Improve Clinical Outcome of CRKP Bloodstream Infections in Critically Ill Patients and in Vitro Study of Monotherapy, Combination Therapy and Molecular Biology of Drug Resistance at Phramongkutklao Hospital: Pr [NCT05862402]	Phase 4	76 participants (Anticipated)	Interventional	2023-05-07	Recruiting
A Phase 3, Multicenter, Randomized, Double-Blind Study To Evaluate The Safety And Efficacy Of Tigecycline Versus Comparator (Clindamycin Or Vancomycin) For The Treatment Of Complicated Skin And Skin Structure Infections, Including Those Due To MRSA, In Pe [NCT00911573]	Phase 3	0 participants (Actual)	Interventional	2011-08-31	Withdrawn
Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years [NCT00914888]	Phase 3	0 participants (Actual)	Interventional	2011-01-31	Withdrawn
A Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of RX 3341 Compared With Tigecycline for the Treatment of Complicated Skin and Skin Structure Infections [NCT00719810]	Phase 2	150 participants (Actual)	Interventional	2008-06-30	Completed
[NCT02573064]		113 participants (Actual)	Observational	2010-01-31	Completed
Population Pharmacokinetics and Dosage Individualization of Biapenem,Meropenem,Piperacillin and Tazobactam,Tigecycline,Levofloxacin .Etc in Elderly Patients Who Was Hospitalized in Intensive Care Unit [NCT04799626]		500 participants (Anticipated)	Observational [Patient Registry]	2021-04-01	Recruiting
A Phase 3, Multicenter, Open-label Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects With Community-acquired Pneumonia [NCT00575094]	Phase 3	9 participants (Actual)	Interventional	2007-11-30	Completed
RCT for the Treatment of Hemodialysis Catheter-Related Bacteremia [NCT02040818]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2013-11-30	Withdrawn(stopped due to no enrollment)
A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection [NCT00230971]	Phase 4	473 participants (Actual)	Interventional	2005-10-31	Completed
Personalized Treatment of Urogenital Cancers Depends on the Microbiome [NCT03962920]		28 participants (Anticipated)	Interventional	2020-05-01	Recruiting
A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections [NCT00488345]	Phase 2	59 participants (Actual)	Interventional	2007-12-31	Completed
A Post-marketing Surveillance (Pms) Study Of Safety And Effectiveness In Patients With Tigecycline Treatment [NCT01072539]		3,172 participants (Actual)	Observational	2010-05-31	Completed
A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection [NCT00195351]	Phase 4	467 participants (Actual)	Interventional	2005-09-30	Completed
Phase II Trial of a Novel Catheter Lock Solution For Adjunctive Treatment of Hemodialysis Catheter-Associated Bacteremia. [NCT01483872]	Phase 3	9 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to The study was stopped due to poor enrollment.)
Use of Tigecycline for Treatment of Serious Infection Due to Rapidly Growing Mycobacteria (Especially M.Abscessus) [NCT00600600]	Phase 2	8 participants (Actual)	Interventional	2002-04-30	Completed
A Phase IV Pharmacovigilance, Post-Authorization Clinical Trial To Evaluate And Assess The Safety Of Tigecycline In The Approved Indications In The Usual Health Care Setting [NCT00827541]		115 participants (Actual)	Observational	2008-08-31	Completed
A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia [NCT00614679]	Phase 1	18 participants (Actual)	Interventional	2006-10-31	Completed
Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units [NCT00481962]		180 participants (Actual)	Observational	2006-02-28	Completed
A Clinical Research Study to Evaluate the Safety and Efficacy of Tigecycline in the Treatment of Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) [NCT00079976]	Phase 3	174 participants (Actual)	Interventional	2003-10-31	Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia [NCT00081575]	Phase 3	434 participants (Actual)	Interventional	2004-01-31	Completed
A Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Tigecycline to Treat Complicated Skin and Skin Structure Infections (cSSSI) in Hospitalized Patients [NCT00488761]	Phase 4	50 participants (Actual)	Interventional	2006-07-31	Completed
Pharmacokinetics of Tigecycline in Critical Ill Patients Undergoing Continuous Renal Replacement Therapy [NCT02931526]		20 participants (Anticipated)	Observational	2016-08-31	Recruiting
A Multicenter, Open Label Study to Evaluate the Efficacy and Safety of Tigecycline to Treat Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Patients [NCT00488306]	Phase 4	50 participants (Actual)	Interventional	2006-08-31	Completed
Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation [NCT01551719]		0 participants (Actual)	Interventional	2012-03-31	Withdrawn
A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia [NCT00079885]	Phase 3	430 participants (Actual)	Interventional	2003-11-30	Completed
A Multicenter, Randomized, Open-Label Comparison of the Safety and Efficacy of Tigecycline> vs Imipenem/Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Chinese Subjects [NCT00136201]	Phase 3	200 participants	Interventional	2005-11-30	Completed
An Open-label, Noncomparative, Multi-center, Emergency Use Protocol Administering Tigecycline for the Treatment of Subjects With Infections Due to Resistant Pathogens. [NCT00205816]	Phase 3	26 participants (Actual)	Interventional	2004-01-31	Completed
A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae [NCT00079989]	Phase 3	115 participants (Actual)	Interventional	2003-12-31	Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Imipenem/Cilastatin For The Treatment Of Subjects With Nosocomial Pneumonia [NCT00080496]	Phase 3	430 participants	Interventional	2003-07-31	Completed
A Multicenter, Double-Blind, Randomized Comparison Study Of the Efficacy and Safety of Tigecycline to Imipenem/ Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects [NCT00081744]	Phase 3	850 participants (Actual)	Interventional	2002-11-30	Completed
Open Label, Single Dose Study Of The Pharmacokinetics Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis [NCT00406237]	Phase 1	8 participants (Actual)	Interventional	2006-12-31	Completed
A Multicenter, Randomized, Double-Blind Comparison of the Safety and Efficacy of Tigecycline With Those of Vancomycin With Aztreonam to Treat Complicated Skin and Skin Structure Infections in Hospitalized Patients. [NCT00228410]	Phase 3	503 participants (Actual)	Interventional	2002-11-30	Completed
An Open-Label Noncomparative, Multicenter, Clinical Trail Measuring Time Related Clinical Response Factors in Relation to Time to Bacterial Eradication With Tigecycline Treatment in Patients With Catheter Infection [NCT00419991]	Phase 4	10 participants (Actual)	Interventional	2007-01-31	Completed
Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD) [NCT01401023]		10 participants (Actual)	Interventional	2011-07-31	Completed
An Open-Label, Multiple-Dose Study of the Pharmacokinetics of Tigecycline in Human Bone [NCT00376324]	Phase 1	36 participants (Anticipated)	Interventional	2006-09-30	Completed
Tygacil Drug Use Investigation (Tigecycline Evaluation Study For Safety And Effectiveness In Patient Infected With Multi-Drug Resistance.) [NCT01789905]		116 participants (Actual)	Observational	2013-04-15	Completed
Concentration and Antibiotic Activity in Antibiotic Lock Solutions [NCT01592032]	Phase 4	125 participants (Anticipated)	Interventional	2012-05-31	Active, not recruiting
Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years [NCT01602874]	Phase 3	0 participants (Actual)	Interventional	2011-01-31	Withdrawn
Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects [NCT01560143]	Phase 4	12 participants (Actual)	Interventional	2012-03-31	Completed
A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) [NCT01970371]	Phase 3	69 participants (Actual)	Interventional	2014-09-16	Completed
A Non-Interventional Study To Evaluate The Safety And Effectiveness Of Tygacil In The Treatment Of Patients With Complicated Intra-Abdominal Infections Or Complicated Skin And Skin Structure Infections [NCT00488488]		1,028 participants (Actual)	Observational	2006-11-30	Completed
A Multicenter, Double-blind, Randomized, Comparison Study Of The Efficacy And Safety Of Tigecycline To Imipenem/Cilastatin To Treat Complicated Intra-abdominal Infections In Hospitalized Subjects. [NCT01721408]	Phase 4	470 participants (Actual)	Interventional	2012-11-30	Completed
A Prospective, Observational Study To Monitor Safety In Patients Who Were Administered With Tigecycline (Tygacil) 50 mg By Intravenous Injection (An Observational Study for Safety - Monitored Release) [NCT00683332]		621 participants (Actual)	Observational	2007-04-30	Completed
Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae [NCT04489459]	Phase 4	60 participants (Anticipated)	Interventional	2019-09-21	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial	Outcome
NCT00195351 (3) [back to overview]	Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit.
NCT00195351 (3) [back to overview]	Number of Patients by Microbiologic Response at Test-of-Cure (TOC) Visit.
NCT00195351 (3) [back to overview]	Number of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit.
NCT00230971 (4) [back to overview]	Number of Microbiologically Evaluable (ME) Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit
NCT00230971 (4) [back to overview]	Number of Days of Inpatient Healthcare Resource Utilization on or Before Test-of-Cure
NCT00230971 (4) [back to overview]	Number of Microbiologically Evaluable (ME) Patients by Microbiological Response at Test-of-Cure (TOC) Visit
NCT00230971 (4) [back to overview]	Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) Visit
NCT00366249 (5) [back to overview]	Number of Patients With Microbiologic Response of Eradication.
NCT00366249 (5) [back to overview]	Number of Patients With Clinical Response of Cure Vs. Failure Assessed at Least 25 - 27 Weeks Post Last Dose.
NCT00366249 (5) [back to overview]	Number of Patients With Clinical Response of Cure Vs. Failure.
NCT00366249 (5) [back to overview]	Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate Assessed at Least 25 - 27 Weeks Post Last Dose.
NCT00366249 (5) [back to overview]	Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.
NCT00368537 (5) [back to overview]	Number of Microbiologically Evaluable Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit
NCT00368537 (5) [back to overview]	Inpatient Healthcare Resource Utilization on or Before Test-of-Cure - Number of Patients
NCT00368537 (5) [back to overview]	Minimum Inhibitory Concentration (MIC) 50 and 90 by Baseline Isolate
NCT00368537 (5) [back to overview]	Number of Microbiologically Evaluable Patients by Microbiologic Response at Test-of-Cure (TOC) Visit
NCT00368537 (5) [back to overview]	Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit
NCT00488345 (5) [back to overview]	Percentage of Participants With Clinical Response (CR) to Tigecycline at Last Day of Therapy (LDOT) and Test-of-Cure (TOC) Assessment
NCT00488345 (5) [back to overview]	Weight Normalized Drug Clearance (CLW)
NCT00488345 (5) [back to overview]	Area Under the Curve (AUCτ) From Time Zero to Time of Estimated Concentration at 12 Hours
NCT00488345 (5) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT00488345 (5) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT00488488 (12) [back to overview]	Reasons for Utilization of Tygacil
NCT00488488 (12) [back to overview]	Percentage of Participants With Resistant Pathogens Identified at Follow-up Due to Treatment Failure
NCT00488488 (12) [back to overview]	Change of Antibiotic Treatment From Tygacil to Alternative Antibiotic
NCT00488488 (12) [back to overview]	Antibiotic Agents Chosen for Combination Therapy With Tigecycline
NCT00488488 (12) [back to overview]	Percentage of Participants With Composite Cure: Nosocomial Infections
NCT00488488 (12) [back to overview]	Percentage of Participants With Composite Cure: Community-acquired Infections
NCT00488488 (12) [back to overview]	Percentage of Participants With Clinical and Microbiological Cure: Nosocomial Infections
NCT00488488 (12) [back to overview]	Percentage of Participants With Clinical and Microbiological Cure: Community-acquired Infections
NCT00488488 (12) [back to overview]	Percentage of Participants With Clinical and Microbiological Cure: All Participants
NCT00488488 (12) [back to overview]	Participants With Probable Failure at Follow-up
NCT00488488 (12) [back to overview]	Overall Mortality: All Participants
NCT00488488 (12) [back to overview]	Percentage of Participants With Composite Cure: All Participants
NCT00575094 (1) [back to overview]	Number of Patients by Clinical Response at Test-of-Cure (TOC) Visit.
NCT00683332 (1) [back to overview]	Number of Participants With Spontaneous Adverse Events
NCT00707239 (17) [back to overview]	Correlation of AUC (0-24) of Tigecycline With Nausea and Vomiting
NCT00707239 (17) [back to overview]	Time to Reach Maximum Observed Serum Concentration (Tmax) of Tigecycline
NCT00707239 (17) [back to overview]	Percentage of Participants With Microbiological Response at the Pathogen Level Population at Test-of-Cure (TOC) Visit
NCT00707239 (17) [back to overview]	Percentage of Participants With Microbiological Response at the Participant Level Population at Test-of-Cure (TOC) Visit
NCT00707239 (17) [back to overview]	Percentage of Participants With Clinical Response in Ventilator Associated Pneumonia (VAP) and Non-VAP Participants at Test-of-Cure (TOC) Visit
NCT00707239 (17) [back to overview]	Percentage of Participants With Clinical Response in Clinically Evaluable (CE) Population at Test-of-Cure (TOC) Visit
NCT00707239 (17) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Tigecycline
NCT00707239 (17) [back to overview]	Percentage of Participants With Clinical Response in Clinical Modified Intent-to-treat (c-mITT) Population at Test-of-Cure (TOC) Visit
NCT00707239 (17) [back to overview]	Correlation of AUC(0-24) to Minimum Inhibitory Concentration (MIC) Ratio (AUC [0-24]/MIC) of Tigecycline With Clinical Outcome
NCT00707239 (17) [back to overview]	Duration of Intravenous Antibiotic Treatment, Hospital and Intensive Care Unit (ICU) Stay
NCT00707239 (17) [back to overview]	Maximum Observed Plasma Concentration of Procalcitonin (Cmaxpd) and Predicted Procalcitonin Plasma Concentration at 24 Hours (Cpd,24) and 48 Hours (Cpd,48)
NCT00707239 (17) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-12)] of Tigecycline
NCT00707239 (17) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Tigecycline
NCT00707239 (17) [back to overview]	Number of Participants Who Experienced Nausea or Vomiting
NCT00707239 (17) [back to overview]	Clearance (CL) of Tigecycline
NCT00707239 (17) [back to overview]	Number of Participants With Abnormal Electrocardiogram (ECG)
NCT00707239 (17) [back to overview]	Number of Participants With Abnormal Laboratory Examinations
NCT00719810 (2) [back to overview]	Clinical Response in Patients With Methicillin-resistant Staphylococcus Aureus (MRSA)
NCT00719810 (2) [back to overview]	Clinical Response at Test of Cure (TOC) in the Clinically Evaluable (CE) Population
NCT00827541 (2) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00827541 (2) [back to overview]	Percentage of Participants With Clinical Response of Cure
NCT01072539 (5) [back to overview]	Percentage of Participants by Microbiologic Response at the Participant Level (Prospective Study Phase)
NCT01072539 (5) [back to overview]	Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), and Unexpected AEs/ADRs
NCT01072539 (5) [back to overview]	Percentage of Participants With Adverse Events by Baseline and Treatment Characteristics
NCT01072539 (5) [back to overview]	Percentage of Participants With Clinical Response of Cure or Improvement at the Test-of-Cure(TOC) or End-of-Treatment (EOT) Assessment
NCT01072539 (5) [back to overview]	Percentage of Participants With Clinical Response of Cure or Improvement at the TOC or EOT Assessment by Infection Site
NCT01401023 (5) [back to overview]	Mean (SD) Minimun Inhibitory Concentration of Tigecycline of Clostridium Difficile Isolates
NCT01401023 (5) [back to overview]	Mean (SD) Serum Tigecycline Concentration Level
NCT01401023 (5) [back to overview]	Pharmacokinetics of Tigecycline Along With Standard Treatments for Clostridium Difficile
NCT01401023 (5) [back to overview]	Pharmacokinetics of Tigecycline Along With Standard Treatments for Clostridium Difficile
NCT01401023 (5) [back to overview]	Mean (SD) Stool Tigecycline Concentration Level
NCT01560143 (1) [back to overview]	Single-dose Serum AUC of Tigecycline Between Time 0 and 96 Hours
NCT01721408 (5) [back to overview]	Clinical Response at the Test-of-Cure (TOC) Assessment Within the Clinically Evaluable (CE) Population
NCT01721408 (5) [back to overview]	Clinical Response at the TOC Assessment Within the Microbiologically Evaluable (ME) Population
NCT01721408 (5) [back to overview]	Clinical Response at the TOC Assessment Within the Modified Intent-to-Treat (mITT) Population
NCT01721408 (5) [back to overview]	Microbiological Response at the Subject Level in the ME Population at the TOC Assessment
NCT01721408 (5) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) by Relationship and Seriousness
NCT01789905 (3) [back to overview]	Clinical Response Rate
NCT01789905 (3) [back to overview]	Clinical Response Rate of Cure
NCT01789905 (3) [back to overview]	Number of Participants With Adverse Drug Reaction (ADR)
NCT01970371 (10) [back to overview]	Plasma Pharmacokinetics (PK): Area Under the Curve From 0 to 24 Hours (AUC 0-24h)
NCT01970371 (10) [back to overview]	Plasma Pharmacokinetics (PK): Maximum Observed Plasma Drug Concentration (Cmax)
NCT01970371 (10) [back to overview]	Percentage of Patients With Dose Adjustment Due to Therapeutic Drug Management (TDM)
NCT01970371 (10) [back to overview]	Percentage of Patients With Adjudicated Clinical Cure at the Test of Cure (TOC) Visit in the mMITT Population in Cohort 1
NCT01970371 (10) [back to overview]	Time to Death Through Day 28 in the mMITT Population in Cohort 1
NCT01970371 (10) [back to overview]	Plasma Pharmacokinetics (PK): Minimum Observed Plasma Drug Concentration (Cmin)
NCT01970371 (10) [back to overview]	Percentage of Patients With All Cause Mortality (ACM) at Day 28 or Significant Disease-Related Complication (SDRC) in the Microbiological Modified Intent to Treat (mMITT) Population in Cohort 1
NCT01970371 (10) [back to overview]	Percentage of Patients With ACM at Day 14 in the mMITT Population in Cohort 1
NCT01970371 (10) [back to overview]	Percentage of Patients With ACM at Day 28 in the mMITT Population in Cohort 1
NCT01970371 (10) [back to overview]	Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs)
NCT02800785 (8) [back to overview]	Rate of Participants With Perforated Appendicitis
NCT02800785 (8) [back to overview]	Patient-reported Quality of Life as Measured by EuroQol (EQ-5D)
NCT02800785 (8) [back to overview]	Number of Participants With at Least One Complications From Treatment
NCT02800785 (8) [back to overview]	Number of Clinic Visits or Emergency Room Visits
NCT02800785 (8) [back to overview]	Days in Hospital After Index Treatment Within 90 Days
NCT02800785 (8) [back to overview]	Eventual Appendectomy Incidence Proportion
NCT02800785 (8) [back to overview]	Rates of Participants With Appendiceal Cancer
NCT02800785 (8) [back to overview]	Total Number of Patients Who Had Resolution of Appendicitis Symptoms at 30 Days
NCT04042077 (5) [back to overview]	Hospital Length of Stay (LOS)
NCT04042077 (5) [back to overview]	Microbiological Response
NCT04042077 (5) [back to overview]	Hospital Infection Related Length of Stay (IRLOS)
NCT04042077 (5) [back to overview]	Number of Participants With Clinical Success at Test Of Cure Visit
NCT04042077 (5) [back to overview]	Number of Participants Eligible to Switch to Oral Formulation According to Blinded Observer's Assessment

Intervention	participants (Number)
Tigecycline	133
Ceftriaxone Sodium + Metronidazole	139

Intervention	participants (Number)
	Eradication and presumed eradication	Persistence and presumed persistence	Superinfection
Ceftriaxone Sodium + Metronidazole	98	39	3
Tigecycline	94	44	7

Intervention	participants (Number)
Tigecycline	91
Ceftriaxone Sodium + Metronidazole	96

Intervention	participants (Number)
Tigecycline	97
Ceftriaxone	86

Intervention	days (Mean)
	Overall inpatient hospitalization	Primary inpatient hospitalization	ICU treatment	Inpatient hospitalization, non-ICU
Ceftriaxone	12.69	12.16	6.14	10.80
Tigecycline	13.03	12.62	8.24	11.09

Intervention	participants (Number)
	Eradication + Presumed Eradication	Persistence + Presumed Persistence	Superinfection
Ceftriaxone	86	22	0
Tigecycline	98	21	3

Intervention	participants (Number)
Tigecycline	162
Ceftriaxone	150

Intervention	patients (Number)
Tigecycline	209
Ertapenem	229

Intervention	patients (Number)
	Cure	Failure
Ertapenem	13	11
Tigecycline	12	26

Intervention	patients (Number)
	Cure	Failure
Ertapenem	334	71
Tigecycline	316	92

Intervention	patients (Number)
	Cure	Failure	Indeterminate
Ertapenem	21	12	0
Tigecycline	19	27	7

Intervention	patients (Number)
	Cure	Failure	Indeterminate
Ertapenem	363	86	17
Tigecycline	340	117	19

Intervention	participants (Number)
Tigecycline	96
Ampicillin-Sulbactam or Amoxicillin-Clavulanate	77

Intervention	participants (Number)
	Intensive care unit	Non-ICU inpatient hospitalization
Ampicillin-Sulbactam or Amoxicillin-Clavulanate	9	263
Tigecycline	6	268

Intervention	mcg/mL (Number)
	Enterococcus Faecalis MIC50 (n=20,20)	Enterococcus Faecalis MIC90 (n=20,20)	Escherichia Coli MIC50 (n=29,29)	Escherichia Coli MIC90 (n=29,29)	Klebsiella Pneumoniae MIC50 (n=13,13)	Klebsiella Pneumoniae MIC90 (n=13,13)	Staphylococcus Aureus MIC50 (n=176,176)	Staphylococcus Aureus MIC90 (n=176,176)	Streptococcus Agalactiae MIC50 (n=18,18)	Streptococcus Agalactiae MIC90 (n=18,18)	Streptococcus Pyogenes MIC50 (n=18,18)	Streptococcus Pyogenes MIC90 (n=18,18)
Ampicillin-Sulbactam or Amoxicillin-Clavulanate	1.00	1.00	8.00	32.00	2.00	8.00	2.00	8.00	0.12	0.12	0.06	0.06
Tigecycline	0.12	0.25	0.25	0.50	0.50	2.00	0.12	0.25	0.03	0.06	0.03	0.06

Intervention	participants (Number)
	Eradication + presumed eradication	Persistence + Presumed persistence	Superinfection
Ampicillin-Sulbactam or Amoxicillin-Clavulanate	76	23	1
Tigecycline	95	25	2

Intervention	participants (Number)
Tigecycline	162
Ampicillin-Sulbactam or Amoxicillin-Clavulanate	152

Intervention	percentage of participants (Number)
	Cure: LDOT	Improved: LDOT	Failure: LDOT	Indeterminate: LDOT	Cure: TOC	Failure: TOC	Indeterminate: TOC
Tigecycline 0.75 mg/kg	82.4	17.6	0.0	0.0	94.1	5.9	0.0
Tigecycline 1 mg/kg	52.4	28.6	0.0	19.0	76.2	4.8	19.0
Tigecycline 1.25 mg/kg	30.0	55.0	0.0	15.0	75.0	10.0	15.0

Intervention	L/hr/kg (Mean)
Tigecycline 0.75 mg/kg	0.490
Tigecycline 1 mg/kg	0.498
Tigecycline 1.25 mg/kg	0.528

Intervention	ng*h/mL (Mean)
Tigecycline 0.75 mg/kg	1650
Tigecycline 1 mg/kg	2557
Tigecycline 1.25 mg/kg	3196

Intervention	ng/mL (Mean)
Tigecycline 0.75 mg/kg	456
Tigecycline 1 mg/kg	1515
Tigecycline 1.25 mg/kg	2599

Intervention	hours (Mean)
Tigecycline 0.75 mg/kg	0.6
Tigecycline 1 mg/kg	0.5
Tigecycline 1.25 mg/kg	0.8

Intervention	percentage of participants (Number)
	Failure on previous antibiotic treatment (n=549)	Suspicion of resistant pathogens (n=470)	Broad efficacy spectrum (n=463)	Primary (n=114)	Intolerability to previous antibiotic (n=21)
Tygacil	53.6	45.9	45.2	11.1	2.0

Intervention	percentage of participants (Number)
	Pseudomonas aeruginosa (n=12)	Other pathogens (unspecified) (n=6)	Klebsiella oxytoca (n=1)	Proteus mirabilis (n=6)	Proteus vulgaris (n=2)	Stenotrophomonas maltophilia (n=4)	Klebsiella pneumoniae (n=9)	Enterococcus faecalis (n=10)	Enterobacter species (spp) (n=11)	Escherichia coli (n=14)	Staphylococcus aureus (n=16)	Enterococcus faecium (n=15)	Staphylococcus spp (n=5)	Serratia spp (n=2)	Citrobacter freundii (n=1)	Acinetobacter spp. (n=1)
Tygacil	100.0	100.0	100.0	50.0	50.0	25.0	22.2	20.0	18.2	7.1	6.3	0	0	0	0	0

Intervention	percentage of participants (Number)
	Other (de-escalation) (n=80)	No clinical response (n=71)	Microbiological resistance (n=26)	Oral treatment continuation (n=14)	Intolerability (n=5)
Tygacil	7.8	6.9	2.5	1.4	0.5

Intervention	percentage of participants (Number)
	ceftazidime (n=191)	ciprofloxacin (n=62)	fluconazole (n=59)	meropenem (n=49)	metronidazole (n=48)	vancomycin (n=27)	cefepime (n=26)	pip/tazo (n=18)	piperacillin (n=14)	caspofungin (n=13)	levofloxacin (n=13)	other antimycotics for system use (n=13)	imipenem (n=12)	primaxin (n=12)	voriconazole (n=11)	erythromycin (n=10)	gentamicin (n=10)	sulbactam (n=10)	tobramycin (n=10)	clarithromycin (n=9)	moxifloxacin (n=9)	aciclovir (n=7)	clindamycin (n=7)	other beta-lactam antibacterials (n=5)	ampicillin (n=4)	fosfomycin (n=4)	linezolid (n=4)	amikacin (n=3)	amphotericin B (n=3)	bactrim (n=3)	flucloxacillin (n=3)	rifampicin (n=3)	unacid (n=3)	benzylpenicillin (n=2)	beta-lactam antibacterials, penicillins (n=2)	ceftriaxone (n=2)	colistin (n=2)	doxycycline (n=2)	ganciclovir (n=2)	tazobactam (n=2)	amoxi-clavulanico (n=1)	antibiotics (n=1)	azithromycin (n=1)	cefotaxime (n=1)	cefuroxime (n=1)	chloramphenicol (n=1)	clemizole penicillin (n=1)	penicillin not otherwise specified (n=1)	piperacillin with tazobactam (n=1)	teicoplanin (n=1)	tienam (n=1)
Tygacil	18.6	6.0	5.8	4.8	4.7	2.6	2.5	1.8	1.4	1.3	1.3	1.3	1.2	1.2	1.1	1.0	1.0	1.0	1.0	0.9	0.9	0.7	0.7	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1

Intervention	percentage of participants (Number)
Tygacil	70.5

Intervention	percentage of participants (Number)
Tygacil	82.3

Intervention	percentage of participants (Number)
Tygacil	29.0

Intervention	percentage of participants (Number)
Tygacil	43.9

Intervention	percentage of participants (Number)
Tygacil	33.8

Intervention	participants (Number)
Tygacil	162

Substance	Relationship Strength	Studies	Trials	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.43	2	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
acetic acid Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.	2.21	1	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	2.43	2	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
betaine glycine betaine : The amino acid betaine derived from glycine.	3.23	1	0	amino-acid betaine; glycine derivative	fundamental metabolite
bupropion Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.	3.23	1	0	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
hippuric acid hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591. N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl.	2.06	1	0	N-acylglycine	human blood serum metabolite; uremic toxin
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	3.58	2	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.05	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2.41	1	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
melatonin [no description available]	2.08	1	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.	3.23	1	0	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	2.08	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
phosphorylethanolamine phosphorylethanolamine: RN given refers to parent cpd; structure. O-phosphoethanolamine : The ethanolamine mono-ester of phosphoric acid, and a metabolite of phospholipid metabolism. This phosphomonoester shows strong structural similarity to the inhibitory neurotransmitter GABA, and is decreased in post-mortem Alzheimer's disease brain.	2.25	1	0	phosphoethanolamine; primary amino compound	algal metabolite; human metabolite; mouse metabolite
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	3.61	2	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
pyridoxine 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).	3.23	1	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
pyruvic acid Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.	2.58	2	0	2-oxo monocarboxylic acid	cofactor; fundamental metabolite
succinic acid Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851). succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.	2.25	1	0	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
thiamine thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.	3.23	1	0	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
1-(3-chlorophenyl)piperazine 1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.	2.46	2	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	3.18	5	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
enprofylline enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.	2.45	2	0	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug
phenytoin [no description available]	3.23	1	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	2.75	3	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.	3.85	3	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	9.27	5	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	4.08	4	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohydroxamic acid acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.	3.23	1	0	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
alaproclate alaproclate: specific 5-hydroxytryptamine uptake inhibitors; RN given refers to (DL)-isomer	3.23	1	0	alpha-amino acid ester
albendazole [no description available]	3.61	2	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	4.08	4	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	3.23	1	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alfuzosin alfuzosin: structure given in first source	3.58	2	0	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
alosetron alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.	3.58	2	0	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	3.85	3	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.75	3	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.	3.23	1	0	triamino-1,3,5-triazine
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	3.85	3	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
ambenonium ambenonium : A symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens.	3.23	1	0	quaternary ammonium ion	EC 3.1.1.8 (cholinesterase) inhibitor
diatrizoic acid Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.	3.87	3	0	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
amifostine anhydrous Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.	3.23	1	0	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.08	1	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	3.23	1	0	N-acylglycine	Daphnia magna metabolite
theophylline [no description available]	4.08	4	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	4.08	4	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
dan 2163 [no description available]	2.47	2	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	4.08	4	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.08	1	0	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	4.08	4	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.	3.61	2	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	2.46	2	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole [no description available]	3.61	2	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
anthralin Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.	2.08	1	0	anthracenes	antipsoriatic
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	2.75	3	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	4.08	4	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.08	1	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	4.08	4	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	3.89	3	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
azelastine azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.	2.45	2	0	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
aztreonam Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.. aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.	8.18	13	5
baclofen [no description available]	3.61	2	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
bendazac bendazac : A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.	3.23	1	0	indazoles; monocarboxylic acid	non-steroidal anti-inflammatory drug; radical scavenger
bendroflumethiazide Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810). bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.	3.23	1	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	3.61	2	0	1-benzofurans; aromatic ketone	uricosuric drug
benzocaine Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.	2.08	1	0	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
benzothiazide benzothiazide: structure. benzthiazide : 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema.	2.11	1	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
betaxolol [no description available]	3.85	3	0	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bethanechol Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.. bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.	3.23	1	0	carbamate ester; quaternary ammonium ion	muscarinic agonist
bevantolol bevantolol: structure given in first source. bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.	2.45	2	0	propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; calcium channel blocker
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	3.61	2	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
bay h 4502 bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1.	2.08	1	0	biphenyls; imidazoles
biperiden Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.	3.58	2	0	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bisacodyl Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)	3.61	2	0	diarylmethane
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	3.85	3	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bromazepam Bromazepam: One of the BENZODIAZEPINES that is used in the treatment of ANXIETY DISORDERS.	2.45	2	0	organic molecular entity
bromopride bromopride: RN given refers to parent cpd; structure	2.75	3	0	benzamides
bronopol [no description available]	2.08	1	0	nitro compound
brotizolam brotizolam: structure	2.04	1	0	organic molecular entity
buflomedil buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure	2.45	2	0	aromatic ketone
bumetanide [no description available]	4.08	4	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin bunazosin: structure	2.04	1	0	quinazolines
bupivacaine Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.	2.45	2	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
buspirone Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.	3.23	1	0	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
busulfan [no description available]	4.08	4	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
secbutabarbital secbutabarbital: Butabarbital (a synonym for Secbutabarbital) should be distinguished from Butobarbital	3.23	1	0	barbiturates
caffeine [no description available]	4.08	4	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	4.29	5	0	aromatic ether; nitrile; polyether; tertiary amino compound
metrizoate Metrizoic Acid: A diagnostic radiopaque that usually occurs as the sodium salt.	2.45	2	0	monocarboxylic acid	radioopaque medium
candesartan candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.	3.23	1	0	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	3.61	2	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carbinoxamine carbinoxamine: Note: tradenames that start with Histex refer to more than one drug. carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.	3.23	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist
carisoprodol Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.	3.23	1	0	carbamate ester	muscle relaxant
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.46	2	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carprofen carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.	2.08	1	0	carbazoles; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent
carvedilol [no description available]	4.08	4	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
celecoxib [no description available]	3.61	2	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	3.23	1	0	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	4.08	4	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlorcyclizine chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness	3.23	1	0	diarylmethane
chlordiazepoxide Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.	4.08	4	0	benzodiazepine
chlormezanone Chlormezanone: A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.. chlormezanone : A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.	3.23	1	0	1,3-thiazine; lactam; monochlorobenzenes; sulfone	antipsychotic agent; anxiolytic drug; muscle relaxant
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	9.56	7	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorothiazide Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.	3.23	1	0	benzothiadiazine	antihypertensive agent; diuretic
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	4.08	4	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	4.08	4	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	4.08	4	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.	4.08	4	0	isoindoles; monochlorobenzenes; sulfonamide
chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.	3.61	2	0	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
cifenline [no description available]	2.75	3	0	diarylmethane
ciclopirox [no description available]	2.08	1	0	cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone	antibacterial agent; antiseborrheic
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	2.08	1	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
cilostazol [no description available]	3.61	2	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	4.28	5	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
ciprofibrate [no description available]	2.08	1	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	8.91	81	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	4.08	4	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	2.08	1	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clobazam Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.. clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.	2.08	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator
clofazimine Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.	2.87	3	0	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	3.61	2	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clomiphene [no description available]	3.61	2	0	tertiary amine	estrogen antagonist; estrogen receptor modulator
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	3.87	3	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	3.85	3	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	3.85	3	0	clonidine; imidazoline
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide [no description available]	2.08	1	0	sulfonamide
chlorazepate clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.	3.58	2	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
clotrimazole [no description available]	3.23	1	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
cyclobenzaprine cyclobenzaprine: RN given refers to parent cpd; Lisseril is synonymous for HCl; structure. cyclobenzaprine : 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.	3.23	1	0	carbotricyclic compound	antidepressant; muscle relaxant; tranquilizing drug
cyclofenil Cyclofenil: A gonadal stimulant and inducer of ovulation. It is used in the treatment of infertility and amenorrhea, but is thought to be less effective than CLOMIPHENE.	3.23	1	0	organic molecular entity
cyproheptadine Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.	3.23	1	0	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
dapsone [no description available]	4.08	4	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	3.23	1	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	4.08	4	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
nordazepam Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.	2.04	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	3.58	2	0	primary amine
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	4.08	4	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	4.08	4	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	3.85	3	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
dichlorphenamide Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.	3.23	1	0	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
dicyclomine Dicyclomine: A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.. dicyclomine : The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.	3.23	1	0	carboxylic ester; tertiary amine	antispasmodic drug; muscarinic antagonist; parasympatholytic
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	3.23	1	0	pentacarboxylic acid	copper chelator
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	3.58	2	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
dimercaprol Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.	3.23	1	0	dithiol; primary alcohol	chelator
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	3.85	3	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	3.61	2	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	4.08	4	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
disulfiram [no description available]	4.4	3	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	3.85	3	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.75	3	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	3.61	2	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
doxapram Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.	3.58	2	0	morpholines; pyrrolidin-2-ones	central nervous system stimulant
doxazosin Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.	3.58	2	0	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent
doxepin Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.	4.08	4	0	dibenzooxepine; tertiary amino compound	antidepressant
doxylamine Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.	3.23	1	0	pyridines; tertiary amine	anti-allergic agent; antiemetic; antitussive; cholinergic antagonist; H1-receptor antagonist; histamine antagonist; sedative
droperidol Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.	3.23	1	0	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
dyphylline Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.	3.58	2	0	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent
ebastine [no description available]	2.08	1	0	organic molecular entity
edrophonium Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.. edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.	3.23	1	0	phenols; quaternary ammonium ion	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
enoxacin Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.	2.46	2	0	1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
estazolam Estazolam: A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than DIAZEPAM or NITRAZEPAM.. estazolam : A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia.	3.23	1	0	triazoles; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA modulator
ethacrynic acid Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.	3.87	3	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
ethosuximide Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.	3.61	2	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
ethotoin ethotoin: was heading 1966-94 (see under HYDANTOINS 1966-90); use HYDANTOINS to search ETHOTOIN 1966-94. ethotoin : An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.	3.23	1	0	imidazolidine-2,4-dione	anticonvulsant
etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.	3.23	1	0	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
etilefrine Etilefrine: A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.	2.45	2	0	phenols
etodolac Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.	3.23	1	0	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
brl 42810 [no description available]	3.61	2	0	2-aminopurines; acetate ester	antiviral drug; prodrug
felbamate Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.	3.23	1	0	carbamate ester	anticonvulsant; neuroprotective agent
4-biphenylylacetic acid biphenyl-4-ylacetic acid : A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis.	2.08	1	0	biphenyls; monocarboxylic acid	non-steroidal anti-inflammatory drug
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	4.08	4	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	3.61	2	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
fenoldopam Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.	3.23	1	0	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
fenoprofen Fenoprofen: A propionic acid derivative that is used as a non-steroidal anti-inflammatory agent.. fenoprofen : A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.	3.23	1	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.04	1	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fenspiride fenspiride: was heading 1975-94 (see under SPIRO COMPOUNDS 1975-90); use SPIRO COMPOUNDS to search FENSPIRIDE 1975-94; bronchodilator agent used in asthma	2.04	1	0	azaspiro compound
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.45	2	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fexofenadine fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.	3.23	1	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
fipexide fipexide: regulates dopaminergic systems at macromolecular level	3.23	1	0	benzodioxoles
flavoxate Flavoxate: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.. flavoxate : A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.	3.23	1	0	carboxylic ester; flavones; piperidines; tertiary amino compound	antispasmodic drug; muscarinic antagonist; parasympatholytic
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	3.85	3	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fleroxacin Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.	2.75	3	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	9.28	5	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	4.08	4	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
fluphenazine [no description available]	3.23	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	4.08	4	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
flunitrazepam Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.	2.04	1	0	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
fluorescite fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.	3.87	3	0	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.08	4	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	3.61	2	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flurazepam Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.	3.23	1	0	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; tertiary amino compound	anticonvulsant; anxiolytic drug; GABAA receptor agonist; sedative
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	3.23	1	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	3.61	2	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
fomepizole Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL.. fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.	3.23	1	0	pyrazoles	antidote; EC 1.1.1.1 (alcohol dehydrogenase) inhibitor; protective agent
foscarnet Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	3.85	3	0	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	9.29	5	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gabapentin Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.	3.85	3	0	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
gemfibrozil [no description available]	3.61	2	0	aromatic ether	antilipemic drug
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	6.02	32	0
glafenine Glafenine: An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.. glafenine : A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.	3.23	1	0	aminoquinoline; carboxylic ester; glycol; organochlorine compound; secondary amino compound	inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
gliclazide Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.	2.08	1	0	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger
glimepiride glimepiride: structure given in first source	4.08	4	0	sulfonamide
glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.	4.08	4	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	4.08	4	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester [no description available]	3.23	1	0	benzenes
granisetron [no description available]	3.85	3	0	aromatic amide; indazoles
guaifenesin Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.	3.23	1	0	methoxybenzenes
guanethidine Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.	3.23	1	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
guanfacine Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.	4.08	4	0	acetamides
guanidine Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.	3.23	1	0	carboxamidine; guanidines; one-carbon compound
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	4.08	4	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hexobarbital Hexobarbital: A barbiturate that is effective as a hypnotic and sedative.. hexobarbital : A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.	2.45	2	0	barbiturates
beta-thujaplicin beta-thujaplicin: structure. beta-thujaplicin : A monoterpenoid that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2 and an isopropyl group at position 4. Isolated from Thuja plicata and Chamaecyparis obtusa, it exhibits antimicrobial activities.	2.6	1	0	cyclic ketone; enol; monoterpenoid	antibacterial agent; antifungal agent; antineoplastic agent; antiplasmodial drug; plant metabolite
ethidium Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.	2.43	2	0	phenanthridines	fluorochrome; intercalator
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	3.85	3	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	3.61	2	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroflumethiazide Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.	3.87	3	0	benzothiadiazine; thiazide	antihypertensive agent; diuretic
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	3.58	2	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyurea [no description available]	4.08	4	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	3.23	1	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
hypericin [no description available]	2.04	1	0
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	3.85	3	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
phenelzine Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.	3.23	1	0	primary amine
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	4.08	4	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifosfamide [no description available]	4.08	4	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	4.08	4	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	4.08	4	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.	3.61	2	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	4.08	4	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	2.74	3	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iopromide iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.	2.45	2	0	dicarboxylic acid diamide; organoiodine compound	environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic
iothalamic acid Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.	2.04	1	0	organic molecular entity
ioversol [no description available]	3.23	1	0	amidobenzoic acid
iproniazid [no description available]	3.61	2	0	carbohydrazide; pyridines
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	3.87	3	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isocarboxazid Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)	3.23	1	0	benzenes
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.87	3	0	carbohydrazide	antitubercular agent; drug allergen
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	3.58	2	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
isoxsuprine Isoxsuprine: A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.	3.23	1	0	alkylbenzene
isradipine Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.	4.08	4	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
itraconazole [no description available]	4.08	4	0	piperazines
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	3.87	3	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.75	3	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	3.61	2	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	3.85	3	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketorolac Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.	3.85	3	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	3.85	3	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lamotrigine [no description available]	3.61	2	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	4.08	4	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	3.61	2	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	4.08	4	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lofepramine Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.	2.08	1	0	aromatic ketone; dibenzoazepine; monochlorobenzenes; tertiary amino compound	antidepressant
lomefloxacin lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.	3.23	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antimicrobial agent; antitubercular agent; photosensitizing agent
lomustine [no description available]	3.61	2	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
loperamide Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	3.23	1	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	3.61	2	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
lorazepam Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.	3.85	3	0	benzodiazepine
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	3.85	3	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
loxapine Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.	3.23	1	0	dibenzooxazepine	antipsychotic agent; dopaminergic antagonist
maprotiline Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.	3.87	3	0	anthracenes
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	4.08	4	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mecamylamine Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.	3.23	1	0	primary aliphatic amine
mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.	3.23	1	0	nitrogen mustard; organochlorine compound	alkylating agent
meclizine Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.	3.23	1	0	diarylmethane
meclofenamic acid Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.	3.23	1	0	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
mefenamic acid Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.	3.61	2	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
mefloquine hydrochloride [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.	2.05	1	0	organofluorine compound; piperidines; quinolines; secondary alcohol
memantine [no description available]	3.23	1	0	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
mepenzolate mepenzolic acid: anticholinergic, antispasmodic agent; RN given refers to parent cpd; structure	3.23	1	0	diarylmethane
meperidine Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.	3.85	3	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	3.23	1	0	imidazolidine-2,4-dione	anticonvulsant
mepivacaine Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.	3.58	2	0	piperidinecarboxamide	drug allergen; local anaesthetic
meprobamate Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)	3.58	2	0	organic molecular entity
mesalamine Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.	3.58	2	0	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug
mesoridazine Mesoridazine: A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.. mesoridazine : A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group.	3.23	1	0	phenothiazines; sulfoxide; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic
metaproterenol Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.	3.23	1	0	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	4.08	4	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methadone Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.	3.85	3	0	benzenes; diarylmethane; ketone; tertiary amino compound
methapyrilene Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.	2.04	1	0	ethylenediamine derivative	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
methazolamide Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.	3.23	1	0	sulfonamide; thiadiazoles
methocarbamol Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.	3.23	1	0	aromatic ether; carbamate ester; secondary alcohol
methoxsalen Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.	3.23	1	0	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite
methyclothiazide Methyclothiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)	3.23	1	0	benzothiadiazine
methylphenidate Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.	3.85	3	0	beta-amino acid ester; methyl ester; piperidines
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	4.08	4	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metolazone Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.	3.85	3	0	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	4.08	4	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	10.9	31	2	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
metyrapone Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.	3.23	1	0	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	4.08	4	0	aromatic ether; primary amino compound	anti-arrhythmia drug
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	4.08	4	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
midodrine Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.. midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.	3.23	1	0	amino acid amide; aromatic ether; secondary alcohol	alpha-adrenergic agonist; prodrug; sympathomimetic agent; vasoconstrictor agent
milrinone [no description available]	3.85	3	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	3.61	2	0	dialkylarylamine; tertiary amino compound
mirtazapine Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.	4.08	4	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
mitotane Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.	3.23	1	0	diarylmethane
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	3.85	3	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
ml 7 ML-7 : An N-sulfonyldiazepane resullting from the formal condensation of 5-iodo-1-naphthylsulfonic acid with one of the nitrogens of 1,4-diazepane. It is a selective inhibitor of myosin light chain kinase (EC 2.7.11.18).	2.31	1	0	N-sulfonyldiazepane; organoiodine compound	EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.	2.75	3	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
modafinil Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.. modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.. 2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.	3.23	1	0	monocarboxylic acid amide; sulfoxide
moxisylyte Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)	3.23	1	0	monoterpenoid
acecainide Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.	2.75	3	0	acetamides; benzamides	anti-arrhythmia drug
nabumetone Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.	3.23	1	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
nadolol [no description available]	3.61	2	0	tetralins
nalidixic acid [no description available]	4.08	4	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
naratriptan naratriptan: structure given in first source	3.85	3	0	heteroarylpiperidine; sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
nefazodone nefazodone: may be useful as an opiate adjunct	4.08	4	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nefopam Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.	2.46	2	0	benzoxazocine; tertiary amino compound
neostigmine Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.	2.08	1	0	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	4.08	4	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nialamide Nialamide: An MAO inhibitor that is used as an antidepressive agent.	3.23	1	0	organonitrogen compound; organooxygen compound
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	4.08	4	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	4.08	4	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nilutamide [no description available]	3.23	1	0	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	3.61	2	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	4.08	4	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nisoldipine Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.	4.08	4	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrazepam Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).	2.75	3	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.75	3	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	3.23	1	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
nitromide nitromide: antibacterial agent for prevention & treatment of Salmonella pullorum infections in chickens & turkeys & for fowl typhoid & paratyphoid; used in feed; structure	3.23	1	0
nizatidine [no description available]	3.85	3	0	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	3.85	3	0	isoquinolines	dopamine uptake inhibitor
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	4.42	6	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	4.08	4	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	10.8	21	6	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	9.43	6	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	3.87	3	0	carbazoles
orphenadrine Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.. orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.	3.23	1	0	ether; tertiary amino compound	antidyskinesia agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
oxaprozin Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.	3.61	2	0	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
oxazepam Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.	3.85	3	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
oxiracetam oxiracetam: structure in first source	2.04	1	0	organonitrogen compound; organooxygen compound
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	3.87	3	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	3.23	1	0	aminobenzoic acid; phenols	antitubercular agent
pamidronate [no description available]	3.58	2	0	phosphonoacetic acid
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	3.85	3	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	4.08	4	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pemoline Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.	3.61	2	0	1,3-oxazoles	central nervous system stimulant
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	3.87	3	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	3.58	2	0	barbiturates	GABAA receptor agonist
pentoxifylline [no description available]	3.87	3	0	oxopurine
perhexiline Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	3.23	1	0	piperidines	cardiovascular drug
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	4.08	4	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.46	2	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	3.85	3	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phenoxybenzamine Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.	3.23	1	0	aromatic amine
phentermine Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.	3.23	1	0	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.	3.23	1	0	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
moxonidine moxonidine: structure given in first source	2.45	2	0	organohalogen compound; pyrimidines
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	2.04	1	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	4.08	4	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	3.61	2	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piracetam Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.	2.08	1	0	organonitrogen compound; organooxygen compound
piretanide piretanide: potent inhibitor of chloride transport; structure	2.45	2	0	aromatic ether
piribedil Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.	2.08	1	0	N-arylpiperazine
polythiazide [no description available]	3.23	1	0	benzothiadiazine
practolol Practolol: A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS.. practolol : N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythmias.	2.05	1	0	acetamides; ethanolamines; propanolamine; secondary alcohol; secondary amino compound	anti-arrhythmia drug; beta-adrenergic antagonist
duodote duodote: consists of atropine and pralidoxime chloride; for treating those exposed to organophosphorus-containing nerve agents	3.23	1	0	pyridinium ion	antidote to organophosphate poisoning; antidote to sarin poisoning; cholinergic drug; cholinesterase reactivator
ono 1078 pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist	2.08	1	0	chromones
pyranoprofen pyranoprofen: RN given refers to unlabled parent cpd; structure given in first source	2.08	1	0	pyridochromene
praziquantel azinox: Russian drug	3.61	2	0	isoquinolines
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	4.08	4	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.. prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.	2.04	1	0	amino acid amide; monocarboxylic acid amide	anticonvulsant; local anaesthetic
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	3.87	3	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
primidone Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.	3.61	2	0	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	4.08	4	0	benzoic acids; sulfonamide	uricosuric drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	4.08	4	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
procarbazine Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	3.23	1	0	benzamides; hydrazines	antineoplastic agent
prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.	3.87	3	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
procyclidine Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.	3.87	3	0	pyrrolidines; tertiary alcohol	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
promazine Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.	2.04	1	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	4.08	4	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	3.87	3	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propantheline Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.	3.23	1	0	xanthenes
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	3.58	2	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	9.29	5	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protriptyline Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.	3.23	1	0	carbotricyclic compound	antidepressant
pyridostigmine [no description available]	3.85	3	0	pyridinium ion
pyrimethamine Maloprim: contains above 2 cpds	3.58	2	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
sch 16134 quazepam: structure given in first source	3.23	1	0	benzodiazepine
quetiapine [no description available]	3.23	1	0	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist
rabeprazole Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.	3.85	3	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
raloxifene raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.	3.23	1	0	1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
ranitidine [no description available]	2.75	3	0	aralkylamine
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	3.61	2	0	benzothiazoles
rimantadine Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	3.23	1	0	alkylamine
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	4.08	4	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
rizatriptan rizatriptan: structure given in first source; RN given refers to benzoate	3.85	3	0	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rofecoxib [no description available]	2.08	1	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
ropinirole [no description available]	3.23	1	0	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist
salicylsalicylic acid salicylsalicylic acid: structure. salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.	3.23	1	0	benzoate ester; benzoic acids; phenols; salicylates	antineoplastic agent; antirheumatic drug; EC 3.5.2.6 (beta-lactamase) inhibitor; hypoglycemic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
secobarbital Secobarbital: A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity.. secobarbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups.	3.23	1	0	barbiturates	anaesthesia adjuvant; GABA modulator; sedative
sibutramine sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride	3.23	1	0	organochlorine compound; tertiary amino compound	anti-obesity agent; serotonin uptake inhibitor
sulfadiazine Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.	4.08	4	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	3.85	3	0	pyridines
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	4.08	4	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
imatinib [no description available]	4.08	4	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.87	3	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
succinylcholine Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.. succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid.	3.23	1	0	quaternary ammonium ion; succinate ester	drug allergen; muscle relaxant; neuromuscular agent
sulfamethizole Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.	3.23	1	0	sulfonamide antibiotic; sulfonamide; thiadiazoles	antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	8.44	7	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfanitran [no description available]	2.08	1	0	sulfonamide
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	3.61	2	0
sulfathiazole Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.	3.23	1	0	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
sulfinpyrazone Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.	2.45	2	0	pyrazolidines; sulfoxide	uricosuric drug
sulfisoxazole Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.	2.75	3	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol [no description available]	3.23	1	0	alkylbenzene
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	2.05	1	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
sumatriptan Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.	4.08	4	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suprofen Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.	2.45	2	0	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	2.45	2	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	3.28	6	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.	2.08	1	0	acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane	keratolytic drug; prodrug; teratogenic agent
temazepam Temazepam: A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.	3.23	1	0	benzodiazepine
temozolomide [no description available]	3.87	3	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terazosin Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia	4.08	4	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terbutaline Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.	4.08	4	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.08	1	0	diarylmethane
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	3.58	2	0	phthalimides; piperidones
thiabendazole Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate	3.23	1	0	1,3-thiazoles; benzimidazole fungicide; benzimidazoles	antifungal agrochemical; antinematodal drug
thioridazine Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.	3.71	2	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	4.08	4	0	aziridines
tiapride [no description available]	2.08	1	0	benzamides
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	3.23	1	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tilorone Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.	2.08	1	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.	4.26	5	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
tiopronin Tiopronin: Sulfhydryl acylated derivative of GLYCINE.	3.23	1	0	N-acyl-amino acid
tizanidine tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.	4.08	4	0	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
nikethamide Nikethamide: A central nervous system stimulant. It was formerly used in the treatment of barbiturate overdose but is now considered to be of no value for such purposes and may be dangerous. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1229)	2.08	1	0	pyridinecarboxamide
tolazamide Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.	3.23	1	0	N-sulfonylurea	hypoglycemic agent; potassium channel blocker
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	4.08	4	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
tolmetin Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.	3.23	1	0	aromatic ketone; monocarboxylic acid; pyrroles	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
tolnaftate [no description available]	2.08	1	0	monothiocarbamic ester	antifungal drug
ultram 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.	3.85	3	0	aromatic ether; tertiary alcohol; tertiary amino compound
tranexamic acid Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.	3.58	2	0	amino acid
trazodone Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.	3.87	3	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	4.08	4	0	pteridines	diuretic; sodium channel blocker
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	3.85	3	0	triazolobenzodiazepine	sedative
trifluoperazine [no description available]	3.23	1	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trihexyphenidyl Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.	3.23	1	0	amine
trimethadione Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.	3.23	1	0	oxazolidinone	anticonvulsant; geroprotector
trimethobenzamide trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.	3.23	1	0	benzamides; tertiary amino compound	antiemetic
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	4.66	8	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
trimetrexate Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.	3.85	3	0
trimipramine Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.	3.58	2	0	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	3.61	2	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
thenoyltrifluoroacetone Thenoyltrifluoroacetone: Chelating agent and inhibitor of cellular respiration.	2.08	1	0
tyramine [no description available]	3.23	1	0	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	3.23	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
undecylenic acid undecylenic acid: a fatty acid with a terminal double bond. 10-undecenoic acid : An undecenoic acid having its double bond in the 10-position. It is derived from castor oil and is used for the treatment of skin problems.. undecenoic acid : A C11, straight-chain fatty acid carrying a C=C double bond at any position.	2.08	1	0	undecenoic acid	antifungal drug; plant metabolite
urapidil [no description available]	2.46	2	0	piperazines
venlafaxine venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.	4.08	4	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
vigabatrin [no description available]	3.61	2	0	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
viloxazine Viloxazine: A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.	2.04	1	0	aromatic ether
pirinixic acid pirinixic acid: structure	2.08	1	0	aryl sulfide; organochlorine compound; pyrimidines
ici 204,219 zafirlukast: a leukotriene D4 receptor antagonist	3.61	2	0	carbamate ester; indoles; N-sulfonylcarboxamide	anti-asthmatic agent; leukotriene antagonist
zaleplon zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.	4.08	4	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
zolpidem Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.	3.85	3	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
zonisamide Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.	3.61	2	0	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
zopiclone zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.	2.96	4	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
cortisone acetate Cortisone Acetate: The acetate ester of cortisone that is used mainly for replacement therapy in adrenocortical insufficiency and in the treatment of many allergic and inflammatory disorders.	3.23	1	0	corticosteroid hormone
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	3.23	1	0	mitomycin	alkylating agent; antineoplastic agent
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	4.08	4	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	3.61	2	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
cephaloridine Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.	2.04	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
phentolamine Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.	3.23	1	0	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).	3.23	1	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	3.23	1	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
dextroamphetamine Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.	3.23	1	0	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.	3.23	1	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
penicillamine Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.	3.61	2	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
cysteine [no description available]	3.23	1	0	cysteine zwitterion; cysteine; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid	EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	4.08	4	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	3.23	1	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
methylprednisolone acetate Methylprednisolone Acetate: Methylprednisolone derivative that is used as an anti-inflammatory agent for the treatment of ALLERGY and ALLERGIC RHINITIS; ASTHMA; and BURSITIS; and for the treatment of ADRENAL INSUFFICIENCY.. methylprednisolone acetate : An acetate ester resulting from the formal condensation of the 21-hydroxy function of 6alpha-methylprednisolone compound with acetic acid.	2.1	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; acetate ester; glucocorticoid; steroid ester; tertiary alpha-hydroxy ketone	anti-inflammatory drug
oxandrolone Oxandrolone: A synthetic hormone with anabolic and androgenic properties.	3.23	1	0	17beta-hydroxy steroid; 3-oxo steroid; anabolic androgenic steroid; oxa-steroid	anabolic agent; androgen
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	4.67	8	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	3.23	1	0	pilocarpine	antiglaucoma drug
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	3.23	1	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.08	1	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	6.9	22	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	3.23	1	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
vincristine [no description available]	3.58	2	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
physostigmine Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.	3.23	1	0	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.46	2	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
tubocurarine Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.	2.08	1	0	bisbenzylisoquinoline alkaloid	drug allergen; muscle relaxant; nicotinic antagonist
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	3.87	3	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
methyltestosterone Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.	3.23	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; enone	anabolic agent; androgen; antineoplastic agent
tetrabenazine 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.	3.23	1	0	benzoquinolizine; cyclic ketone; tertiary amino compound
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.17	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
cephalothin Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.	2.95	4	0	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
uridine [no description available]	3.23	1	0	uridines	drug metabolite; fundamental metabolite; human metabolite
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	4.11	4	0	kanamycins	bacterial metabolite
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	4.56	7	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.75	3	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	4.34	5	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.25	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
cysteamine Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.	3.23	1	0	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
acetylcholine chloride acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug.	3.23	1	0	quaternary ammonium salt
mepazine mepazine: major descriptor (66-85); on-line search PHENOTHIAZINES (66-85); Index Medicus search MEPAZINE (66-85); RN given refers to parent cpd. pacatal : A phenothiazine derivative in which 10H-phenothiazine has an N-methylpiperidin-4-ylmethyl substituent at the N-10 position.	3.23	1	0	phenothiazines
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	8.57	8	0	penicillin allergen; penicillin	antibacterial drug
cloxacillin Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.	3.23	1	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
calcium acetate calcium acetate: a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer. calcium acetate : The calcium salt of acetic acid. It is used, commonly as a hydrate, to treat hyperphosphataemia (excess phosphate in the blood) in patients with kidney disease: the calcium ion combines with dietary phosphate to form (insoluble) calcium phosphate, which is excreted in the faeces.	3.23	1	0	calcium salt	chelator
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	3.23	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	3.87	3	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
mebanazine mebanazine: RN given refers to parent cpd without isomeric designation; structure	3.23	1	0	benzenes
oxacillin Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.	10.12	13	0	penicillin	antibacterial agent; antibacterial drug
triamcinolone diacetate triamcinolone diacetate: lysyl oxidase antagonist; Polcortolon may also refers to triamcinolone	2.08	1	0	corticosteroid hormone
cycloserine Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).	3.23	1	0	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
benziodarone benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)	3.23	1	0	aromatic ketone
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	8	24	1	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
mannitol [no description available]	3.23	1	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine [no description available]	8.91	3	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
medroxyprogesterone acetate [no description available]	2.08	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	3.23	1	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
trichloroacetic acid Trichloroacetic Acid: A strong acid used as a protein precipitant in clinical chemistry and also as a caustic for removing warts.. trichloroacetic acid : A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.	2.41	1	0	monocarboxylic acid; organochlorine compound	carcinogenic agent; metabolite; mouse metabolite
perflutren Definity: a fluorocarbon-filled ultrasonic contrast agent; Definity is tradename. octafluoropropane : A fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines.	3.23	1	0	fluoroalkane; fluorocarbon
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	2.46	2	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
fluoxymesterone Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.	3.23	1	0	11beta-hydroxy steroid; 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid; fluorinated steroid	anabolic agent; antineoplastic agent
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.45	2	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
methsuximide methsuximide: anticonvulsant effective in petit mal & psychomotor epilepsy; has a number of unpleasant & toxic side effects; minor descriptor (75-86); on-line & INDEX MEDICUS search SUCCINIMIDES (75-86); RN given refers to parent cpd without isomeric designation	3.23	1	0	organic molecular entity
dimethyl sulfate dimethyl sulfate: RN given refers to unlabeled cpd; structure. dimethyl sulfate : The dimethyl ester of sulfuric acid.	2.02	1	0	alkyl sulfate	alkylating agent; immunosuppressive agent
tromethamine Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)	3.23	1	0	primary amino compound; triol	buffer
dichloroacetic acid [no description available]	2.04	1	0	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	4.27	5	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.08	1	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
brompheniramine Brompheniramine: Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.. brompheniramine : Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	3.23	1	0	organobromine compound; pyridines	anti-allergic agent; H1-receptor antagonist
acriflavine chloride 3,6-diamino-10-methylacridinium chloride : The 10-methochloride salt of 3,6-diaminoacridine. Note that a mixture of this compound with 3,6-diaminoacridine (proflavine) is known as acriflavine or neutral acriflavine.	2.03	1	0	organic chloride salt	antibacterial agent; antiseptic drug; carcinogenic agent; histological dye; intercalator
penicillin v Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.	3.85	3	0	penicillin allergen; penicillin
isosorbide dinitrate Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.	3.58	2	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
penicillanic acid Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed). penicillanic acid : A penam that consists of 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane bearing a carboxy group at position 2 and having (2S,5R)-configuration.	4.84	7	1	penicillanic acids
thymol Thymol: A phenol obtained from thyme oil or other volatile oils used as a stabilizer in pharmaceutical preparations, and as an antiseptic (antibacterial or antifungal) agent.. thymol : A phenol that is a natural monoterpene derivative of cymene.	2.6	1	0	monoterpenoid; phenols	volatile oil component
pseudoephedrine Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.	3.23	1	0	phenylethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; bronchodilator agent; central nervous system drug; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
diethylpropion Diethylpropion: A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290). diethylpropion : An aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.	3.23	1	0	aromatic ketone; tertiary amine	appetite depressant
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.11	1	0	xanthene
phenothiazine 10H-phenothiazine : The 10H-tautomer of phenothiazine.	3.19	1	0	phenothiazine	ferroptosis inhibitor; plant metabolite; radical scavenger
benzonatate benzonatate: structure in Merck Index, 9th ed, #1107. benzonatate : The ester obtained by formal condensation of 4-butylaminobenzoic acid with nonaethylene glycol monomethyl ether. Structurally related to procaine and benzocaine, it has an anaesthetic effect on the stretch sensors in the lungs, and is used as a non-narcotic cough suppressant.	3.23	1	0	benzoate ester; secondary amino compound; substituted aniline	anaesthetic; antitussive
ergotamine Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.	2.04	1	0	peptide ergot alkaloid	alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent
methylergonovine Methylergonovine: A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)	3.23	1	0	ergoline alkaloid
neostigmine bromide neostigmine bromide : The bromide salt of neostigmine.	2.04	1	0	bromide salt
phenformin Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.	2.52	2	0	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	2.5	2	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94	3.23	1	0	quinolines
nafcillin Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.	3.85	3	0	penicillin allergen; penicillin	antibacterial drug
methohexital Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.	3.58	2	0	acetylenic compound; barbiturates	drug allergen; intravenous anaesthetic
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	2.21	1	0	1,3-benzoxazoles; mancude organic heterobicyclic parent
adamantane Adamantane: A tricyclo bridged hydrocarbon.	3.23	1	0	adamantanes; polycyclic alkane
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	3.61	2	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.03	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
ephedrine Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.	3.23	1	0	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
pirinitramide Pirinitramide: A diphenylpropylamine with intense narcotic analgesic activity of long duration. It is a derivative of MEPERIDINE with similar activity and usage.	2.45	2	0	nitrile
edrophonium bromide [no description available]	2.04	1	0
aminophylline Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.	3.61	2	0	mixture	bronchodilator agent; cardiotonic drug
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	3.58	2	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.	4.08	4	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
nandrolone decanoate Nandrolone Decanoate: Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.	3.23	1	0	steroid ester
procarbazine hydrochloride procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	2.08	1	0	hydrochloride	antineoplastic agent
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	2.75	3	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
dextropropoxyphene Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.	3.58	2	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
ketobemidone ketobemidone: structure	2.04	1	0	piperidines
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	3.23	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.08	1	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
4-hydroxybutyric acid 4-hydroxybutyric acid: was an entry term to Sodium Oxybate (74-98). 4-hydroxybutyric acid : A 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group.	3.23	1	0	4-hydroxy monocarboxylic acid; hydroxybutyric acid	general anaesthetic; GHB receptor agonist; neurotoxin; sedative
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	3.23	1	0
dihydroergotamine Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.	3.23	1	0	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
medroxyprogesterone [no description available]	3.23	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
dimenhydrinate gravinol: has antioxidant and ant-inflammatory activities; structure in first source	3.61	2	0	diarylmethane
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	3.23	1	0	C-nitro compound; imidazoles	antitubercular agent
chlormethiazole Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.	2.45	2	0	thiazoles
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	3.58	2	0	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
levocarnitine (R)-carnitine : The (R)-enantiomer of carnitine.	3.23	1	0	carnitine	antilipemic drug; nootropic agent; nutraceutical; Saccharomyces cerevisiae metabolite; water-soluble vitamin (role)
sulfanilylurea sulfanilylurea: antimicrobial agent; structure	3.23	1	0	benzenes; sulfonamide
gentian violet Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.	3.02	4	0	organic chloride salt	anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye
resazurin resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure	2.11	1	0	phenoxazine
1-naphthylisothiocyanate 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.	2.08	1	0	isothiocyanate	insecticide
lithium carbonate Lithium Carbonate: A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.	2.04	1	0	carbonate salt; lithium salt	antimanic drug
glycylglycine [no description available]	4.36	3	0	dipeptide zwitterion; dipeptide	human metabolite
congo red Congo Red: An acid dye used in testing for hydrochloric acid in gastric contents. It is also used histologically to test for AMYLOIDOSIS.. Congo Red : An indicator dye that is blue-violet at pH 3.0 and red at pH 5.0.	2.11	1	0	bis(azo) compound
lactulose [no description available]	3.23	1	0	glycosylfructose	gastrointestinal drug; laxative
megestrol acetate [no description available]	2.08	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
pamabrom [no description available]	3.23	1	0
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	8.05	6	2	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	10.54	21	0	cyclic ketone; erythromycin
hydroxychloroquine sulfate [no description available]	2.08	1	0
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	3.87	3	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
lormetazepam lormetazepam: RN given refers to cpd with specified locant for methyl group; structure given in first source. lormetazepam : A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position.	2.45	2	0	1,4-benzodiazepinone; organochlorine compound	sedative
vinblastine [no description available]	2.45	2	0
diphenoxylate Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.	3.23	1	0	ethyl ester; nitrile; piperidinecarboxylate ester; tertiary amine	antidiarrhoeal drug
ethambutol hydrochloride ethambutol dihydrochloride : The dihydrchloride salt of ethambutol. A bacteriostatic antimycobacterial drug, it is effective against Mycobacterium tuberculosis and some other mycobacteria. It is used in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol dihydrochloride is used alone.	2.08	1	0	hydrochloride	antitubercular agent
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	3.85	3	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
ethidium bromide [no description available]	2.03	1	0	organic bromide salt	geroprotector; intercalator; trypanocidal drug
durapatite Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).	2.07	1	0
antimycin a [no description available]	2.08	1	0	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	14.71	127	7	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	4.16	4	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
pregnenolone carbonitrile Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage.	2.08	1	0	aliphatic nitrile
ibufenac ibufenac: used in the treatment of rheumatism; also possesses antipyretic properties; minor descriptor (75-84); on-line & Index Medicus search PHENYLACETATES (75-84); RN given refers to parent cpd. ibufenac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.	3.23	1	0	monocarboxylic acid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug
metylperon metylperon: RN given refers to parent cpd	2.46	2	0	aromatic ketone
metaxalone [no description available]	3.23	1	0	aromatic ether
spectinomycin Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.	3.58	2	0	cyclic acetal; cyclic hemiketal; cyclic ketone; pyranobenzodioxin; secondary alcohol; secondary amino compound	antibacterial drug; antimicrobial agent; bacterial metabolite
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	3.58	2	0	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	3.23	1	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.	3.23	1	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
benperidol Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)	2.04	1	0	aromatic ketone
dexbrompheniramine dexbrompheniramine : The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	3.23	1	0	brompheniramine	anti-allergic agent; H1-receptor antagonist
chlordesmethyldiazepam [no description available]	2.04	1	0	benzodiazepine
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	4.08	4	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.	2.45	2	0	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
dicloxacillin Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.	4.08	4	0	dichlorobenzene; penicillin	antibacterial drug
megestrol Megestrol: A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.. megestrol : A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.	3.23	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
streptomycin [no description available]	5.2	8	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
cladribine [no description available]	4.08	4	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
carbenicillin Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.	4.09	4	0	penicillin allergen; penicillin	antibacterial drug
metocurine metocurine: from Chinese herb Cyclea hainanensis Mrr	2.08	1	0	isoquinolines
floxacillin Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.	2.45	2	0	penicillin allergen; penicillin	antibacterial drug
clomacran clomacran: RN given refers to parent cpd; structure	3.23	1	0	acridines
beclomethasone dipropionate beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.	2.04	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; enone; glucocorticoid; propanoate ester; steroid ester	anti-arrhythmia drug; anti-asthmatic drug; anti-inflammatory drug; prodrug
methenamine hippurate methenamine hippurate: both parts of molecule contribute to its antibacterial action	3.23	1	0	N-acylglycine
olsalazine olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.	3.58	2	0	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug
terodiline [no description available]	2.45	2	0	diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene 1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd	2.04	1	0
etidronate disodium etidronate disodium : An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions.	2.08	1	0	organic sodium salt	antineoplastic agent; bone density conservation agent; chelator
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	2.46	2	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
silver Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.	2.21	1	0	copper group element atom; elemental silver	Escherichia coli metabolite
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.46	2	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
metocurine iodide [no description available]	2.45	2	0	aromatic ether
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.08	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
tricalcium phosphate tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.	2.48	2	0	calcium phosphate
sodium thiosulfate sodium thiosulfate: do not confuse synonym sodium hyposulfite with sodium hyposulfite, synonym for di-Na salt of dithionous acid. sodium thiosulfate : An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.	3.23	1	0	inorganic sodium salt	antidote to cyanide poisoning; antifungal drug; nephroprotective agent
mafenide acetate [no description available]	2.08	1	0	carboxylic acid
apazone Apazone: An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.. apazone : A member of the class of benzotriazines that is 1,2-dihydro-1,2,4-benzotriazine bearing a dimethylamino substitutent at position 3 and a methyl substituent at position 7 and in which the nitrogens at positions 1 and 2 are both acylated by a carboxy group of propylmalonic acid.	2.04	1	0	benzotriazines	non-steroidal anti-inflammatory drug; uricosuric drug
diacerein diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;	2.08	1	0	anthraquinone
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	3.85	3	0	selegiline; terminal acetylenic compound	geroprotector
selegiline hydrochloride, (r)-isomer [no description available]	2.08	1	0	hydrochloride; terminal acetylenic compound	antiparkinson drug; dopaminergic agent; EC 1.4.3.4 (monoamine oxidase) inhibitor
clemastine Clemastine: A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.. clemastine : 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.	3.23	1	0	monochlorobenzenes; N-alkylpyrrolidine	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
thiamphenicol [no description available]	2.57	2	0	monocarboxylic acid amide; sulfone	antimicrobial agent; immunosuppressive agent
pancuronium bromide pancuronium bromide : A bromide salt consisting of two bromide ions and one pancuronium dication.	2.08	1	0	bromide salt	cholinergic antagonist; muscle relaxant; nicotinic antagonist
cephalexin Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.	3.85	3	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
isosorbide-5-mononitrate isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug	2.45	2	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
ornidazole Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.	2.08	1	0	C-nitro compound; imidazoles; organochlorine compound; secondary alcohol	antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	3.61	2	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
fenclozic acid fenclozic acid: an analgesic & antipyretic with anti-inflammatory properties; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZOLES (75-86); RN given refers to parent cpd	3.23	1	0
laxagetten 4,4'-diacetoxydiphenylpyridylemethane [no description available]	3.23	1	0
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	3.23	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
cephapirin Cephapirin: Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.. cephapirin : A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms.	2.04	1	0	cephalosporin	antibacterial drug
fludarabine phosphate fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.	3.61	2	0	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
alclofenac alclofenac: was heading 1975-94 (was see under PHENYLACETATES 1975-90); use PHENYLACETATES to search ALCLOFENAC 1975-94; an anti-inflammatory agent used in the treatment of rheumatoid arthritis; acts also as an analgesic and an antipyretic. alclofenac : An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.	3.23	1	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	3.23	1	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
oxyphenisatin [no description available]	3.23	1	0	indoles
fludrocortisone Fludrocortisone: A synthetic mineralocorticoid with anti-inflammatory activity.	3.23	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; fluorinated steroid; mineralocorticoid	adrenergic agent; anti-inflammatory drug
ursodeoxycholic acid Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	3.23	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
pregnanolone Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.	2.04	1	0	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2.08	1	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
du-21220 Ritodrine: An adrenergic beta-2 agonist used to control PREMATURE LABOR.. 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol : A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group.	2.04	1	0	benzyl alcohols; polyphenol; secondary alcohol; secondary amino compound
bisbenzimidazole trihydrochloride [no description available]	2.21	1	0
dexchlorpheniramine dexchlorpheniramine: RN given refers to parent cpd(S)-isomer	3.23	1	0	chlorphenamine
ribostamycin Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).	2.04	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	antibacterial drug; antimicrobial agent; metabolite
clometacin clometacin: structure	3.23	1	0	N-acylindole
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	9.41	6	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	5.03	12	0	penicillin allergen; penicillin	antibacterial drug
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	4.08	4	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
indoramin Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.	2.46	2	0	tryptamines
oxcarbazepine Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.	3.61	2	0	cyclic ketone; dibenzoazepine	anticonvulsant; drug allergen
carbidopa carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.	3.61	2	0	catechols; hydrazines; monocarboxylic acid	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
toloxatone toloxatone: oxazolidinone derivative; psychotropic drug; structure. toloxatone : A racemate consisting of equimolar amounts of (R)- and (S)-toloxatone. It is a reversible monoamine oxidase A inhibitor and antidepressant.. 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one : A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3.	2.45	2	0	oxazolidinone; primary alcohol; toluenes
moricizine Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.	3.23	1	0	carbamate ester; morpholines; phenothiazines	anti-arrhythmia drug
amineptin amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.	3.23	1	0	amino acid; carbocyclic fatty acid; carbotricyclic compound; secondary amino compound	antidepressant; dopamine uptake inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	9.45	6	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
feprazone Feprazone: A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)	2.08	1	0	organic molecular entity
pirprofen pirprofen: anti-inflammatory agent used in therapy of rheumatoid arthritis; prostaglandin synthetase inhibitor; more potent than indomethacin; structure	3.23	1	0	pyrroline
sisomicin Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).	4.27	5	0	amino cyclitol glycoside; aminoglycoside antibiotic; beta-L-arabinoside; monosaccharide derivative
amdinocillin Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.. mecillinam : A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.	2.04	1	0	penicillin	antibacterial drug; antiinfective agent
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	9.67	26	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	4.43	6	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.87	3	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
dobutamine Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.	3.23	1	0	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
ticarcillin Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.	3.55	8	0	penicillin allergen; penicillin	antibacterial drug
trimazosin trimazosin: RN given refers to parent cpd; structure	2.04	1	0	N-arylpiperazine
penbutolol Penbutolol: A nonselective beta-blocker used as an antihypertensive and an antianginal agent.	3.23	1	0	ethanolamines
ribavirin Rebetron: Rebetron is tradename	4.29	5	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adinazolam adinazolam: structure in first source. adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.	2.45	2	0	triazolobenzodiazepine	anticonvulsant; antidepressant; anxiolytic drug; sedative
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	9.2	86	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
tolamolol [no description available]	2.04	1	0
cephradine Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.	3.85	3	0	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
ticrynafen Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.. tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.	3.23	1	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	3.85	3	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
tocainide Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.	2.45	2	0	monocarboxylic acid amide	anti-arrhythmia drug; local anaesthetic; sodium channel blocker
sulbenicillin Sulbenicillin: Semisynthetic penicillin-type antibiotic.. sulbenicillin : A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.	2.45	2	0	penicillin
sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.	2.45	2	0
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	4.08	4	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
vecuronium bromide Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.	2.46	2	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent; nicotinic antagonist
vecuronium vecuronium : A 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidino- and 16beta-N-methylpiperidinium substituents.	3.23	1	0	acetate ester; androstane; quaternary ammonium ion	drug allergen; muscle relaxant; neuromuscular agent; nicotinic antagonist
benoxaprofen benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.	3.23	1	0	1,3-benzoxazoles; monocarboxylic acid; monochlorobenzenes	antipsoriatic; antipyretic; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; hepatotoxic agent; nephrotoxin; non-narcotic analgesic; non-steroidal anti-inflammatory drug; protein kinase C agonist
exifone [no description available]	3.23	1	0	benzophenones
mefloquine (-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.	3.23	1	0	[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol	antimalarial
meptazinol Meptazinol: A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.	2.45	2	0	azepanes
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	3.86	3	0	benzamides; carboxylic ester
sufentanil Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.	3.85	3	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
acarbose [no description available]	3.61	2	0	tetrasaccharide derivative	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; geroprotector; hypoglycemic agent
torsemide Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.	3.85	3	0	aminopyridine; N-sulfonylurea; secondary amino compound	antihypertensive agent; loop diuretic
medroxalol medroxalol: RN given refers to parent cpd without isomeric designation	2.04	1	0	salicylamides
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	3.85	3	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefmetazole Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.	2.04	1	0	cephalosporin	antibacterial drug
lorcainide [no description available]	2.75	3	0	acetamides
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	3.85	3	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
ceforanide ceforanide: RN given refers to (6R-(trans))-isomer. ceforanide : A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.	2.04	1	0	cephalosporin	antibacterial drug
piperacillin Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.	9.05	42	1	penicillin allergen; penicillin	antibacterial drug
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	3.85	3	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	4.08	4	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.	7.22	14	2	cephalosporin	antibacterial drug
staurosporine [no description available]	2.08	1	0	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
foscarnet sodium trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	2.08	1	0	one-carbon compound; organic sodium salt	antiviral drug
atracurium Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.	3.58	2	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
atracurium besylate atracurium besylate : The bisbenzenesulfonate salt of atracurium.	2.08	1	0	organosulfonate salt; quaternary ammonium salt	muscle relaxant; nicotinic antagonist
moxalactam Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.. moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.	2.45	2	0	cephalosporin; oxacephem	antibacterial drug
nicorandil Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.	2.08	1	0	nitrate ester; pyridinecarboxamide	potassium channel opener; vasodilator agent
endralazine BQ 22-708: RN given refers to parent cpd	2.04	1	0	benzamides
pergolide Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	3.23	1	0	diamine; methyl sulfide; organic heterotetracyclic compound	antiparkinson drug; dopamine agonist
pergolide mesylate pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	2.08	1	0	methanesulfonate salt	antiparkinson drug; dopamine agonist; geroprotector
cefadroxil anhydrous Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	4.08	4	0	cephalosporin	antibacterial drug
encainide Encainide: One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.. encainide : 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.	2.45	2	0	benzamides; piperidines	anti-arrhythmia drug; sodium channel blocker
talniflumate talniflumate: an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma	2.08	1	0	benzofurans
fenoldopam mesylate [no description available]	2.08	1	0	benzazepine
fialuridine [no description available]	3.23	1	0
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.61	2	0	cephalosporin	antibacterial drug; drug allergen
pefloxacin Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.	2.97	4	0	fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; antiinfective agent; DNA synthesis inhibitor
alfentanil Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.	3.85	3	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
miglustat miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.	3.23	1	0	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
haloperidol decanoate [no description available]	3.23	1	0	organic molecular entity
cefotetan Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.	3.87	3	0
recainam recainam: structure given in first source	2.45	2	0
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	4.08	4	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	2.75	3	0	aminopyridine
tolrestat tolrestat: RN & structure given in first source	3.23	1	0	naphthalenes	EC 1.1.1.21 (aldehyde reductase) inhibitor
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.75	3	0	aromatic ketone
stepronin [no description available]	2.08	1	0	N-acyl-amino acid
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	3.61	2	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
idazoxan Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.	2.46	2	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
remoxipride Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.	2.75	3	0	dimethoxybenzene
balsalazide balsalazide: a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine; structure in first source. balsalazide : A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.	3.23	1	0
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	3.85	3	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
cabergoline Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.	3.61	2	0	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist
bambuterol bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.	2.04	1	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
atomoxetine hydrochloride Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.. atomoxetine hydrochloride : The hydrochloride salt of atomoxetine.	2.08	1	0	hydrochloride	adrenergic uptake inhibitor; antidepressant
atomoxetine atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.	3.85	3	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
quinapril Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.	3.61	2	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
alpidem [no description available]	3.23	1	0	imidazoles
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	3.61	2	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
trospectomycin trospectomycin: active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer	2.04	1	0	dioxanes
fosphenytoin fosphenytoin: structure given in first & second source	3.23	1	0	imidazolidine-2,4-dione
salmeterol xinafoate Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.	2.08	1	0	naphthoic acid
ranolazine Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.	3.23	1	0	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	4.08	4	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.	2.08	1	0	imidazoquinoline	antineoplastic agent; interferon inducer
sematilide sematilide: RN refers to HCl; structure given in first source	2.45	2	0
esmolol methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.	3.58	2	0	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
clinafloxacin clinafloxacin: structure given in first source; RN given is for monoHCl	2.45	2	0	quinolines
sertindole sertindole : A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.	2.08	1	0	heteroarylpiperidine; imidazolidinone; organochlorine compound; organofluorine compound; phenylindole	alpha-adrenergic antagonist; H1-receptor antagonist; second generation antipsychotic; serotonergic antagonist
adapalene Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.	2.08	1	0	adamantanes; monocarboxylic acid; naphthoic acid	dermatologic drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; non-steroidal anti-inflammatory drug
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	3.85	3	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
loxiglumide loxiglumide: cholecystokinin receptor antagonist; RN refers to (+-)-isomer; structure in first source	2.04	1	0	organic molecular entity
aromasil [no description available]	3.61	2	0	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic
sparfloxacin [no description available]	2.75	3	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone
zileuton [no description available]	3.61	2	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
clopidogrel Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.	3.23	1	0	methyl ester; monochlorobenzenes; thienopyridine	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	4.08	4	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
tiagabine Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.	3.85	3	0	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	2.04	1	0	tetralins	T-type calcium channel blocker
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	3.85	3	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
bromfenac bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.	4.08	4	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
gemcitabine hydrochloride [no description available]	2.08	1	0	hydrochloride; organofluorine compound	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral drug; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; immunosuppressive agent; radiosensitizing agent
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	3.85	3	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
ibutilide ibutilide: RN & structure in first source; RN refers to the fumarate salt	3.85	3	0	benzenes; organic amino compound
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	3.87	3	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
remifentanil Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.	3.85	3	0	alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester	intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative
atorvastatin calcium anhydrous [no description available]	2.08	1	0	organic calcium salt
atorvastatin [no description available]	3.23	1	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
lamivudine [no description available]	4.08	4	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
duloxetine hydrochloride Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.	2.08	1	0	duloxetine hydrochloride	antidepressant
duloxetine [no description available]	3.23	1	0	duloxetine
irinotecan [no description available]	3.85	3	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	4.08	4	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	3.85	3	0
ziprasidone ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.	3.85	3	0	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.45	2	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.	4.08	4	0	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
adefovir dipivoxil bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.	2.08	1	0	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
emtricitabine Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.	3.61	2	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
tasosartan tasosartan: angiotensin II antagonist; structure given in first source	3.23	1	0	biphenyls
tiludronic acid tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source	3.23	1	0	organochlorine compound
tirofiban Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.	3.85	3	0	L-tyrosine derivative; piperidines; sulfonamide	anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist
capecitabine Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.	3.23	1	0	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	3.23	1	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
paroxetine hydrochloride paroxetine hydrochloride : The hydrochloride salt of paroxetine. It is an antidepressant drug.	2.08	1	0	hydrochloride	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
bupropion hydrochloride [no description available]	2.08	1	0	aromatic ketone
cisatracurium cisatracurium: RN refers to (1R-(1alpha,2alpha(1'R,2'R)))-isomer. cisatracurium : A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. The active species in the skeletal muscle relaxant cisatracurium besylate.	2.04	1	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
trazodone hydrochloride Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.	2.08	1	0	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
fosinoprilat fosinoprilat: active phosphinic acid metabolite of prodrug fosenopril, which is activated by esterases in vivo; structure given in first source; binds zinc with phosphinic acid group. fosinoprilat : A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure.	2.04	1	0	L-proline derivative; phosphinic acids	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	4.07	4	0
cefprozil [no description available]	3.58	2	0	cephalosporin; semisynthetic derivative	antibacterial drug
doxazosin mesylate Cardura: Trade name in United States.	2.08	1	0	methanesulfonate salt	geroprotector
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	3.61	2	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	3.61	2	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	2.08	1	0	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
bupivacaine hydrochloride bupivacaine hydrochloride (anhydrous) : A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride : A hydrochloride obtained by combining 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with one molar equivalent of hydrochloric acid.	2.08	1	0	hydrochloride; racemate	adrenergic antagonist; amphiphile; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; local anaesthetic
fenofibric acid fenofibric acid: RN given refers to parent cpd without isomeric designation; structure. fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.	3.23	1	0	aromatic ketone; chlorobenzophenone; monocarboxylic acid	drug metabolite; marine xenobiotic metabolite
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	3.61	2	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
amprenavir [no description available]	3.61	2	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	3.23	1	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
ticlopidine hydrochloride [no description available]	2.08	1	0	hydrochloride
epirubicin hydrochloride [no description available]	2.08	1	0
iopamidol Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.	2.04	1	0	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
histamine phosphate histamine phosphate : A phosphate salt that is the diphosphate salt of histamine.	3.23	1	0	phosphate salt	histamine agonist
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	9.78	43	1	cephalosporin	fungal metabolite
imipramine n-oxide imipramine N-oxide: RN given refers to parent cpd; structure	2.04	1	0	dibenzooxazepine
tilbroquinol [no description available]	3.23	1	0	organohalogen compound; quinolines
bendamustine [no description available]	3.23	1	0	benzimidazoles
droxicam droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.	3.23	1	0	organic heterotricyclic compound; pyridines	cyclooxygenase 1 inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; prodrug
ebrotidine ebrotidine: an H2-receptor antagonist and gastric mucosa protector	3.23	1	0	sulfonamide
dexloxiglumide dexloxiglumide: a CCK receptor antagonist; structure given in first source	2.45	2	0	glutamic acid derivative
intoplicine intoplicine: structure in first source	2.04	1	0	pyridoindole
pazufloxacin [no description available]	2.08	1	0	quinolines
repaglinide [no description available]	4.08	4	0	piperidines
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	4.08	4	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
dexfenfluramine Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.	2.04	1	0	fenfluramine	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
ethinyl estradiol-17-sulfate ethinyl estradiol-17-sulfate: RN given refers to the (17alpha)-isomer	2.04	1	0
benzofurazan benzofurazan: structure	7.21	1	0	benzoxadiazole
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.79	3	0	1,2,3-triazole
miconazole nitrate miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.08	1	0
ethinylestradiol-3-sulfate ethinylestradiol-3-sulfate: binds to albumin at 2 sites	2.04	1	0	17beta-hydroxy steroid; steroid sulfate	antineoplastic agent; estrogen
sertraline Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.	3.23	1	0	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
cefcanel cefcanel: RN given refers to (6R-(6 alpha,7 beta(R*)))-isomer; structure	2.04	1	0
arbekacin arbekacin: structure given in first source. arbekacin : A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring.	2.96	4	0	aminoglycoside; kanamycins	antibacterial agent; antibacterial drug; antimicrobial agent; protein synthesis inhibitor
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	4.08	4	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
epristeride epristeride: structure given in first source	2.45	2	0	steroid acid
talinolol [no description available]	2.45	2	0	ureas
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.08	1	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
brinzolamide brinzolamide: an antiglaucoma agent	2.08	1	0	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor
drospirenone drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source	2.08	1	0	3-oxo-Delta(4) steroid; steroid lactone	aldosterone antagonist; contraceptive drug; progestin
artemether Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.08	1	0	artemisinin derivative; cyclic acetal; organic peroxide; semisynthetic derivative; sesquiterpenoid	antimalarial
denaverine denaverine: RN given refers to parent cpd; structure	2.04	1	0	diarylmethane
acamprosate Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.	3.23	1	0	acetamides; organosulfonic acid	environmental contaminant; neurotransmitter agent; xenobiotic
isaxonine isaxonine: promotes nerve growth	3.23	1	0	aminopyrimidine
diprafenone diprafenone: structure given in first source	2.45	2	0	aromatic compound
nebivolol 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.	3.58	2	0	chromanes; diol; organofluorine compound; secondary alcohol; secondary amino compound
uk 68798 [no description available]	4.08	4	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
ljc 10627 biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.	2.45	2	0	carbapenems; organic sulfide; pyrazolotriazole	antibacterial drug
hp 873 iloperidone: an atypical, negative symptom antipsychotic agent. iloperidone : A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia.	3.61	2	0	1,2-benzoxazoles; aromatic ether; aromatic ketone; methyl ketone; monoamine; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
dexrazoxane Dexrazoxane: The (+)-enantiomorph of razoxane.	3.85	3	0	razoxane	antineoplastic agent; cardiovascular drug; chelator; immunosuppressive agent
loxapine succinate [no description available]	2.08	1	0	succinate salt	geroprotector
tocophersolan tocophersolan: RN given refers to parent cpd	2.69	2	0	tocol
fenoxypropazine [no description available]	3.23	1	0	aromatic ether
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	4.83	5	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
betamipron [no description available]	2.46	2	0	organonitrogen compound; organooxygen compound
bufuralol bufuralol: RN given refers to cpd without isomeric designation; structure	2.45	2	0	benzofurans
uroxatral [no description available]	2.08	1	0	hydrochloride
aceclofenac [no description available]	3.61	2	0	amino acid; carboxylic ester; dichlorobenzene; monocarboxylic acid; secondary amino compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
nitrefazole [no description available]	3.23	1	0	imidazoles
panipenem panipenem: synthetic cpd; structure given in first source	2.04	1	0	organic molecular entity
perindoprilat perindoprilat : A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril.	2.04	1	0	dicarboxylic acid; dipeptide; L-alanine derivative; organic heterobicyclic compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
thiocolchicoside [no description available]	2.08	1	0	glycoside
7-hydroxystaurosporine [no description available]	2.04	1	0
methotrimeprazine Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.	2.04	1	0	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
gentamicin c1a [no description available]	2.21	1	0	gentamycin C
9-aminocamptothecin [no description available]	2.04	1	0	pyranoindolizinoquinoline
sch 34343 Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer	2.45	2	0
squalamine squalamine: from dogfish shark Squalus acanthias; structure given in first source	2.04	1	0	bile acid
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	8.3	26	0	carbapenems
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	12.28	84	1	carbamate ester; oxazolidinone	metabolite
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	3.85	3	0	hydroxy-1,2-naphthoquinone
rivastigmine [no description available]	3.85	3	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
frovatriptan [no description available]	3.85	3	0	carbazoles
eletriptan eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.	3.58	2	0	indoles; N-alkylpyrrolidine; sulfone	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rosiglitazone [no description available]	4.08	4	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
tamiflu [no description available]	2.08	1	0	phosphate salt
bexarotene [no description available]	3.61	2	0	benzoic acids; naphthalenes; retinoid	antineoplastic agent
s20098 [no description available]	2.08	1	0	acetamides
flunisolide flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones	2.08	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent
ketorolac tromethamine Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.	2.08	1	0	organoammonium salt	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	7.26	31	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.75	3	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	6.24	8	1	iditol	fungal metabolite
moexipril [no description available]	3.23	1	0	peptide
gliquidone gliquidone: structure; RN given refers to parent cpd	2.08	1	0	isoquinolines
mci 9038 [no description available]	3.58	2	0	peptide
lopinavir [no description available]	2.08	1	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
moxifloxacin hydrochloride moxifloxacin hydrochloride : A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.	2.08	1	0	hydrochloride	antibacterial drug
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	3.61	2	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
mizoribine [no description available]	2.08	1	0	imidazoles	anticoronaviral agent
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	13.09	103	11	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
sr141716 [no description available]	2.08	1	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	3.87	3	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
racecadotril racecadotril: parenterally active enkephalinase inhibitor	2.08	1	0	N-acyl-amino acid
perindopril Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline	3.23	1	0	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
asulacrine asulacrine: derivative of amsacrine; structure given in first source	2.04	1	0	acridines
hydroxycotinine hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure. trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer).	2.04	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid
quinaprilat quinaprilat: metabolite of quinapril. quinaprilat : A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril.	2.45	2	0	dicarboxylic acid; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; vasodilator agent
2-hydroxyimipramine 2-hydroxyimipramine: RN given refers to parent cpd	2.45	2	0	dibenzoazepine
ecteinascidin 743 [no description available]	2.04	1	0	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
tadalafil [no description available]	3.61	2	0	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
florfenicol florfenicol: structure given in first source. florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture.	7.41	1	0	organochlorine compound; organofluorine compound; secondary alcohol; secondary carboxamide; sulfone	antimicrobial agent
paliperidone 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one : A member of the class of pyridopyrimidines that is 9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.. paliperidone : A racemate comprising equimolar amounts of (R)- and (S)-paliperidone. Paliperidone is the primary active metabolite of the older antipsychotic risperidone and is used for treatment of schizophrenia.	3.23	1	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine; secondary alcohol
nitisinone [no description available]	3.23	1	0	(trifluoromethyl)benzenes; C-nitro compound; cyclohexanones; mesotrione	EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
plavix [no description available]	2.08	1	0	azaheterocycle sulfate salt; organoammonium sulfate salt	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
clofarabine [no description available]	3.61	2	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
pramipexole Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.	3.61	2	0	benzothiazoles; diamine	antidyskinesia agent; antiparkinson drug; dopamine agonist; radical scavenger
valdecoxib [no description available]	3.61	2	0	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.15	1	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
almotriptan almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.	3.85	3	0	indoles; sulfonamide; tertiary amine	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
mk 0663 [no description available]	2.46	2	0	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
tazobactam Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.	4.84	9	0	penicillanic acids; triazoles	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
gefitinib [no description available]	3.87	3	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
desloratadine desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.	3.61	2	0	benzocycloheptapyridine	anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist
garenoxacin garenoxacin: a des-fluoro(6) quinolone with antibacterial activity. garenoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8.	2.01	1	0	aromatic ether; cyclopropanes; isoindoles; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; non-steroidal anti-inflammatory drug
desvenlafaxine O-desmethylvenlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.	3.23	1	0	cyclohexanols; phenols; tertiary amino compound	antidepressant; drug metabolite; marine xenobiotic metabolite
methotrexate [no description available]	4.08	4	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
tamsulosin [no description available]	3.85	3	0	5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide	alpha-adrenergic antagonist; antineoplastic agent
rufinamide rufinamide: for treatment of Lennox-Gastaut syndrome; structure in first source	3.23	1	0	aromatic amide; heteroarene
sulbactam [no description available]	11.13	50	3	penicillanic acids
olmesartan medoxomil Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.	3.61	2	0	biphenyls
dexpanthenol dexpanthenol: The alcohol of pantothenic acid	3.23	1	0	amino alcohol; monocarboxylic acid amide	cholinergic drug; provitamin
fosamprenavir fosamprenavir: a prodrug of the protease inhibitor amprenavir. fosamprenavir : A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir.	3.23	1	0	sulfonamide	prodrug
abiraterone [no description available]	2.08	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; pyridines	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
febuxostat Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.	3.61	2	0	1,3-thiazolemonocarboxylic acid; aromatic ether; nitrile	EC 1.17.3.2 (xanthine oxidase) inhibitor
dilevalol (R,R)-labetalol : A 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration.	2.04	1	0	2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
carbapenems [no description available]	13.67	216	0
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	9.42	33	1	beta-lactam antibiotic allergen; beta-lactam
escitalopram Escitalopram: S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.. escitalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram.	3.23	1	0	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile	antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
lexapro Lexapro: Trade name of escitalopram, the active S-enantiomer of the racemic citalopram.	2.08	1	0
10-propargyl-10-deazaaminopterin 10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.	3.23	1	0	N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel [no description available]	2.45	2	0	hydrate; secondary alpha-hydroxy ketone	antineoplastic agent
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	3.61	2	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
irofulven irofulven: structure in first source	2.04	1	0	cyclohexenones
atazanavir atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).	3.23	1	0	carbohydrazide	antiviral drug; HIV protease inhibitor
ym 872 YM 872: structure in first source	2.04	1	0
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	12.73	63	6	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ezetimibe Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).	3.61	2	0	azetidines; beta-lactam; organofluorine compound	anticholesteremic drug; antilipemic drug; antimetabolite
ertapenem Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.	10.32	36	1	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
nepafenac nepafenac: amide analog of amfenac; structure in first source. nepafenac : A monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery.	2.03	1	0	monocarboxylic acid amide	cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
dx 8951 [no description available]	2.04	1	0	pyranoindolizinoquinoline
cox 189 lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.	3.61	2	0	amino acid; monocarboxylic acid; organochlorine compound; organofluorine compound; secondary amino compound	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
cilomilast [no description available]	2.45	2	0	methoxybenzenes
conivaptan conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).	3.58	2	0	benzazepine	aquaretic; vasopressin receptor antagonist
tezosentan tezosentan: structure in first source	2.04	1	0
sabarubicin sabarubicin: structure given in first source	2.04	1	0
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	6.34	28	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
pralnacasan pralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source	3.23	1	0
clevidipine clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source	3.58	2	0	dihydropyridine
solifenacin [no description available]	3.85	3	0	isoquinolines
dexmethylphenidate dexmethylphenidate : A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate.	3.23	1	0	methyl phenyl(piperidin-2-yl)acetate	adrenergic agent
xamoterol Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.	2.75	3	0	morpholines
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	3.61	2	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
cinacalcet cinacalcet : A secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group.	3.23	1	0	(trifluoromethyl)benzenes; naphthalenes; secondary amino compound	calcimimetic; P450 inhibitor
lubiprostone [no description available]	3.23	1	0
telbivudine [no description available]	3.61	2	0	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
abanoquil [no description available]	2.04	1	0
paromomycin Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.	3.23	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	anthelminthic drug; antibacterial drug; antiparasitic agent; antiprotozoal drug
anidulafungin Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.	8.89	3	0	antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative
17 alpha-hydroxyprogesterone caproate 17 alpha-Hydroxyprogesterone Caproate: Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.	3.23	1	0	corticosteroid hormone
varenicline Varenicline: A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.. varenicline : An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.	3.23	1	0
temocillin temocillin: beta-lactam antibiotic with unusual spectrum of antibacterial activity & exceptional stability to bacterial beta-lactamases; RN given refers to di-Na salt (2S-(2alpha,5alpha,6alpha))-isomer; structure in first source. temocillin : A penicillin compound having a 6alpha-methoxy and 6beta-[2-carboxy(thiophen-3-yl)acetamido side-groups.	3.15	1	0	penicillin
fiduxosin fiduxosin: fiduxosin (ABT-980) is the (3aR,9bR)-isomer; structure in first source	3.23	1	0
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	4.08	4	0
ropivacaine Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.	2.04	1	0	piperidinecarboxamide; ropivacaine	local anaesthetic
erlotinib [no description available]	3.23	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
melagatran [no description available]	2.45	2	0	azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor
etravirine [no description available]	3.23	1	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
dronedarone Dronedarone: A non-iodinated derivative of amiodarone that is used for the treatment of ARRHYTHMIA.. dronedarone : A member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias.	3.23	1	0	1-benzofurans; aromatic ether; aromatic ketone; sulfonamide; tertiary amino compound	anti-arrhythmia drug; environmental contaminant; xenobiotic
tesaglitazar tesaglitazar: structure in first source	2.45	2	0
ramelteon ramelteon: melatonin MT1/MT2 receptor agonist	4.24	5	0	indanes
lapatinib [no description available]	3.23	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	3.23	1	0	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
iclaprim iclaprim: has antiviral activity. iclaprim : A racemate consisting of equimolar amounts of (R)- and (S)-iclaprim. Both enantiomers exhibit similar, potent bactericidal activity against major Gram-positive pathogens, notably methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA, respectively).. 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine : An aminopyrimidine that is 5-methylpyrimidine-2,4-diamine in which one of the hydrogens of the methyl group has been replaced by a 2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl group.	4.06	2	0	aminopyrimidine; chromenes; cyclopropanes
deferasirox Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.	9.12	4	0	benzoic acids; monocarboxylic acid; phenols; triazoles	iron chelator
bms204352 BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source	2.46	2	0
fosfluconazole fosfluconazole: prodrug of fluconazole	2.04	1	0	conazole antifungal drug; triazole antifungal drug; triazoles	prodrug
tbc-11251 sitaxsentan: endothelin A receptor antagonist; structure in first source	3.61	2	0	benzodioxoles
tolvaptan [no description available]	3.61	2	0	benzazepine; benzenedicarboxamide	aquaretic; vasopressin receptor antagonist
sorafenib [no description available]	8.68	2	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
colistimethate sodium [no description available]	10.06	7	0
lenalidomide [no description available]	3.61	2	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
regadenoson [no description available]	3.23	1	0	purine nucleoside
lacosamide Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.	3.61	2	0	N-acyl-amino acid
cp 101,606 traxoprodil mesylate: a selective NMDA antagonist; structure given in first source	2.45	2	0
vincaleukoblastine [no description available]	3.61	2	0	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite
vincristine sulfate [no description available]	2.08	1	0	organic sulfate salt	antineoplastic agent; geroprotector
benzarone benzarone: antihemorrhagic agent; structure	3.23	1	0	1-benzofurans
nsc-89199 estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.	2.04	1	0	carbamate ester; organochlorine compound; steroid phosphate
estramustine Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.	3.23	1	0	17beta-hydroxy steroid; carbamate ester; organochlorine compound	alkylating agent; antineoplastic agent; radiation protective agent
phenethicillin phenethicillin: minor descriptor (85); major descriptor (63-84); on-line search PENICILLIN, PHENOXYMETHYL/AA (66-85); Index Medicus search PHENETHICILLIN (63-84); RN given refers to (2S-(2alpha,5alpha,6beta))-isomer. phenethicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.	2.04	1	0	penicillin allergen; penicillin
acivicin [no description available]	2.04	1	0	isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound	antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite
wortmannin [no description available]	2.08	1	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
trimethoprim, sulfamethoxazole drug combination Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.	6.92	21	0
bortezomib [no description available]	3.87	3	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	3.61	2	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
tizoxanide tizoxanide: major metabolite of nitazoxanide; structure in first source	2.03	1	0	salicylamides
mbx 1066 MBX 1066: structure in first source	2.05	1	0
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	3.23	1	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
pentostatin Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.	3.93	3	0	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	4.08	4	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	11.76	127	1	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
griseofulvin Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.	3.23	1	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
cefoxitin Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.	6.17	23	0	beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative	antibacterial drug
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.46	2	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	3.87	3	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
pancuronium Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.	3.58	2	0	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist
rocuronium Rocuronium: An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM.. rocuronium : A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.04	1	0	3alpha-hydroxy steroid; acetate ester; androstane; morpholines; quaternary ammonium ion; tertiary amino compound	drug allergen; muscle relaxant; neuromuscular agent
abacavir abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.	3.85	3	0	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
netilmicin Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.	8.18	5	0
perindopril erbumine [no description available]	2.08	1	0	addition compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol [no description available]	4.08	4	0	piperidines
metyrosine alpha-methyl-L-tyrosine : An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.	3.23	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	antihypertensive agent; EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
rocuronium bromide rocuronium bromide : The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.08	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent
linezolid [no description available]	12.83	128	1	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
n-formylmethionine leucyl-phenylalanine N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.	2.07	1	0	tripeptide
phenylalanine arginine beta-naphthylamide phenylalanine arginine beta-naphthylamide: a drug efflux pump inhibitor; structure in first source	3.54	2	0	peptide
clindamycin phosphate [no description available]	3.23	1	0
pemirolast potassium salt [no description available]	2.08	1	0
eplerenone Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.	3.61	2	0	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
tolterodine [no description available]	3.85	3	0	tertiary amine	antispasmodic drug; muscarinic antagonist; muscle relaxant
ao 128 AO 128: alpha-glucosidase inhibitor; structure given in first source	2.08	1	0	organic molecular entity
sultamicillin sultamicillin: contains ampicillin & sulbactam	5.32	4	1	penicillanic acid ester
loteprednol etabonate Loteprednol Etabonate: An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.	2.08	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; etabonate ester; organochlorine compound; steroid acid ester; steroid ester	anti-inflammatory drug
darifenacin darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.	3.58	2	0	1-benzofurans; monocarboxylic acid amide; pyrrolidines	antispasmodic drug; muscarinic antagonist
fluticasone propionate fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.	2.46	2	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester	adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug
acarbose [no description available]	2.04	1	0	amino cyclitol; glycoside
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	3.61	2	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
retinol Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).	3.23	1	0	retinol; vitamin A	human metabolite; mouse metabolite; plant metabolite
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	4.43	6	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
cerivastatin cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.	2.45	2	0	dihydroxy monocarboxylic acid; pyridines; statin (synthetic)
rosuvastatin rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).	3.85	3	0	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.45	2	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
eicosapentaenoic acid icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.	2.03	1	0	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	3.23	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
mupirocin Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.	8.19	5	0	alpha,beta-unsaturated carboxylic ester; epoxide; monocarboxylic acid; oxanes; secondary alcohol; triol	antibacterial drug; bacterial metabolite; protein synthesis inhibitor
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	7.42	37	0
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	9.28	54	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	6.88	26	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
cyfluthrin cethromycin: a ketolide;. cethromycin : A macrolide antibiotic which displays in vitro activity against both gram-positive and gram-negative bacteria and is currently under investigation for the treatment of community-acquired pneumonia. The US Food and Drug Administration (FDA) have also granted orphan drug designation to cethromycin for the treatment of anthrax prophylaxis, tularemia, and plague (PDB entry: 1NWX).	2.42	2	0
bms 214662 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.	2.04	1	0	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
octreotide [no description available]	3.23	1	0
eptifibatide [no description available]	3.58	2	0	homodetic cyclic peptide; macrocycle; organic disulfide	anticoagulant; platelet aggregation inhibitor
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	2.45	2	0	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
decitabine [no description available]	4.08	4	0	2'-deoxyribonucleoside
sm 8668 Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive	2.04	1	0
teniposide [no description available]	4.08	4	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine troxacitabine: shows good anti-HIV activity without cytotoxicity	2.04	1	0	carbohydrate derivative; nucleobase-containing molecular entity
valrubicin [no description available]	2.08	1	0	anthracycline; trifluoroacetamide
cefamandole Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.. cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.	7.74	3	0	cephalosporin; semisynthetic derivative	antibacterial drug
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	3.23	1	0	actinomycin	mutagen
tiazofurin tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).	2.04	1	0	1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide	antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	4.08	4	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
sitafloxacin [no description available]	2.74	3	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	3.85	3	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
posaconazole [no description available]	3.61	2	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
l 743,872 [no description available]	2.17	1	0
dibekacin Dibekacin: Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.. dibekacin : A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.	2.96	4	0	kanamycins	antibacterial agent; protein synthesis inhibitor
rubitecan rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor. rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.	2.08	1	0	C-nitro compound; delta-lactone; pyranoindolizinoquinoline; semisynthetic derivative; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	3.91	3	0	antibiotic antifungal drug; echinocandin	antiinfective agent
abt 492 WQ 3034: structure in first source	4.41	1	1
favipiravir favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.	2.6	1	0	hydroxypyrazine; organofluorine compound; primary carboxamide	anticoronaviral agent; antiviral drug; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
riboflavin vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).	3.23	1	0	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite
sodium bicarbonate Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.	3.23	1	0	one-carbon compound; organic sodium salt	antacid; food anticaking agent
arsenic trioxide Tetraarsenic Oxide: A form of As2O3 that exists as As4O6 in the solid state. It dissociates to As2O3 upon heating to the vapor phase above 800 degrees Celsius.	3.23	1	0	arsenic oxide	antineoplastic agent; insecticide
sr 90107 fondaparinux sodium : An organic sodium salt, being the decasodium salt of fondaparinux.	3.23	1	0
meglumine iodipamide [no description available]	3.23	1	0	organoammonium salt	radioopaque medium
glycosides [no description available]	2.08	1	0
thyrotropin-releasing hormone PR 546: no other info available 9/89. protirelin : A tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence.	3.23	1	0	peptide hormone; tripeptide	human metabolite
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	3.61	2	0	vasopressin	cardiovascular drug; hematologic agent; mitogen
s 1033 [no description available]	3.23	1	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
mezlocillin Mezlocillin: Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.. mezlocillin : A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.	2.45	2	0	penicillin allergen; penicillin	antibacterial drug
trilostane trilostane: inhibits conversion of pregnenolone to progesterone; adrenal blocking agent used in treatment of Cushing's syndrome. trilostane : An epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions.	2.08	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; androstanoid; epoxy steroid; nitrile	abortifacient; antineoplastic agent; EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
tropisetron Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.	2.04	1	0	indolyl carboxylic acid
leuprolide acetate leuprolide acetate : An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.08	1	0	acetate salt	antineoplastic agent; gonadotropin releasing hormone agonist
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.04	1	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
fludarabine [no description available]	2.04	1	0	purine nucleoside
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	4.08	4	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.	3.58	2	0	ethyl ester; imidazoles	intravenous anaesthetic; sedative
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	4.08	4	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
levosulpiride (S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).	2.08	1	0	sulpiride	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
1-(1-naphthylmethyl)piperazine [no description available]	7.48	2	0
pyrantel Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920). pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'.	3.23	1	0	1,4,5,6-tetrahydropyrimidines; carboxamidine; thiophenes	antinematodal drug
cotinine Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.	2.04	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
thiothixene [no description available]	3.23	1	0	N-methylpiperazine	anticoronaviral agent
eszopiclone Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.	3.61	2	0	zopiclone	central nervous system depressant; sedative
benztropine Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.	3.23	1	0	diarylmethane
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	3.87	3	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
cinnarizine Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.	2.08	1	0	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	3.61	2	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
terbinafine [no description available]	3.23	1	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
epalrestat epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.	2.08	1	0	monocarboxylic acid; thiazolidines	EC 1.1.1.21 (aldehyde reductase) inhibitor
drotaverin drotaverin: Hungarian drug; RN given refers to parent cpd; structure	2.75	3	0	isoquinolines
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	3.23	1	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
succimer Succimer: A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.. succimer : A sulfur-containing carboxylic acid that is succinic acid bearing two mercapto substituents at positions 2 and 3. A lead chelator used as an antedote to lead poisoning.	3.23	1	0	dicarboxylic acid; dithiol; sulfur-containing carboxylic acid	chelator
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	10.46	4	1	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
streptozocin [no description available]	3.23	1	0
tamoxifen [no description available]	3.61	2	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.	3.23	1	0	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
cancidas [no description available]	3.58	2	0
fusidic acid Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.	8.32	6	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
lincomycin Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.	3.91	3	0	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
valinomycin Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.	2.08	1	0	cyclodepsipeptide; macrocycle	antimicrobial agent; antiviral agent; bacterial metabolite; potassium ionophore
thiopental Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.45	2	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
ranitidine Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.	3.23	1	0	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
aplaviroc aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source	3.23	1	0
hmr 3647 [no description available]	4.65	8	0
latoconazole latoconazole: RN refers to cpd without isomeric designation; latoconazole is (E)-isomer; structure given in first source	2.08	1	0	conazole antifungal drug; imidazole antifungal drug
maraviroc [no description available]	3.61	2	0	tropane alkaloid
toremifene citrate [no description available]	2.08	1	0	stilbenoid	anticoronaviral agent
toremifene Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.	3.23	1	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	3.87	3	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
sq-641 SQ-641: a MurX inhibitor with antitubercular activity; structure in first source	3.23	1	0
laccase Laccase: A copper-containing oxidoreductase enzyme that catalyzes the oxidation of 4-benzenediol to 4-benzosemiquinone. It also has activity towards a variety of O-quinols and P-quinols. It primarily found in FUNGI and is involved in LIGNIN degradation, pigment biosynthesis and detoxification of lignin-derived products.	2.6	1	0
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine [no description available]	2.45	2	0	aromatic ether
dermatan sulfate Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed). alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.. dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units.	3.23	1	0	amino disaccharide; glycosylgalactose derivative; iduronic acids; oligosaccharide sulfate
dolasetron [no description available]	3.58	2	0	indolyl carboxylic acid
or 1259 [no description available]	2.04	1	0	hydrazone; nitrile; pyridazinone	anti-arrhythmia drug; cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; vasodilator agent
gestodene Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer	2.46	2	0	steroid	estrogen
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	3.61	2	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine [no description available]	4.26	5	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
isepamicin [no description available]	7.44	2	0
ifetroban ifetroban: thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative	2.04	1	0	benzenes; monocarboxylic acid
lamifiban lamifiban: a nonpeptide glycoprotein IIb/IIIa antagonist; prevents platelet loss during experimental cardiopulmonary bypass	2.04	1	0	N-acylglycine
fospropofol [no description available]	3.23	1	0	alkylbenzene
azilect [no description available]	2.08	1	0
rasagiline [no description available]	3.23	1	0	indanes; secondary amine; terminal acetylenic compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; neuroprotective agent
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	3.61	2	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
telavancin telavancin: an anti-infective agent; structure in first source. telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.	6.02	14	0	glycopeptide	antibacterial drug; antimicrobial agent
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	2.03	1	0	organic sodium salt	detergent; protein denaturant
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	4.08	4	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	4.08	4	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
sq 109 N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine: has antitubercular activity	3.23	1	0
quercetin [no description available]	2.46	2	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
bilirubin [no description available]	3.46	1	1	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	3.61	2	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
alprostadil [no description available]	2.08	1	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	3.61	2	0	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	4.18	2	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	3.15	5	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	4.08	4	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
oxymetholone Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed). oxymetholone : A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.	3.61	2	0
pyrvinium pyrvinium: RN given refers to parent cpd; synonyms vanquin & vankin refer to pamoate[2:1]; structure in Merck Index, 9th ed, #7810. pyrvinium : A quinolinium ion that is 1-methylquinolinium substituted by dimethylamino group at position 6 and a (E)-2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl at position 2. It is a anthelminthic drug active against pinworms. The salts of pyrvinium can also be used as anticancer agents.	7.41	1	0	quinolinium ion	anthelminthic drug; antineoplastic agent
eprosartan eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.	4.08	4	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
montelukast montelukast: a leukotriene D4 receptor antagonist	3.85	3	0	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
mivacurium Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.	3.58	2	0	isoquinolines
brompheniramine maleate brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.08	1	0	maleate salt	anti-allergic agent
dexchlorpheniramine maleate [no description available]	2.08	1	0	organic molecular entity
hemabate carboprost tromethamine : The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.	3.23	1	0
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	3.61	2	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
entacapone entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.	4.08	4	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol [no description available]	3.85	3	0	hydroxy seco-steroid; seco-cholestane	antiparathyroid drug
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	2.04	1	0	homodetic cyclic peptide
l 660,711 [no description available]	2.08	1	0	quinolines
travoprost Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.. travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.	2.08	1	0	(trifluoromethyl)benzenes; isopropyl ester; prostaglandins Falpha	antiglaucoma drug; antihypertensive agent; ophthalmology drug; prodrug; prostaglandin receptor agonist
tranilast tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group.	2.08	1	0	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent
7432 s Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections.. ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections.	3.23	1	0	cephalosporin; dicarboxylic acid	antibacterial drug
imipenem [no description available]	2.08	1	0	carbapenems
etretinate retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.	2.08	1	0	enoate ester; ethyl ester; retinoid	keratolytic drug
isotretinoin Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.	3.61	2	0	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
ketotifen fumarate ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug.	2.08	1	0	organoammonium salt	anti-asthmatic drug; H1-receptor antagonist
epoprostenol [no description available]	3.23	1	0	prostaglandins I	mouse metabolite
indocyanine green [no description available]	3.58	2	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
dinoprost tromethamine [no description available]	2.08	1	0	organic molecular entity
triprolidine Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.	3.23	1	0	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
pitavastatin pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.	3.23	1	0	cyclopropanes; dihydroxy monocarboxylic acid; monofluorobenzenes; quinolines; statin (synthetic)	antioxidant
rosuvastatin calcium S 4522: structure in first source	2.08	1	0	N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine; organic calcium salt	anti-inflammatory agent; cardioprotective agent; CETP inhibitor
terbinafine hydrochloride terbinafine hydrochloride : A hydrochloride obtained by reaction of terbinafine with one molar equivalent of hydrogen chloride.	2.08	1	0	allylamine antifungal drug; hydrochloride	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor
ethamolin monoethanolamine oleate: used for treatment of pyogenic granuloma	3.23	1	0	long-chain fatty acid
alatrofloxacin mesylate [no description available]	3.23	1	0
codeine [no description available]	3.85	3	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	4.08	4	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
natamycin [no description available]	2.08	1	0	antibiotic antifungal drug; dicarboxylic acid monoester; epoxide; macrolide antibiotic; monosaccharide derivative; polyene antibiotic	antifungal agrochemical; antimicrobial food preservative; apoptosis inducer; bacterial metabolite; ophthalmology drug
acitretin Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.	3.61	2	0	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug
estropipate estropipate: used therapeutically in menopausal patients	3.23	1	0	piperazinium salt; steroid sulfate
hydromorphone Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.	3.58	2	0	morphinane alkaloid; organic heteropentacyclic compound	mu-opioid receptor agonist; opioid analgesic
levetiracetam Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.	3.61	2	0	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic
ly 163892 loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.	3.23	1	0	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
nabilone nabilone: cannabinol deriv; RN given refers to cpd without isomeric designation; structure	3.23	1	0
nalmefene nalmefene: RN given refers to 5-alpha isomer	2.75	3	0	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	4.08	4	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxycodone Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.	3.85	3	0	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
oxymorphone Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)	3.23	1	0	morphinane alkaloid
vitamin k 1 Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.	3.23	1	0	phylloquinones; vitamin K	cofactor; human metabolite; plant metabolite
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	3.23	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	3.61	2	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
trospium chloride trospium chloride : An organic chloride salt of trospium. It is an antispasmodic drug used for the treatment of overactive bladder.	3.23	1	0
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.04	1	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	3.85	3	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
demycarosylturimycin h [no description available]	2.08	1	0
acipimox acipimox: lipolysis inhibitor	2.08	1	0	pyrazinecarboxylic acid
atosiban [no description available]	2.08	1	0	oligopeptide
benzphetamine Benzphetamine: A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222). benzphetamine : Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.	3.23	1	0	amphetamines; tertiary amine	adrenergic uptake inhibitor; appetite depressant; dopamine uptake inhibitor; sympathomimetic agent
bimatoprost Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.	2.08	1	0	monocarboxylic acid amide	antiglaucoma drug; antihypertensive agent
cicaprost cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R,4R),5beta,6aalpha))-isomer	2.04	1	0	monoterpenoid
deamino arginine vasopressin Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.	3.23	1	0	heterodetic cyclic peptide	diagnostic agent; renal agent; vasopressin receptor agonist
dexmedetomidine [no description available]	3.58	2	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
goserelin Goserelin: A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.	3.23	1	0	organic molecular entity
iloprost Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.	2.44	2	0	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
latanoprost Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.	2.08	1	0	isopropyl ester; prostaglandins Falpha; triol	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor; prodrug
lysophosphatidylcholines lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.	2.13	1	0	1-O-acyl-sn-glycero-3-phosphocholine
nalbuphine Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.	3.85	3	0	organic heteropentacyclic compound	mu-opioid receptor antagonist; opioid analgesic
nateglinide Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.	4.08	4	0	phenylalanine derivative
vinorelbine [no description available]	3.85	3	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent
silodosin silodosin: an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source	3.23	1	0	indolecarboxamide
fluvoxamine Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.	3.23	1	0	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
su 11248 [no description available]	3.23	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
romidepsin depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.	2.04	1	0	cyclodepsipeptide; heterocyclic antibiotic; organic disulfide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.	3.87	3	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
molsidomine [no description available]	2.08	1	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
levorphanol Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.	3.23	1	0	morphinane alkaloid
bismuth Bismuth: A metallic element that has the atomic symbol Bi, and atomic number 83. Its principal isotope is Bismuth 209.	7.41	1	0	metal atom; pnictogen
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	3.58	2	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
morphine-6-glucuronide morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer	2.04	1	0	morphinane alkaloid
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	3.23	1	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
butorphanol Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.	4.08	4	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
cefodizime cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	2.04	1	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer	2.04	1	0	phenanthrenes
cefixime [no description available]	4.08	4	0	cephalosporin	antibacterial drug; drug allergen
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	4.08	4	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.	3.23	1	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ramipril Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.	3.61	2	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
verteporfin (2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.	3.23	1	0
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	4.08	4	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
zimeldine Zimeldine: One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)	3.23	1	0	styrenes
bedaquiline bedaquiline: a diarylquinoline Antitubercular Agent. bedaquiline : A quinoline-based antimycobacterial drug used (as its fumarate salt) for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of the mycobacteria.	3.61	2	0	aromatic ether; naphthalenes; organobromine compound; quinolines; tertiary alcohol; tertiary amino compound	antitubercular agent; ATP synthase inhibitor
enalapril maleate enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.	2.08	1	0	maleate salt	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
enalapril Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).	3.23	1	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
trientine hydrochloride [no description available]	3.23	1	0
n-methylscopolamine bromide scopolamine methobromide : A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.	3.23	1	0
bleomycin [no description available]	3.23	1	0	bleomycin	antineoplastic agent; metabolite
enalaprilat anhydrous Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.	4.08	4	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ximelagatran ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.	3.23	1	0	amidoxime; azetidines; carboxamide; ethyl ester; hydroxylamines; secondary amino compound; secondary carboxamide; tertiary carboxamide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug; serine protease inhibitor
cefuroxime [no description available]	4.4	6	0	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone [no description available]	6.83	18	0	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	14.54	39	2	cephalosporin; oxime O-ether	antibacterial drug
hr 810 cefpirome: structure in first source. cefpirome : A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	2.74	3	0	cephalosporin; cyclopentapyridine
pafuramidine pafuramidine: a prodrug of furamidine	3.23	1	0
ceftazidime [no description available]	6.9	33	0	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.	3.61	2	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
pregabalin Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.	4.07	4	0	gamma-amino acid	anticonvulsant; calcium channel blocker
cefetamet cefetamet: active against Neisseria gonorrhoeae; structure given in first source. cefetamet : A cephalosporin compound having methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a cephalosporin antibiotic active against Neisseria gonorrhoeae.	2.45	2	0	cephalosporin
alvimopan anhydrous alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain	3.61	2	0	peptide
aliskiren aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.	3.23	1	0	monocarboxylic acid amide; monomethoxybenzene	antihypertensive agent
famotidine [no description available]	4.08	4	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	5.8	27	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
aztreonam [no description available]	6.51	22	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cci 15641 [no description available]	2.08	1	0	cephalosporin
ginkgolide b [no description available]	2.04	1	0
cefpodoxime [no description available]	3.23	1	0	carboxylic acid; cephalosporin	antibacterial drug
palonosetron Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.	3.58	2	0	azabicycloalkane; delta-lactam; organic heterotricyclic compound	antiemetic; serotonergic antagonist
tenofovir disoproxil fumarate tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.	2.08	1	0	fumarate salt	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug
vlx600 VLX600: has antineoplastic activity; structure in first source	2.58	2	0
cefatrizine Cefatrizine: Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.. cefatrizine : A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be an inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.	2.45	2	0	amino acid amide; carboxylic acid; cephalosporin; phenols; semisynthetic derivative; triazoles	antibacterial drug; EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
eniporide eniporide: inhibits NHE-1 isoform; structure in first source	2.04	1	0
dexbrompheniramine maleate dexbrompheniramine maleate : The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.08	1	0	brompheniramine maleate	anti-allergic agent; H1-receptor antagonist
cilastatin [no description available]	9.93	16	10	carboxamide; L-cysteine derivative; non-proteinogenic L-alpha-amino acid; organic sulfide	EC 3.4.13.19 (membrane dipeptidase) inhibitor; environmental contaminant; protease inhibitor; xenobiotic
rifaximin [no description available]	3.86	3	0	acetate ester; cyclic ketal; lactam; macrocycle; organic heterohexacyclic compound; rifamycins; semisynthetic derivative	antimicrobial agent; gastrointestinal drug; orphan drug
everolimus [no description available]	3.61	2	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
ixabepilone [no description available]	3.58	2	0	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent
azlocillin Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin.. azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.	2.45	2	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial drug
opc-67683 OPC-67683: an antitubercular agent	3.23	1	0	piperidines
verlukast verlukast: LTD4 receptor antagonist	2.04	1	0
cefpodoxime proxetil cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.	2.08	1	0	carboxylic acid; carboxylic ester; cephalosporin	antibacterial drug; prodrug
ceftizoxime [no description available]	3.85	3	0	cephalosporin	antibacterial drug
1-methyl-d-lysergic acid butanolamide [no description available]	3.23	1	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
carumonam carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.	2.04	1	0	monobactam	antibacterial drug
fluphenazine [no description available]	2.08	1	0
nitrofurantoin Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.	5.62	9	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
eritoran eritoran : A lipid A derivative used for the treatment of severe sepsis.	2.04	1	0	lipid As
dantrolene [no description available]	3.58	2	0
roxithromycin (E)-roxithromycin : A major geometrical isomer of roxithromycin.	2.08	1	0	roxithromycin	environmental contaminant; xenobiotic
cefdinir [no description available]	3.61	2	0	cephalosporin; ketoxime	antibacterial drug
etonogestrel [no description available]	3.23	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin
bisoprolol, fumarate (1:1) salt [no description available]	2.08	1	0
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.46	2	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
evernimicin [no description available]	2	1	0
etoposide phosphate [no description available]	2.08	1	0	furonaphthodioxole
dexniguldipine niguldipine: structure given in first source; clinical modulator of multidrug resistance	2.04	1	0	diarylmethane
ciclesonide ciclesonide: nasal spray approved for seasonal and perennial allergic rhinitis	2.08	1	0	organic molecular entity
napsagatran napsagatran: structure given in first source	2.04	1	0
temsirolimus [no description available]	3.87	3	0	macrolide lactam
dutasteride Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.	3.61	2	0	(trifluoromethyl)benzenes; aza-steroid; delta-lactam	antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
tekturna [no description available]	2.08	1	0	fumarate salt	antihypertensive agent
lu 208075 ambrisentan: an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension	3.23	1	0	diarylmethane
bms188797 [no description available]	2.04	1	0
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	3.23	1	0	substituted aniline
vildagliptin [no description available]	2.08	1	0	amino acid amide
fesoterodine fesoterodine: a muscarinic antagonist for treatment of overactive bladder	3.23	1	0	diarylmethane
sgd 301-76 [no description available]	2.08	1	0	conazole antifungal drug; imidazole antifungal drug; organic nitrate salt	antiinfective agent
fluvoxamine maleate [no description available]	2.08	1	0	(trifluoromethyl)benzenes
thioacetazone Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.	2.08	1	0
azimilide azimilide: structure given in first source; RN given refers to dihydrochloride	2.04	1	0	imidazolidine-2,4-dione
gemifloxacin Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.	4.07	4	0	1,8-naphthyridine derivative; fluoroquinolone antibiotic; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; topoisomerase IV inhibitor
ceftazidime monobactam ceftazidime monobactam: ceftazidime monobactam analog; structure given in first source	2.1	1	0
dexlansoprazole Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.	3.61	2	0	benzimidazoles; sulfoxide
gemifloxacin mesylate gemifloxacin mesylate : The mesylate salt of gemifloxacin.	2.08	1	0	methanesulfonate salt	antimicrobial agent; topoisomerase IV inhibitor
cefoselis cefoselis: structure given in first source. cefoselis : A cephalosporin compound having [2-(2-hydroxyethyl)-3-imino-2,3-dihydro-1H-pyrazol-1-yl]methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively. A 4th generation broad-spectrum cephalosporin.	2.6	1	0
fosinopril [no description available]	3.23	1	0
armodafinil armodafinil : A 2-[(diphenylmethyl)sulfinyl]acetamide that has R configuration at the sulfur atom. Like its racemate, modafinil, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. Peak concentration in the blood later occurs later following administration than with modafinil, so it is thought that armodafinil may be more effective than modafinil in treating people with excessive daytime sleepiness.	3.23	1	0	2-[(diphenylmethyl)sulfinyl]acetamide	central nervous system stimulant; eugeroic
amoxicillin-potassium clavulanate combination Amoxicillin-Potassium Clavulanate Combination: A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.	6.51	8	2
tomopenem [no description available]	2.45	2	0
omacor Omacor: a drug containing the n-3 fatty acids that corrects plasma lipid; antiarrhthymic	2.03	1	0
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	3.23	1	0	oligopeptide
efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination: Inhibitor of reverse transcriptases or of RNA-directed DNA polymerases.	2.25	1	0
avibactam avibactam : A member of the class of azabicycloalkanes that is (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group. Used (in the form of its sodium salt) in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.	3.09	4	0	azabicycloalkane; hydroxylamine O-sulfonic acid; monocarboxylic acid amide; ureas	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
tapentadol Tapentadol: An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.	3.23	1	0	alkylbenzene
bb-83698 BB-83698: peptide deformylase inhibitor	2.04	1	0
ppi-0903 ceftaroline : A cephalosporin that is the active metabolite of the prodrug ceftaroline fosamil. Used for the treatment of adults with acute bacterial skin and skin structure infections.	4.9	10	0	1,3-thiazoles; cephalosporin; iminium betaine; organic phosphoramidate; oxime O-ether; thiadiazoles	antibacterial drug; antimicrobial agent; prodrug
pentagastrin Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid.	3.23	1	0	organic molecular entity
cefditoren cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.	3.23	1	0	carboxylic acid; cephalosporin	antibacterial drug
rivaroxaban Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.	2.08	1	0	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
zotarolimus zotarolimus: synthetic analog of rapamycin; structure in first source	2.04	1	0	lactam; macrolide
lipid a Lipid A: Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.. lipid A : The glycolipid moiety of bacterial lipopolysaccharide (R can be either hydrogen or a fatty acyl group).	3.23	1	0	dodecanoate ester; lipid A; tetradecanoate ester	Escherichia coli metabolite
n-formylmethionyl-leucyl-phenylalanyl-lysine [no description available]	2.07	1	0
gentamicin sulfate [no description available]	4.91	34	0
bn 52020 [no description available]	2.04	1	0
hki 272 [no description available]	2.08	1	0	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	2.08	1	0	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
fidaxomicin Fidaxomicin: A narrow-spectrum macrolide antibacterial agent that is used in the treatment of diarrhea associated with CLOSTRIDIUM DIFFICILE INFECTION.. fidaxomicin : An 18-membered macrolide that is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. A narrow spectrum antibiotic used for treatment of Clostridium difficile-related infections.	3.03	4	0
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	3.61	2	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
prasugrel hydrochloride Prasugrel Hydrochloride: A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.. prasugrel hydrochloride : A racemate comprising equal amounts of (R)- and (S)-prasugrel hydrochloride. Used to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.	3.23	1	0
artenimol artenimol: derivative of antimalarial drug artemisinin (quinghaosu)	2.05	1	0
amg 009 AMG 009: an anti-inflammatory agent; structure in first source	2.08	1	0
cefotaxime sodium [no description available]	2.08	1	0	organic sodium salt
baci-im [no description available]	3.23	1	0	homodetic cyclic peptide; polypeptide; zwitterion	antibacterial agent; antimicrobial agent
negamycin negamycin: broad spectrum hydrazide antibiotic obtained from Streptomyces species; action seems to be due to its binding to ribosomes & interference with amino coding in protein synthesis; precursor is probably leucyl-negamycin; minor descriptor (76-85); on-line & Index Medicus search AMINO ACIDS, DIAMINO (76-85); RN given refers to (threo-L)-isomer	2.1	1	0
tedizolid DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.	4.24	4	0	carbamate ester; organofluorine compound; oxazolidinone; primary alcohol; pyridines; tetrazoles	antimicrobial agent; drug metabolite; protein synthesis inhibitor
bms 477118 [no description available]	3.23	1	0	adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	3.23	1	0	nystatins
tedizolid phosphate tedizolid phosphate: a prodrug of DA-7157; structure in first source. tedizolid phosphate : A phosphate monoester resulting from the formal condensation of equimolar amounts of phosphoric acid with the hydroxy group of tedizolid . It is a prodrug of tedizolid, used for the treatment of acute bacterial skin infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.	2.08	1	0	carbamate ester; organofluorine compound; oxazolidinone; phosphate monoester; pyridines; tetrazoles	antimicrobial agent; prodrug; protein synthesis inhibitor
milnacipran [no description available]	3.23	1	0	acetamides
vindesine [no description available]	2.04	1	0
ru 66647 telithromycin: a ketolide; semisynthetic derivative of erythromycin with cycling of the C11-12 positions to form a carbamate ring to avoid acquired resistance to macrolides; binds 70S bacterial rRNA, specifically to the 23S part (23S RIBOSOMAL RNA), preventing protein synthesis;	5.22	6	0
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	2.08	1	0
scopolamine hydrobromide [no description available]	3.58	2	0
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.08	1	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
virginiamycin Virginiamycin: A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.. virginiamycin : A mixture of cyclic polypeptide streptogramin antibiotics produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. The two major components are virginiamycin M1 (also known as pristinamycin IIA) and virginiamycin S1. Virginiamycin has been widely used as a growth promotion agent in livestock and has been to have bacteriostatic activity against Gram-positive organisms such as staphylococci and streptococci.	7.87	26	0
nemonoxacin nemonoxacin: has antibacterial activity	2.75	3	0	quinolines
rifamycins [no description available]	3.58	2	0
rabeprazole sodium [no description available]	2.08	1	0	organic sodium salt
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.	2.17	1	0	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.08	1	0
bisaramil [no description available]	2.04	1	0
bivalirudin bivalirudin: designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition. bivalirudin : A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.	3.61	2	0	polypeptide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor
somatostatin [no description available]	2.08	1	0	heterodetic cyclic peptide; peptide hormone
teicoplanin teicoplanin A2-1 : A teicoplanin A2 that has (4Z)-dec-4-enoyl as the variable N-acyl group.	2.45	2	0
enfuvirtide Enfuvirtide: A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.. enfuvirtide : A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.	3.23	1	0
ganirelix [no description available]	3.23	1	0	polypeptide
hes1 protein, human HES1 protein, human: RefSeq NM_005524	2.13	1	0
pexiganan [no description available]	7.17	1	0
teriparatide [no description available]	3.23	1	0	polypeptide
salmon calcitonin [no description available]	3.23	1	0	heterodetic cyclic peptide; peptide hormone; polypeptide	bone density conservation agent; metabolite
tannins Tannins: Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). The two main types are HYDROLYZABLE TANNINS and CONDENSED TANNINS. Historically, the term has applied to many compounds and plant extracts able to render skin COLLAGEN impervious to degradation. The word tannin derives from the Celtic word for OAK TREE which was used for leather processing.	2.11	1	0
ly-146032 [no description available]	6.6	14	0	heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide	antibacterial drug; bacterial metabolite; calcium-dependent antibiotics
dalbavancin [no description available]	2.04	1	0	carbohydrate acid derivative; glycopeptide; monosaccharide derivative; semisynthetic derivative	antibacterial drug; antimicrobial agent
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide: FE-200486 is the acetate salt	3.23	1	0	polypeptide
oritavancin oritavancin : A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.	10.49	6	0	disaccharide derivative; glycopeptide; semisynthetic derivative	antibacterial drug; antimicrobial agent
exenatide [no description available]	3.23	1	0
warfarin sodium warfarin sodium : A racemate comprising equal amounts of (R)- and (S)-warfarin sodium. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.	2.08	1	0
pravastatin sodium pravastatin sodium : An organic sodium salt that is the sodium salt of pravastatin. A reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), it is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	2.08	1	0	organic sodium salt; statin (semi-synthetic)	anticholesteremic drug
alendronate sodium [no description available]	2.08	1	0
cilastatin, imipenem drug combination Cilastatin, Imipenem Drug Combination: Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent.	9.47	11	9
sl 80.0750 [no description available]	2.08	1	0
chitosan [no description available]	2.85	3	0
mesna Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.	3.61	2	0	organosulfonic acid
clavulanate potassium potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.	2.08	1	0	potassium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
sodium lactate Sodium Lactate: The sodium salt of racemic or inactive lactic acid. It is a hygroscopic agent used intravenously as a systemic and urinary alkalizer.. sodium lactate : An organic sodium salt having lactate as the counterion.	3.23	1	0	lactate salt; organic sodium salt	food acidity regulator; food preservative
piperacillin sodium [no description available]	2.08	1	0	organic sodium salt
sodium iothalamate [no description available]	3.23	1	0
oxacillin sodium [no description available]	2.08	1	0	organic sodium salt
cefazolin sodium cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.	2.08	1	0	organic sodium salt
ro13-9904 Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.	7.37	13	2
azlocillin sodium [no description available]	2.08	1	0	organic sodium salt
piperacillin, tazobactam drug combination Piperacillin, Tazobactam Drug Combination: An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS.	5.42	7	2
quinupristin quinupristin: component of RP 59500; structure in first source	4.33	3	0	cyclodepsipeptide
quinupristin-dalfopristin quinupristin-dalfopristin: RP 59500 is a combination of RP 57669 & RP 54476, which are water soluble derivatives of pristinamycin IA & pristinamycin IIB, respectively	7.58	23	0	organic molecular entity
cetrorelix cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.	3.58	2	0	oligopeptide	antineoplastic agent; GnRH antagonist
achn 490 plazomicin: structure in first source	4.1	4	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.1	1	0
colistin Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.	12.85	235	0
tylosin [no description available]	2.41	1	0
exenatide Exenatide: A synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exenatide increases CYCLIC AMP levels in pancreatic acinar cells and acts as a GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist and incretin mimetic, enhancing insulin secretion in response to increased glucose levels; it also suppresses inappropriate glucagon secretion and slows gastric emptying. It is used an anti-diabetic and anti-obesity agent.	2.03	1	0
wzb117 WZB117: structure in first source	2.21	1	0
fr 264205 ceftolozane: cephalosporin anti-bacterial agent with enhanced activity against Pseudomonas aeruginosa. ceftolozane : A fifth-generation cephalosporin antibiotic having (5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of infections with gram-negative bacteria that have become resistant to conventional antibiotics.	4	2	0
heme Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.	2.1	1	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	3.61	2	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
raltegravir [no description available]	3.23	1	0	1,2,4-oxadiazole; dicarboxylic acid amide; hydroxypyrimidine; monofluorobenzenes; pyrimidone; secondary carboxamide	antiviral drug; HIV-1 integrase inhibitor
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	2.49	2	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	8.11	64	0
chlortetracycline Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.	3.06	4	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	4.63	7	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	24.48	1,392	69
methacycline Methacycline: A broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.. methacycline : A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.	2.21	1	0
piroxicam [no description available]	3.61	2	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
roquinimex roquinimex: structure in first source	2.46	2	0	aromatic amide
meclocycline [no description available]	2.21	1	0
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	4.08	4	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.	2.75	3	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
isoxicam isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.	2.75	3	0	benzothiazine; isoxazoles; monocarboxylic acid amide	antirheumatic drug; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	10.46	4	1	benzenes; hydroxycoumarin; methyl ketone
metastat tetracycline CMT-3: a non-antimicrobial tetracycline; structure in second source	2.21	1	0
demeclocycline Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.	3.89	3	0
tipranavir tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.	3.56	2	0	sulfonamide	antiviral drug; HIV protease inhibitor
rolitetracycline Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.	2.04	1	0
minocycline hydrochloride [no description available]	2.08	1	0
lornoxicam lornoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.	2.08	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; organochlorine compound; pyridines; thienothiazine	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
6-demethyl-9-(n,n-dimethylglycylamido)-6-deoxytetracycline 6-demethyl-9-(N,N-dimethylglycylamido)-6-deoxytetracycline: a glycylcycline; structure given in first source	2	1	0
omadacycline omadacycline: demonstrated in vitro activity against a broad range of Gram-positive and select Gram-negative pathogens; structure in first source	5.32	14	0	tetracyclines
eravacycline eravacycline: has antibacterial activity	7.04	22	0	tetracyclines
calca protein, human CALCA protein, human: RefSeq NM_001741	3.21	1	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.1	1	0
pbtz169 macozinone: an antitubercular agent; structure in first source	3.23	1	0
sybr green i SYBR Green I: binds to double stranded DNA of less than 20 pg following agarose or polyacrylamide gel electrophoresis; excited at 497 nm and emits at 520 nm. SYBR Green I : A benzothiazolium ion resulting from the methylation of the nitrogen of the benzothiazole group of N-[4-(1,3-benzothiazol-2-ylmethylene)-1-phenyl-1,4-dihydroquinolin-2-yl]-N',N'-dimethyl-N-propylpropane-1,3-diamine. A cationic unsymmetrical cyanine dye that binds to double-stranded DNA and is used as a nucleic acid stain in molecular biology.	2.25	1	0	benzothiazolium ion; cyanine dye; quinolines; tertiary amine	fluorescent dye
cpzen-45 CPZEN-45: caprazamycin derivative; structure in first source	3.23	1	0
rome Rome: The capital city of Italy.. (2R)-2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol : A 2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol that has R-configuration. It is a sphingosine kinase-2 inhibitor.	2.05	1	0	2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol	EC 2.7.1.91 (sphingosine kinase) inhibitor
agar Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.	3.59	8	0
fertinex [no description available]	3.23	1	0
cefiderocol cefiderocol: structure in first source. cefiderocol : A fourth-generation siderophore cephalosporin antibiotic having {1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidinium-1-yl}methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively, developed to combat a variety of bacterial pathogens, including beta-lactam- and carbapenem-resistant organisms.	7.63	2	0	carboxylic acid; cephalosporin	antibacterial drug; siderophore
daptomycin [no description available]	11.18	101	0
dalfopristin dalfopristin: component of RP-59500; structure in first source. dalfopristin : A macrolide that is pristinamycin IIA in which the double bond between positions 26 and 26a of the pyrroline ring has been reduced and position 26R carries a [2-(diethylamino)ethyl]sulfonyl group. It is a semi-synthetic streptogramin antibiotic and often used as a mixture with quinupristin for the treatment of vancomycin-resistant Enterococcus faecium.	4.32	3	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	7.45	2	0
exudates Malaysia: A parliamentary democracy with a constitutional monarch in southeast Asia, consisting of 11 states (West Malaysia) on the Malay Peninsula and two states (East Malaysia) on the island of BORNEO. It is also called the Federation of Malaysia. Its capital is Kuala Lumpur. Before 1963 it was the Union of Malaya. It reorganized in 1948 as the Federation of Malaya, becoming independent from British Malaya in 1957 and becoming Malaysia in 1963 as a federation of Malaya, Sabah, Sarawak, and Singapore (which seceded in 1965). The form Malay- probably derives from the Tamil malay, mountain, with reference to its geography. (From Webster's New Geographical Dictionary, 1988, p715 & Room, Brewer's Dictionary of Names, 1992, p329)	2.86	3	0
entecavir entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.	3.61	2	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	4.08	4	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	3.23	1	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	9.26	59	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	4.08	4	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	3.87	3	0	dacarbazine
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	4.08	4	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	4.27	5	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
valtrex [no description available]	2.08	1	0	organic molecular entity
valacyclovir Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.	3.23	1	0	L-valyl ester	antiviral drug
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	3.85	3	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	3.61	2	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.45	2	0	2-aminopurines; propane-1,3-diols	antiviral drug
raltitrexed [no description available]	2.08	1	0	N-acyl-amino acid
vardenafil vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.	3.85	3	0	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	4.08	4	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
citrovorum factor [no description available]	3.61	2	0	tetrahydrofolic acid
leucovorin 5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.	3.85	3	0	formyltetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
rifapentine rifapentine: cyclopentyl derivative of rifampicin	3.61	2	0	N-alkylpiperazine; N-iminopiperazine; rifamycins	antitubercular agent; leprostatic drug
bl 4162a anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.	3.23	1	0	imidazoquinazoline	anticoagulant; antifibrinolytic drug; cardiovascular drug; platelet aggregation inhibitor
tegaserod tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source	3.85	3	0	carboxamidine; guanidines; hydrazines; indoles	gastrointestinal drug; serotonergic agonist
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	3.23	1	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
tirapazamine Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.	2.04	1	0	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer
sildenafil citrate Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.	2.45	2	0	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
valganciclovir Valganciclovir: A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor.. valganciclovir : The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.	3.62	2	0	L-valyl ester; purines	antiviral drug; prodrug
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	3.87	3	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
fosaprepitant fosaprepitant: a pro-drug form of aprepitant. fosaprepitant : A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.	3.23	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; phosphoramide; triazoles	antiemetic; neurokinin-1 receptor antagonist; prodrug
tegaserod maleate [no description available]	2.08	1	0	maleate salt	serotonergic agonist
ceftobiprole ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).	6.75	16	0	cephalosporin; thiadiazoles	antimicrobial agent
rifabutin [no description available]	4.08	4	0
3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin KRM 1648: structure in first source	2.03	1	0	phenoxazine
levomefolate calcium levomefolate calcium: an ingredient in Contraceptives, Oral, Combined. levomefolate calcium : An organic calcium salt of (6S)-5-methyltetrahydrofolic acid.	3.23	1	0	organic calcium salt	antidepressant
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.1	1	0

Intervention	mg*hr/mL (Mean)
	Experienced nausea (n = 4)	Did not experience nausea (n = 35)	Experienced vomiting (n = 4)	Did not experience vomiting (n = 35)
Tigecycline	8.668	8.206	6.863	8.412

Intervention	percentage of participants (Number)
	VAP: Cure (n = 7, 7, 9)	VAP: Failure (n = 7, 7, 9)	Non-VAP: Cure (n = 16, 13, 15)	Non-VAP: Failure (n = 16, 13, 15)
Imipenem/Cilastatin 1 Gram	77.8	22.2	73.3	26.7
Tigecycline 100 mg	85.7	14.3	84.6	15.4
Tigecycline 75 mg	71.4	28.6	68.8	31.3

Intervention	nanogram/milliliter (ng/mL) (Mean)
Tigecycline 75 mg	479
Tigecycline 100 mg	1217

Intervention	percentage of participants (Number)
	Cure	Failure	Indeterminate
Imipenem/Cilastatin 1 Gram	52.9	17.6	29.4
Tigecycline 100 mg	71.4	14.3	14.3
Tigecycline 75 mg	52.8	27.8	19.4

Intervention	percentage of participants (Number)
	Acinetobacter calcoaceticus: Eradication (n=3,2,3)	Acinetobacter calcoaceticus: Persistence (n=3,2,3)	Enterobacter cloacae: Eradication (n=0,0,2)	Enterobacter cloacae: Persistence (n=0,0,2)	Escherichia coli: Eradication (n=1,1,2)	Escherichia coli: Persistence (n=1,1,2)	Haemophilus: Eradication (n=1,0,0)	Haemophilus influenzae: Eradication (n=0,1,1)	Haemophilus influenzae: Persistence (n=0,1,1)	Klebsiella oxytoca: Eradication (n=1,0,0)	Klebsiella pneumoniae: Eradication (n=2,2,5)	Klebsiella pneumoniae: Persistence (n=2,2,5)	Serratia marcescens: Eradication (n=0,2,0)	Staphylococcus aureus (SA): Eradication (n=8,6,9)	SA: Persistence (n=8,6,9)	MRSA:Eradication (n=4,2,4)	MRSA:Persistence (n=4,2,4)	Methicillin-suseptible SA: Eradication (n=4,4,5)	Methicillin-suseptible SA: Persistence (n=4,4,5)	Streptococcus anginosus: Eradication (n=1,0,0)	Streptococcus mitis: Eradication (n=1,0,0)	Streptococcus oralis: Eradication (n=0,0,1)	Streptococcus pneumonia: Eradication (n=1,1,0)
Imipenem/Cilastatin 1 Gram	66.7	33.3	50.0	50.0	50.0	50.0	NA	0	100.0	NA	80.0	20.0	NA	88.9	11.1	100.0	0	80.0	20.0	NA	NA	100.0	NA
Tigecycline 100 mg	50.0	50.0	NA	NA	0	100.0	NA	100.0	0	NA	50.0	50.0	100.0	83.3	16.7	100.0	0	75.0	25.0	NA	NA	NA	100.0
Tigecycline 75 mg	66.7	33.3	NA	NA	0	100.0	100.0	NA	NA	100.0	50.0	50.0	NA	62.5	37.5	50.0	50.0	75.0	25.0	100.0	100.0	NA	100.0

Intervention	percentage of participants (Number)
	Eradication	Persistence	Superinfection
Imipenem/Cilastatin 1 Gram	80.0	13.3	6.7
Tigecycline 100 mg	80.0	20.0	0.0
Tigecycline 75 mg	61.5	38.5	0.0

Intervention	ratio (Mean)
	Cure (n = 17)	Failure/indeterminate (n = 8)
Tigecycline	24.3	22.8

Intervention	days (Median)
	Intravenous antibiotic treatment (n = 36, 35, 34)	Hospital stay (n = 36, 35, 34)	ICU stay (n = 25, 25, 29)
Imipenem/Cilastatin 1 Gram	8.50	15.50	10.00
Tigecycline 100 mg	9.00	13.00	9.00
Tigecycline 75 mg	8.00	13.00	8.00

Intervention	ng/mL (Mean)
	Cmax	Cpd,24	Cpd,48
Tigecycline or Imipenem/Cilastatin	2.83	1.86	1.74

Intervention	participants (Number)
	Nausea	Vomiting
Imipenem/Cilastatin 1 Gram	1	4
Tigecycline 100 mg	3	1
Tigecycline 75 mg	1	3

Intervention	Participants (Number)
Delafloxacin 300 mg IV q12h	13
Delafloxacin 450 mg IV q12h	19
Tigecycline 100 mg IV x 1, Followed by 50 mg IV q12h	12

Intervention	participants (Number)
	AEs	SAEs
Complicated Intra-Abdominal Infections	45	28
Complicated Skin and Soft-tissue Infections	11	4

Intervention	percentage of participants (Number)
	On Days 2 to 5 (n= 19, 94)	On Days 7 to 14 (n= 13, 70)	On Days 21 to 28 (n= 6, 32)	On Days 1 to 3 after end of treatment (n= 19, 96)
Complicated Intra-Abdominal Infections	18.1	42.9	68.8	76.0
Complicated Skin and Soft-tissue Infections	10.5	46.2	66.7	68.4

Intervention	Percentage of Participants (Number)
	Eradication (Documented or Presumed) (n=514)	Persistence (Documented or Presumed) (n=514)	Unevaluable (n=514)
Tygacil	46.69	32.68	20.62

Intervention	Percentage of Participants (Number)
	AEs	ADRs	SAEs	SADRs	Unexpected AEs	Unexpected ADRs
Tygacil	32.98	9.85	13.22	0.13	8.24	0.44

Intervention	Percentage of Participants (Number)
	Prospectively Collected Data	Retrospectively Collected Data	Geriatric: <65 Years	Geriatric: >=65 Years	Age: <30 Years	Age: 40 to 49 Yeas	Age: 50 to 64 Years	Age: >=65 Years	Sex: Male	Sex: Female	Duration of Disease: <3 Months	Duration of Disease: >=3 Months and <6 Months	Duration of Disease: >=6 Months	Infection Site: cSSSI	Infection Site: cIAI	Infection Site: CAP	Infection Site: cIAI + cSSSI	Infection Site: cIAI + CAP	Severity of Infection: Mild	Severity of Infection: Moderate	Severity of Infection: Severe	General Medical History: Yes	General Medical History: No	General Medical History (Present): Yes	General Medical History (Present): No	General Medical History (Past): Yes	General Medical History (Past): No	Kidney Disorder: Yes	Kidney Disorder: No	Liver Disorder: Yes	Liver Disorder: No	Total Treatment Period of Tygacil: <7 Days	Total Treatment Period of Tygacil: 7 to 14 Days	Total Treatment Period of Tygacil: >14 Days	Mean Daily Dose of Tygacil: <50 mg	Mean Daily Dose of Tygacil: 50 to <100 mg	Mean Daily Dose of Tygacil: 100 to <200 mg	Mean Daily Dose of Tygacil: >=200 mg	Past Medication and Therapy: Yes	Past Medication and Therapy: No	Concomitant Medications: Yes	Concomitant Medications: No
Tygacil	34.15	32.62	30.98	35.55	30.16	27.46	31.99	35.55	32.55	33.79	32.88	33.63	32.20	28.79	34.87	34.30	50.00	50.00	26.83	27.27	49.75	34.91	6.48	35.03	9.45	37.10	31.00	46.86	29.69	39.82	30.20	34.74	29.94	34.99	100.00	39.92	30.57	60.00	33.48	27.02	33.77	14.06

Intervention	Percentage of Participants (Number)
	Prospectively Collected Data	Retrospectively Collected Data	Total
Tygacil	59.68	74.97	71.59

Intervention	percentage of participants (Number)
	Cure	Failure
Imipenem/Cilastatin	96.6	3.4
Tigecycline 50mg	89.9	10.1

Intervention	percentage of participants (Number)
	Eradication (N=125, 107)	Documented Eradication (N=110, 102)	Presumed Eradication (N=110, 102)	Persistence (N=125, 107)	Documented Persistence (N=13, 5)	Presumed Persistence (N=13, 5)	Superinfection (N=125, 107)
Imipenem/Cilastatin	95.3	0.0	100.0	4.7	20.0	80.0	0.0
Tigecycline 50mg	88.0	2.7	97.3	10.4	7.7	92.3	1.6

Intervention	participants (Number)
	Number (#) of Participants with AEs	# of Participants with Treatment-Related AEs	# of Participants with SAEs	# of Participants with Treatment-Related SAEs
Imipenem/Cilastatin	108	29	15	7
Tigecycline 50mg	131	53	32	19

Intervention	percentage of patients (Number)
Plazomicin in Combination With Meropenem or Tigecycline	77.8
Plazomicin in Combination With Adjunctive Antibiotic	86.7

Intervention	percentage of patients (Number)
	EOT Visit: Clinical Cure	EOT Visit: Clinical Failure	TOC Visit: Clinical Cure	TOC Visit: Clinical Failure	TOC Visit: Indeterminate Response
Colistin in Combination With Meropenem or Tigecycline	45	55	35	65	0
Plazomicin in Combination With Meropenem or Tigecycline	64.7	35.3	35.3	58.8	5.9

Intervention	percentage of patients (Number)
	% of patients who died by Day 28	% of patients censored at 28 days	% of patients censored at <28 days	Kaplan-Meier estmate of ACM at Day 28
Colistin in Combination With Meropenem or Tigecycline	40.0	60.0	0.0	40
Plazomicin in Combination With Meropenem or Tigecycline	11.8	88.2	0.0	11.8

Intervention	percentage of patients (Number)
Plazomicin in Combination With Meropenem or Tigecycline	23.5
Colistin in Combination With Meropenem or Tigecycline	50

tigecycline

Cross-References

Synonyms (95)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Pathways (1)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Biological Processes (41)

Molecular Functions (24)

Ceullar Components (17)

Bioassays (1801)

Research

Studies (1,936)

Study Types

Clinical Trials (58)

Trial Overview

Trial Outcomes

Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit.

Number of Patients by Microbiologic Response at Test-of-Cure (TOC) Visit.

Number of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit.

Number of Microbiologically Evaluable (ME) Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit

Number of Days of Inpatient Healthcare Resource Utilization on or Before Test-of-Cure

Number of Microbiologically Evaluable (ME) Patients by Microbiological Response at Test-of-Cure (TOC) Visit

Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) Visit

Number of Patients With Microbiologic Response of Eradication.

Number of Patients With Clinical Response of Cure Vs. Failure Assessed at Least 25 - 27 Weeks Post Last Dose.

Number of Patients With Clinical Response of Cure Vs. Failure.

Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate Assessed at Least 25 - 27 Weeks Post Last Dose.

Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.

Number of Microbiologically Evaluable Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit

Inpatient Healthcare Resource Utilization on or Before Test-of-Cure - Number of Patients

Minimum Inhibitory Concentration (MIC) 50 and 90 by Baseline Isolate

Number of Microbiologically Evaluable Patients by Microbiologic Response at Test-of-Cure (TOC) Visit

Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit

Percentage of Participants With Clinical Response (CR) to Tigecycline at Last Day of Therapy (LDOT) and Test-of-Cure (TOC) Assessment

Weight Normalized Drug Clearance (CLW)

Area Under the Curve (AUCτ) From Time Zero to Time of Estimated Concentration at 12 Hours

Maximum Observed Plasma Concentration (Cmax)

Time to Reach Maximum Observed Plasma Concentration (Tmax)

Reasons for Utilization of Tygacil

Percentage of Participants With Resistant Pathogens Identified at Follow-up Due to Treatment Failure

Change of Antibiotic Treatment From Tygacil to Alternative Antibiotic

Antibiotic Agents Chosen for Combination Therapy With Tigecycline

Percentage of Participants With Composite Cure: Nosocomial Infections

Percentage of Participants With Composite Cure: Community-acquired Infections

Percentage of Participants With Clinical and Microbiological Cure: Nosocomial Infections

Percentage of Participants With Clinical and Microbiological Cure: Community-acquired Infections

Percentage of Participants With Clinical and Microbiological Cure: All Participants

Participants With Probable Failure at Follow-up

Overall Mortality: All Participants

Percentage of Participants With Composite Cure: All Participants

Number of Patients by Clinical Response at Test-of-Cure (TOC) Visit.

Number of Participants With Spontaneous Adverse Events

Correlation of AUC (0-24) of Tigecycline With Nausea and Vomiting

Time to Reach Maximum Observed Serum Concentration (Tmax) of Tigecycline

Percentage of Participants With Microbiological Response at the Pathogen Level Population at Test-of-Cure (TOC) Visit

Percentage of Participants With Microbiological Response at the Participant Level Population at Test-of-Cure (TOC) Visit

Percentage of Participants With Clinical Response in Ventilator Associated Pneumonia (VAP) and Non-VAP Participants at Test-of-Cure (TOC) Visit

Percentage of Participants With Clinical Response in Clinically Evaluable (CE) Population at Test-of-Cure (TOC) Visit

Maximum Observed Serum Concentration (Cmax) of Tigecycline

Percentage of Participants With Clinical Response in Clinical Modified Intent-to-treat (c-mITT) Population at Test-of-Cure (TOC) Visit

Correlation of AUC(0-24) to Minimum Inhibitory Concentration (MIC) Ratio (AUC [0-24]/MIC) of Tigecycline With Clinical Outcome

Duration of Intravenous Antibiotic Treatment, Hospital and Intensive Care Unit (ICU) Stay

Maximum Observed Plasma Concentration of Procalcitonin (Cmaxpd) and Predicted Procalcitonin Plasma Concentration at 24 Hours (Cpd,24) and 48 Hours (Cpd,48)

Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-12)] of Tigecycline

Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Tigecycline

Number of Participants Who Experienced Nausea or Vomiting

Clearance (CL) of Tigecycline

Number of Participants With Abnormal Electrocardiogram (ECG)

Number of Participants With Abnormal Laboratory Examinations

Clinical Response in Patients With Methicillin-resistant Staphylococcus Aureus (MRSA)

Clinical Response at Test of Cure (TOC) in the Clinically Evaluable (CE) Population

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Percentage of Participants With Clinical Response of Cure

Intervention	Participants (Count of Participants)
	TOC Visit72552475		TOC Visit72552474	EOT Visit72552474	EOT Visit72552475
	Eradicated	Persisted
Delafloxacin	94
Best Available Therapy	81
Delafloxacin	11
Best Available Therapy	21
Delafloxacin	80
Best Available Therapy	64
Delafloxacin	25
Best Available Therapy	38